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Résumé 
Les Erythropoietin-producing hepatocyte (EPH) sont la plus grande famille de récepteurs 
tyrosine kinase. Leurs ligands, les éphrines (EFNs), sont aussi des molécules exprimées à la 
surface cellulaire. Les EPH/EFNs sont impliqués dans de nombreux processus biologiques. 
L'hypertension artérielle (PA) est une maladie chronique qui, aujourd'hui, est devenue un 
problème médical critique dans le monde entier et un enjeu de santé publique. La découverte de 
nouvelles thérapeutiques de l'hypertension sont d'une grande importance pour la santé publique. 
Jusqu’à tout récemment, il existe seulement quelques études concernant le rôle de l’axe 
EPH/EFNs sur la fonction des cellules musculaires lisses vasculaires (CMLV). Dans nos études 
précédentes, nous avons montré qu'EPHB6 et EFNB1, de concert avec les hormones sexuelles, 
régulent la  PA. 
Dans la présente étude, nous avons constaté que les différents membres de la famille EPH/EFN 
peuvent réguler soit positivement, soit négativement, la contractilité des CMLV et la PA: tandis 
que EPHB4 et EFNB2 appartiennent à la première catégorie, EFNB1, EFNB3 et EPHB6 
appartiennent à la deuxième.  
In vivo, des souris males, mais non pas des femelles, porteuses d’une mutation EPHB4 (KO) 
spécifique du muscle lisse présentent une PA diminuée, comparée aux souris témoins (WT). Les 
CMLV de souris EPHB4 KO, en présence de testostérone, ont montré une contractilité réduite 
lors de la stimulation par la phényléphrine (PE). Au niveau moléculaire, la phosphorylation de 
la protéine kinase II dépendante de Ca2+/calmoduline et de la kinase de la chaine légère de la 
myosine (CLM) est augmentée, tandis que la phosphorylation de la kinase de la CLM est réduite 
dans les CMLV KO lors de la stimulation par PE, par rapport au WT CMLV. Cela fournit une 
base moléculaire à la réduction de la PA et de la contractilité des CMLV chez les souris EPHB4 
KO.  
EFNB2 est le ligand majeur de l’EPHB4. Comme attendu, les souris EFNB2 KO  spécifique du 
muscle lisse avaient un phénotype de PA semblable, quoique non identique, aux souris EPHB4 
KO. Les souris mâles EFNB2 KO, mais pas femelles, sous régime régulier ou riche en sel, 
présentent une PA réduite, par rapport à leurs homologues WT. Au niveau cellulaire, les CMLV 
des souris KO ont montré une contractilité réduite lors de la stimulation par PE par rapport aux 
témoins WT. Une région de l’acide aminé (aa) 313 à l’aa 331 dans la partie intracellulaire 
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d’EFNB2 est  essentielle pour la signalisation inverse qui régule la contractilité des CMLV, 
selon des études de mutation-délétion. Dans une étude de génétique humaine, nous avons 
identifié, dans le gène EFNB2, six SNP qui étaient associées significativement au risque 
d'hypertension artérielle, de façon dépendante du sexe, ce qui corrobore nos résultats chez les 
souris. 
En revanche, la délétion du gène EFNB3 (KO) chez les souris femelles aboutit à une PA élevée 
et à une augmentation des résistances des petites artères in vivo, améliore la contractilité des 
petites artères ex-vivo et augmente la contractilité des CMLV in vitro. Les souris mâles KO ont 
une PA normale, mais la castration conduit à une augmentation significative de la PA dans les 
souris KO, mais pas dans les souris WT. Les CMLV des souris KO femelles ont montré une 
phosphorylation accrue de la CLM et une phosphorylation réduite de la kinase de la CLM, ce 
qui fournit à nouveau une base moléculaire aux phénotypes de PA et de contractilité des CMLV 
observés. Ce changement de signalisation est attribuable à une protéine adaptatrice Grip1. En 
effet, dans une étude d'association pan génomique par le Consortium International pour la 
Pression Sanguine, un SNP dans le gène GRIP1 a approché le seuil de significativité de la valeur 
p pour son association avec la pression diastolique. 
Nos recherches, pour la première fois, ont révélé que EPH/EFNs sont de nouveaux composants 
dans le système de régulation de la PA. Les membres de la famille EPH/EFN peuvent agir 
comme des forces Yin et Yang pour régler finement le tonus des vaisseaux pour assurer 
l'homéostasie de la PA et de sa régulation. Ces effets de EPH/EFNs dépendent du sexe et des 
niveaux d’hormones sexuelles. À partir de ces nouvelles connaissances, nous pourrions 
développer une nouvelle thérapie personnalisée pour l’hypertension artérielle, utilisant des 
antagonistes d'hormones sexuelles ou des thérapies de remplacement d'hormones sexuelles, 
selon les niveaux d'hormones sexuelles des patients et les mutations dans les gènes de 
l'EPH/EFN. 
 
Mots-clés: Erythropoietin-producing hepatocyte (EPH), éphrines, cellules musculaires lisses 
vasculaires, hypertension artérielle, hormones sexuelles 
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Abstract 
Erythropoietin-producing hepatocyte (EPH) kinases are the largest family of receptor tyrosine 
kinases. Their ligands, ephrins (EFNs), are also cell surface molecules. Ephs/EFNs are 
implicated in many biological processes. 
Hypertension is a chronic medical condition of high arterial blood pressure (BP). New 
hypertension therapeutic treatments are of great importance for public health. Until recently, 
there are only a few studies related to the role of EPHs/EFNs in vascular smooth muscle cell 
(VSMC) function. In our previous studies, we have found that EPHB6 and EFNB1 function in 
concert with sex hormones to regulate BP.  
In the present investigation, we found that different EPH/EFN family members can either 
positively or negatively regulate the VSMC contractility and BP: while EPHB4 and EFNB2 
belong to the former category, EFNB1, EFNB3 and EPHB6, the latter.  
In vivo, male but not female smooth muscle-specific EPHB4 knockout (KO) mice presented 
decreased BP, compared to WT controls. VSMCs from EPHB4 KO mice in the presence of 
testosterone showed reduced contractility.  
EFNB2 is the major ligand of EPHB4. As expected, smooth muscle-specific EFNB2 KO mice 
had a similar although not identical BP phenotype as EPHB4 KO mice. Male but not female 
EFNB2 KO mice on regular or high-salt diet presented reduced BP, compared to WT 
counterparts. At the cellular level, the KO VSMCs showed reduced contractility compared to 
WT controls. In a human genetic study, we identified in the EFNB2 gene six SNPs that were 
significantly associated with hypertension risk in a sex-dependent way, corroborating our 
findings in mice. 
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On the other hand, EFNB3 gene KO in female mice resulted in elevated BP and small artery 
resistance in vivo, enhanced small arterial contractility ex vivo, and augmented VSMC 
contractility in vitro. Male KO mice had normal BP, but castration led to significant BP 
elevation in KO but not in WT mice. VSMCs from female KO mice showed heightened MLC 
phosphorylation and reduced MLC kinase phosphorylation. This signaling change was mediated 
through an adaptor protein Grip1. Indeed, in a genome-wide association study by the 
International Consortium for Blood Pressure, an SNP in the GRIP1 gene approached the 
significant threshold p-value for its association with diastolic BP.  
Our research for the first time revealed that EPHs/EFNs are novel components in the BP 
regulation system. Members of the EPH/EFN family may act as Yin and Yang forces to finely 
tune the vessel tone for BP homeostasis and regulation. Such effects of EPHs/EFNs depend on 
sex and sex-hormone levels. Based on this new knowledge, we could develop novel 
personalized hypertension therapy using sex hormone antagonists or sex hormone replacement 
therapy, depending on the sex hormone levels of the patients and mutations in EPH/EFN genes. 
Keywords: Erythropoietin-producing hepatocyte (EPH), ephrins, vascular smooth muscle 
cells, hypertension, sex hormones 
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CHAPTER 1 INTRODUCTION 
 
Part I. Function and signal pathways of Eph/Ephrins 
 
Receptor tyrosine kinases (RTKs) are a large group of cell surface molecules with an 
intracellular tail that contains tyrosine kinase activity. They function as a sensor to detect 
extracellular signals and transmit them to the cells (Yarden & Ullrich, 1988). The effects of 
many growth factors are known to be mediated by high-affinity RTKs (Fantl, Johnson, & 
Williams, 1993).  
Erythropoietin-producing hepatocyte (EPHs) form the largest family of RTKs, their 
corresponding ligands being named ephrins (Efn). About 20 years ago, the first member of the 
Eph kinase family was identified by Hirai et al.(Hirai, Maru, Hagiwara, Nishida, & Takaku, 
1987) and was called Eph. Multiple other members were subsequently identified (Beckmann et 
al., 1994; Bennett et al., 1995; Davis et al., 1994; Drescher et al., 1995; Lackmann et al., 1996; 
Shao, Lou, Pandey, Pasquale, & Dixit, 1994; Winslow et al., 1995). Within a few years of the 
identification of EPHs, their ligands ephrins were identified (Bartley et al., 1994; Beckmann 
MP, 1994). Since then, active research has been carried out to understand their functions.  
Structure of Eph/ephrin family members 
Both EPHs and ephrins are membrane-bound proteins. According to sequence similarity, Eph 
receptors and the ligands are classified into A and B subfamilies. There are nine members of the 
EphA subfamily, EphA1-8 and EphA10, and five members of the EphB subfamily, EphB1-4 
and EphB6. EphrinAs (A1–A6) anchor into the cell membrane by a 
glycosylphosphatidylinositol moiety, while ephrinBs (B1–B3) pass through the plasma 
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membrane by a short cytoplasmic tail. There is a PDZ-binding domain at ephrinBs’ C-terminus 
in the cytoplasmic tail (Figure 1) (Arvanitis & Davy, 2008).  
 
Figure 1. Features of Eph/ephrin signaling 
Both types of Eph receptors (EphAs and EphBs) contain an extracellular region, a single 
transmembrane spanning domain, and an intracellular region which comprises a tyrosine kinase 
domain, a sterile alpha motif (SAM), and PDZ-binding motif (Surawska, Ma, & Salgia, 2004). 
The extracellular domain comprises a ligand-binding domain, including a highly conserved N-
terminal globular domain, a cysteine-rich domain, and two fibronectin type III repeats. The A-
type receptors preferentially bind A-type ligands while the B-class receptors bind B-type ligands, 
but there are exceptions. For example, EphA4 can bind both A and B-type ephrins. One of the 
unique features of Eph/ephrin signaling is the fact that both receptors and ligands are competent 
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to transduce signals into the cells upon interaction (Lisle, Mertens-Walker, Rutkowski, 
Herington, & Stephenson, 2013). 
Functions of Eph/ephrin family members 
Signaling pathways  
Both EPHs and their corresponding ephrin ligands are membrane-bound proteins, they require 
direct cell-cell interactions for Eph receptor activation. The interactions between Eph receptors 
and ephrins can happen in trans (between two opposing cells) or in cis (within the same cell), 
and both can result in either cell-to-cell adhesion or de-adhesion. The Eph receptors are activated 
by ephrin ligands though forward signaling while the ephrin ligands are activated by Eph 
receptors through reverse signaling. Such bidirectional signalings are the characteristics of 
Eph/Ephrin signaling.  
The interaction of the extracellular domains of Eph receptors and ephrins was described by 
Himanen et al.(Himanen et al., 2001a) on EphB2 and ephrinB2. This interaction forms a crystal 
structure on the cell surface. In the crystals, there are two different structures of bi-directional 
signaling presenting through a multiple-step process: dimeric and tetrameric. First, pre-clustered 
unbound ephrins form low-affinity ephrin-ephrin homodimers. Then Eph receptors bind to the 
ephrins in 1:1 ratio, forming high affinity and specificity heterodimers. Next, the dimer pairs of 
Eph-ephrin join into tetrameric complexes. The tetrameric complex contains two ligands 
interacting with two receptors and forming a circular structure (Himanen, Henkemeyer, & 
Nikolov, 1998). This ring-like tetrameric structure is necessarily required by the functional 
bidirectional signaling (Himanen & Nikolov, 2003). It allows the membrane-associated ephrins 
and Eph receptors to interact with the surfaces of adjacent cells (Drescher, 2002). 
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In solution, the range of EPHs and ephrins concentration can vary widely from 10 nM to 20 mM. 
At moderate concentration, EPHs and ephrins usually form heterodimers at a 1:1 stoichiometry, 
while, throughout higher concentration, those dimer pairs can form high-order tetramers 
(Himanen et al., 2001b). The Eph tyrosine kinase can then trans-phosphorylate each other on 
the tyrosine kinase domain and initiate forward and signalings via the tetramers, which can also 
mediate the phosphorylation of other proteins and associate with the receptor of various effector 
proteins. Importantly, the formation of the heterotetramers not only modulates the forward 
signaling but also repositions the ephrin transmembrane and cytoplasmic domains, converting 
them to a signaling-competent configuration. Tyrosine phosphorylation of the ephrin 
cytoplasmic tail follows, initiating reverse signaling. These reverse signaling acts through two 
types of residuals:  the tyrosine/serine phosphorylation sites and the intracellular PDZ domain-
binding motif (Himanen, Saha, & Nikolov, 2007). Besides, the extracellular cysteine-rich 
domain and the intracellular SAM domain of the EphB receptors also play a significant role in 
Eph–ephrin interaction by binding to the Ephrin carboxy-terminal PDZ domain binding motif 
(Himanen et al., 2001a; Holder & Klein, 1999; Stapleton, Balan, Pawson, & Sicheri, 1999). 
The main downstream signaling pathway of Eph/Ephrin is mediated by G-proteins (Noren & 
Pasquale, 2004). There is a multiple, critical connection between these cell surface proteins and 
small GTPases of the Ras and Rho families. Eph/Ephrin work like a switch to regulate the 
GTPases cycled between the inactive state and active state (Van Aelst & D'Souza-Schorey, 
1997). These components are modulated by some adhesion molecules and growth factor 
receptors (Noren & Pasquale, 2004), resulting in cell morphologic and cell behavioral regulation.  
Rho proteins are key regulators of actin cytoskeleton dynamics in cells (Ramachandran, Patil, 
Combrink, Sharif, & Srinivas, 2011). EphrinB reverse signaling also activates Rho GTPases. It 
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performs in a phosphotyrosine-independent docking mechanisms by the Src family tyrosine 
kinases (Van Aelst & D'Souza-Schorey, 1997).  
The Eph/ephrin signaling pathway is also connected to the Ras/ mitogen-activated protein 
kinase (MAPK) cascade. Once the Eph receptors are activated, adaptor molecules associated 
with them will transmit signals into the cell. Then the extracellular-signal regulated kinase (ERK) 
/ MAPK pathway will be suppressed (Figure 2)(Coulthard et al., 2012). Consequently, the 
communication from the cell surface to the DNA in the nucleus of the cell and the activity of 
the transcription factors are suppressed (Chang et al., 2003; Miao et al., 2001). 
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Figure 2. Eph/Ephrin bidirectional pathways  
Beside the classical bidirectional signal pathway, Eph receptor and ephrins could also interact 
with other cell-surface communication systems, independent of receptor-ligand association. For 
example, recent studies have shown that members of the epidermal growth factor (EGF) receptor 
family can cooperate with EphA2 and promote cell motility and proliferation(Brantley-Sieders 
et al., 2008); ephrinBs could be phosphorylated on their intracellular tyrosine residues in 
response to platelet-derived growth factor receptor activation(Arvanitis & Davy, 2008).  
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Moreover, there are still many other proteins working in concert with Eph/Ephrins, such as Src 
Homology 2(SH2) and SH3 adaptor proteins(C. A. Cowan & Henkemeyer, 2001; Holland et al., 
1997); phosphatidylinositol 3-kinase(Guan et al., 2010); focal adhesion kinase(Krupke & Burke, 
2014); low-molecular-weight protein tyrosine phosphatase(Park, Warner, Mood, Pawson, & 
Daar, 2002); Abelson murine leukemia viral oncogene homolog (Abl) and Arginine (Arg) 
kinases(H. H. Yu, Zisch, Dodelet, & Pasquale, 2001); chemokine receptors(Zlotnik & Yoshie, 
2000) and some adhesion molecules(Huynh-Do et al., 1999). 
The function of EPHs/ephrins in different biological processes and systems 
A great number of studies about Eph/ephrin functions have been carried out. EPHs/ephrins are 
implicated in many biological processes such as embryonic development, tissue boundary 
formation and cell migration. Additionally, they also play critical roles in angiogenesis (Cheng, 
Brantley, & Chen, 2002) and stem cell differentiation (Genander & Frisen, 2010). 
EPHs and EPHRINs are expressed in many tissues and organs. They play important roles in the 
central nervous system(Dumas et al., 2000; Xin, Deng, Rishniw, Ji, & Kotlikoff, 2002), immune 
system(H. Luo, Charpentier, et al., 2011; H. Luo, Wan, Wu, & Wu, 2001; H. Luo, Wu, et al., 
2011; H. Luo, Yu, Tremblay, & Wu, 2004; Hongyu Luo, Yu, Wu, & Wu, 2002; J. Wu & Luo, 
2005; G. Yu, Luo, Wu, & Wu, 2003a, 2003b, 2004; G. Yu, Mao, Wu, Luo, & Wu, 2006), 
digestive system(Batlle et al., 2002), bone metabolism (Davy, Bush, & Soriano, 2006; C. Zhao 
et al., 2006), cardiovascular system (H. U. Wang, Chen, & Anderson, 1998) and other systems 
(Dravis et al., 2007; Hashimoto et al., 2007; Konstantinova et al., 2007). 
EPHs/ephrins in the nervous system 
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The first described function of EPHs and ephrins was to regulate cell-cell communication in the 
central nervous system (Himanen et al., 2007). Later, more and more important functions of 
EPHs/Ephrins in the nervous system were found.  
During neuron development, axons first need to find their appropriate target regions, and then 
have to recognize the correct area to form specific connections. During this process, many pieces 
of evidence showed that the EPHs/ephrins are critical in axon guidance (Flanagan & 
Vanderhaeghen, 1998). 
GPI-anchored ephrinAs are involved in axon repulsion. Before cell–cell contact, A-Disintegrin-
And-Metalloprotease (ADAM) will associate with ephrinA2 on the same cell. When 
encountering a second cell expressing EphA3 receptors, the interaction between ephrinA2 and 
EphA3 leads to the formation of higher-order ligand–receptor clusters, which help the ADAM10 
to cleavage ephrin ectodomain (Egea & Klein, 2007), terminating the ephrinA2/EphA4 
interaction, hence the repulsion.  
Another report demonstrated that EPHs/ephrins cause axon guidance through the Rho family 
GEF Vav. During axon guidance, Vav-dependent endocytosis triggers EPHs and ephrins to form 
a ligand-receptor complex, leading to the generation of growth cone collapses, which is 
necessary for axon guidance. This endocytosis is blocked when Vav protein is absent, 
suggesting that Rho family GEF Vav can be a key molecular in Eph/ephrin signaling pathways 
relevant to axon guidance (C. W. Cowan et al., 2005). 
Neural crest cells come from the neural epithelium. They can migrate to particular destinations, 
and differentiate into many cell types, including most neurons and glia cell of the peripheral 
nervous system, and most of the connective and skeletal tissue in the head. These cells migrate 
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following a particular pattern, either repulsive or attractive. EphrinB ligands are one set of 
repulsive cues, controlling the segmental migration of trunk and branchial neural crest cells 
(Wilkinson, 2001). 
EphA4 is required for typical fasciculation of spiral ganglion neurons (SGN) axons in their 
fringe directions. In vivo study in mice demonstrated that a lack of EphA4 in SGN peripheral 
axons causes significantly smaller fascicles. A similar phenotype also happens when ephrinB2 
is mutated (Cramer & Gabriele, 2014). 
EPHs/Ephrins also help to maintain the functional plasticity in neuronal circuits. Some members 
of Eph receptor family, such as EphB1–3 and EphA4, are expressed in the subventricular zone 
while their ligands ephrinBs are expressed in astrocytes. Their interaction will disrupt the 
migration of neuroblasts and increase cell proliferation (Conover et al., 2000; Lledo, Alonso, & 
Grubb, 2006).  
EPHs/ephrins in cancer 
As EPHs/Ephrins play key roles in the regulation of cell migration and adhesion, they are 
strongly related to tumorigenesis. They are upregulated essentially in all types of cancer cells 
(Garber, 2010). Eph signaling in tumor suppressor activities has been reported in many different 
types of tumors, including colorectal, breast, prostate, and skin tumors (Pasquale, 2008). 
Both ephrinBs and their receptors play a role in the growth and development of colon carcinoma 
(CC). In the intestinal epithelium, the activation of EphBs will enhance cell sorting and 
compartmentalization of CC cells (Cortina et al., 2007), and control the cell differentiation 
through E-cadherin–mediated adhesion (Herath et al., 2006). One particular pair of 
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EPHs/ephrins in CC is EphB4 and ephrin B2. Both of them are overexpressed in the epithelium 
of the intestinal luminal surface in CCs, regulating the tumor angiogenesis and vasculogenesis 
(Stephenson, Slomka, Douglas, Hewett, & Hardingham, 2001). 
EPHs/Ephrins are overexpressed in ovarian cancers (Herath et al., 2006). EphrinA2 in tumor 
cells or endothelial cells has been observed in >75% of ovarian cancers. It is associated with 
increased microvascular density and increased expression of ovarian cancer special markers 
such as matrix metalloproteinases 2, 9, and 14 (Y. G. Lin et al., 2007). Overexpression of EphA2 
is correlated to increased microvessel density (MVD), which is strongly associated with critical 
factors involved in angiogenesis and tumor invasion (Y. G. Lin et al., 2007).  
EphA2 inhibitors are especially effective in treating ovarian cancers when used in combination 
with taxanes (a type of antimicrotubule agent), indicating that EphA2 is an attractive target for 
ovarian cancer therapy (Landen, Kinch, & Sood, 2005). 
There are different types of EPHs expressed in breast cancers. EphB4 functions as a tumor 
suppressor in breast cancer. In breast cancer cells, EphB4 activates an anti-oncogenic pathway 
involving Abl family tyrosine kinases and the Crk adaptor protein. This Abl-Crk pathway 
downregulates the pro-invasive MMP2, not only inhibits breast cancer cell viability and 
proliferation, but also affect the motility and invasion,(Noren, Foos, Hauser, & Pasquale, 2006). 
In some breast cancers, the tumor suppressor gene HIC1 (hypermethylated in cancer 1) restricts 
ephrinA1 expression, the default function of which is to reduce tumor growth (W. Zhang et al., 
2010). 
 31 
The existing data show that EphA2 receptor overexpression and phosphorylation play a role in 
the progression of malignant prostate cancer, involving processes of cell adhesion, motility, 
invasion, and formation of metastases. EphA2 kinase deficient in the prostate tumor cells are 
correlated to cell rounding, retraction fiber formation, de-adhesion from the extracellular matrix, 
RhoA and Rac1 GTPase regulation, three-dimensional matrix invasion, and in vivo 
metastasis(Taddei et al., 2009).  
Beside EphA2, EphB4 protein overexpression is also found in most prostate tumors. Such 
overexpression is induced by a loss of phosphatase and tensin homolog (PTEN) or p53, or 
induced by epidermal growth factor/epidermal growth factor and insulin-like growth factor-I. 
One report indicates that knockdown of the EphB4 protein by siRNA or antisense significantly 
inhibits cell viability, migration and invasion, and induces apoptosis in prostate cancer cell 
lines(Xia et al., 2005). 
There seems to be a competition amongst Eph kinase family members in prostate cancer cells, 
in regulating tumor cell locomotion and invasiveness. Many members, such as EphB3, EphB4 
and ephrin-B2, join in this competition. The balance between the different members leads to the 
switch of the migration of cancer cells from restrained to invasive (Astin et al., 2010). 
Increased EphB4 and ephrin-B2 expression may reflect increased potential for growth and 
tumorigenicity in endometrial carcinomas. Furthermore, the EphB4 receptor kinases may 
modulate the biological behavior of endometrial carcinomas through autocrine and paracrine 
activation. That’s caused by Efnb2 ligand which expresses on the same or adjacent cells surface 
(Takai, Miyazaki, Fujisawa, Nasu, & Miyakawa, 2001). 
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The expression of EphA1 in nonmelanoma skin cancers is augmented. It seems to be a marker 
of the normal differentiated epidermis. The downregulation of EphA1 in nonmelanoma skin 
cancer may contribute to carcinogenesis of this cancer (Hafner, Becker, Landthaler, & Vogt, 
2006). 
The expression of EphA2 and its ligand, ephrinA1, is significantly increased in carcinomas of 
the urinary bladder (Abraham et al., 2006). 
EPHs/ephrins in the immune system  
Eph/ephrin signaling is incorporated with inflammation disorders actuated by infection, injury, 
and inflammation.  
First, EPHs/ephrins are involved in the activation of T cells. A prominent Eph function in T 
cells relates to T-cell costimulation. With the solid-phase antibody against EphB6 or solid-phase 
EPHRINB1-3 Fc, T-cell responses to suboptimal T-cell receptor (TCR) ligation could 
increase(H. Luo et al., 2004; G. Yu et al., 2003a, 2003b).  
Normally, the TCR signaling strength could be positively or negatively modulated by certain 
EPHs, leading to different thymocyte selection results (Freywald, Sharfe, Rashotte, Grunberger, 
& Roifman, 2003). 
Stimulation of Eph receptors on human CD4+ T cells by ephrinA1 enhances their migration 
(Hjorthaug & Aasheim, 2007). EphA receptor activation induces rapid tyrosine phosphorylation 
of the Casitas B-lineage Lymphoma (c-Cbl) proto-oncogene. In T cells that express EphA1 and 
EphA4 receptors, Cbl phosphorylation is observed. The following signaling events involve 
adaptors Crk-L and Crk-II (Sharfe, Freywald, Toro, & Roifman, 2003), resulting regulation of 
T cell migration into inflamed tissues (Y. Huang et al., 2015). 
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Another pathway through which ephrinA1 regulates T cell function is via proline-rich tyrosine 
kinase 2 (PYK2). After the binding of ephrinA1 to its receptors, the phosphorylation and kinase 
activity of the Src kinase family member Lck will be induced. This activates focal adhesion-like 
kinase Pyk2 (Aasheim, Delabie, & Finne, 2005), which has an essential role in T cell activation 
and polarized secretion of cytokines (Sancho et al., 2002). 
Chemotaxis is a necessary process in T cell migration. Ephrin-A1 strongly inhibits chemotaxis 
by altering the balance of activities of different small G proteins. In the same time, Ephrin-A1 
also prevented Rho activation, lead to stromal cell-derived factor (SDF)-1α induced activation 
of cdc42. The cdc42 activation can further increase calcium flux and activation of MAPK 
(Sharfe, Freywald, Toro, Dadi, & Roifman, 2002). As we mentioned before, EPHs/Ephrins 
activate MAPK strongly, downstream of which are Jun N-terminus kinase (JNK), p38 and Erk. 
All those molecules play crucial roles in cell migration (C. Huang, Jacobson, & Schaller, 2004).  
Secondly, Eph/ephrin signals are involved in thymus development. During thymus development, 
different signals drive precursors to mature into functional T lymphocytes. The Eph family 
members are implicated in this process by regulating cytoskeleton function and cell adhesion 
(Munoz et al., 2002). For example, mice deficient of EphB in thymocytes experience a 
significant reduction of thymocyte subsets (Alfaro et al., 2008). The reduced EphA4 expression 
results in decreased numbers of double-positive (CD4+ CD8+) thymocytes (Munoz et al., 2006). 
Besides, the development and organization of thymic epithelial cell (TEC) was also influenced 
by EphB2 and EphB3 (Munoz et al., 2011). The migration of the thymic primordium into the 
thoracic cavity requires ephrinB2 expression (Foster et al., 2010).  
Thirdly, EPHs’s function is not restricted to the enhancement of the strength of TCR signaling. 
They might modulate T-cell survival and death by modulating immune cell apoptosis, 
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depending on their activation status (J. Wu & Luo, 2005). After soluble EphrinA1 stimulation 
of CD4+ T cells, the IL-2 expression is reduced. So is IL-4 but not IFN-γ. As activation-induced 
cell death (AICD) depends on IL-2 and IL-4 cytokines and their receptors (Zubiaga, Munoz, & 
Huber, 1992), EphrinA1 could thus prevent AICD (Wohlfahrt et al., 2004). 
EPHs/ephrins in Glucose Homeostasis  
In order to maintain glucose homeostasis in the body, the glucose levels in the blood are 
controlled by insulin from β cells in the pancreas. The underlying molecular mechanisms of how 
β cells modulate insulin secretion is not entirely understood. Recently, some studies 
demonstrated that both Eph/ephrins A and B family members are expressed in mouse and human 
islets, and their signaling is strongly related to the β cell function.  
A recent study shows that certain communication between β cells is via EphA receptors and 
ephrinA ligands both in vitro and in vivo. EphA forward signaling will inhibit insulin secretion 
while ephrinA reverse signaling could enhance insulin secretion. Those functions lead to a two-
way autoregulation in pancreatic cells. When blood sugar level is low, EphA forward signaling 
can be activated, leading to increasing insulin secretion; when blood glucose level is high, EphA 
receptor is dephosphorylated, leading to downregulation of insulin secretion (Kulkarni & Kahn, 
2007).  
A new hypothesis is that EphA receptors not only exist on the cell surface but also in the 
intracellular insulin secretory granules. This suggests that EphA levels on the plasma membrane, 
and, therefore, EphA-ephrinA complexes, increases upon insulin release. This causes a feedback 
loop that negatively limits insulin secretion through increased EphA signaling. On the other 
hand, there is a positive feedback loop: when glucose levels are low, the ephrinA signaling will 
upregulate to increase insulin secretion (Konstantinova et al., 2007). 
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One animal experiment showed that ephrinA5 KO mice are mildly glucose intolerant. When 
subjected to the same concentration of glucose stimulation, compared with the control group, 
the significant reduction in their insulin secretion. In contrast, the insulin content of these islets 
was not significantly changed. Also, knockdown of ephrinA5 in MIN6 cells reduces glucose-
stimulated insulin secretion (Konstantinova et al., 2007; Pasquale, 2008). 
Another relevant peptide for glucose homeostasis is glucagon. When the inhibition of glucagon 
secretion is out of control, types 1 and 2 diabetes happen. However, the molecular mechanisms 
that regulate glucagon secretion in normal and diabetic states are not fully understood. A new 
study shows that the tonic stimulation of α-cell EphA receptors between neighboring islet cells 
could negatively regulate glucagon secretion. The effect of EphA is mediated by juxtacrine. 
Sorted α-cells lacking endogenous stimulation of EphA forward signaling from neighboring 
cells will result in enhanced basal glucagon secretion and the elimination of glucose-induced 
inhibition of glucagon secretion. In these cells, both normal basal glucagon secretion and 
glucose-induced inhibition of glucagon secretion can be recapitulated by restoration of EphA 
forward signaling. In vivo. α-cell-specific EphA4-/- mice exhibit abnormal glucagon dynamics 
(Hutchens & Piston, 2015). 
EPHs/ephrins in bone maintenance and homeostasis  
Bone homeostasis strictly maintains balance, this maintenance in the cell largely depends on the 
cellular communication between osteoclasts and osteoblasts, and closely related to the coupling 
between bone resorption and bone formation. A range of pathologic disorders, including 
osteoporosis and cancer-induced bone diseases, disrupt this coupling and cause subsequent 
alterations in bone homeostasis.  
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Eph receptors and their associated ligands, ephrins, are also expressed in the bone marrow 
microenvironment, including osteoclasts and osteoblasts. More and more evidence suggests that 
this receptor family is closely related to regulating normal and pathological bone remodeling 
(Edwards & Mundy, 2008). 
Some skeletal malformations are caused by the developmental deficiencies in EphB/ephrinB 
signaling, including cleft palate, defective development of the skull vault, craniosynostosis, and 
other bone abnormalities. The mutations of EphA2, EphA3 or ephrinB1 in mice may cause the 
X-linked developmental disorder of craniofrontonasal syndrome (Davy & Soriano, 2005; 
Pasquale, 2008).  
Genetic and another evidence supports a model in which EphB/ephrinB1 bidirectional signaling 
at the ectopic boundaries that form between ephrinB1-positive and negative osteoblast 
precursors leads to impaired gap junction communication, which inhibits osteoblast 
differentiation and delays ossification of developing calvarial bones(Pasquale, 2008). 
EphB4 receptors are expressed on osteoblasts, whereas osteoclasts express the ligand ephrinB2. 
Forward signaling through EphB4 into osteoblasts enhances osteogenic differentiation. Reverse 
signaling through ephrinB2 into osteoclast precursors suppresses osteoclast differentiation. 
Cytokines produced by osteoblasts activate the transcription factors c-Fos and NFATc1 in 
osteoclast precursors, and then promote osteoclast differentiation and increase ephrinB2 
expression. EphB4 / EphrinB2 protein signaling complex mediated a significant bone 
remodeling process: activating bone formation while inhibiting bone resorption (Pasquale, 2008; 
Raggatt & Partridge, 2010). 
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Besides these developmental roles, EphB/ephrinB bidirectional signaling between osteoblasts 
and osteoclasts has been implicated in the regulation of bone homeostasis in the adult (C. Zhao 
et al., 2006). 
EPHs/ephrins in the cardiovascular system  
The studies about EPHs/ephrins in the cardiovascular system are limited, and those studies are 
mainly focused on EphrinAs. 
In the adult human myocardium, cardiomyocytes preferentially express ephrinA1 ligand. 
Human cardiac stem cells (hCSCs) express EphA2 receptor (Goichberg et al., 2010). EphrinA1 
promotes the motility of EphA2-positive hCSCs, enhancing cardiac repair. Thus, in stem cell 
therapy, ephrinA1 stimulation to hCSCs before their myocardial delivery can improve cell 
targeting to the sites of injury (Goichberg et al., 2011). 
EphrinA1is also a regulatory factor in cardiac valve formation. A loss of ephrinA1 results in 
thickened aortic and mitral valves in newborn and adult animals. Animal study shows that 
deficient of ephrinA1 may cause congenital heart defects (Frieden et al., 2010).  
Decreased ephrinB1 is associated with molecular/functional cardiac defects. EphirnB1 acts as a 
stabilizer of the cardiomyocyte morphology and the overall cardiac tissue cohesion, and may 
represent a new factor in the pathogenesis of heart failure (Genet et al., 2012).  
EPHs/ephrins in angiogenesis  
Angiogenesis is a highly complex process, through which new blood vessels form from pre-
existing vessels (Birbrair et al., 2014). It plays a critical role in normal development and the 
pathophysiology of multiple disease processes, including tumor neovascularization, ischaemic 
recovery, and wound healing (Makrilia, Lappa, Xyla, Nikolaidis, & Syrigos, 2009). More 
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recently, there have been many research on the participation of EPHs/Ephrins in angiogenesis. 
It has been revealed that EPHs/Ephrins play pivotal roles in modulating the angiogenic process 
in the cardiovascular system and tumor vascularization (J. Zhang & Hughes, 2006).  
Most studies focused on the EphB/ephrinB sub-families, as they can induce capillary sprouting 
in vitro with a similar efficiency as VEGF, and contribute to the development and demarcation 
of the boundaries between arterial and venous vessels in the murine embryonic cardiovascular 
system (Adams et al., 1999; Kubis & Levy, 2003). 
The interaction between EphrinB2 and EphB4 has been studied extensively with respect to 
angiogenesis. Recent reports show that the ephrinB2 ligand is an important artery endothelial 
marker in the initial stages of embryo angiogenesis, and its receptor EphB4 marks the embryo 
vein endothelium. These findings suggest that ephrinB2 and EphB4 are involved in establishing 
arterial versus venous identity and perhaps in anastomosing arterial and venous vessels at their 
junctions (Gale et al., 2001). One report demonstrates that ephrinB2 functions in the early 
embryonic stage as a typical instructive ligand to stimulate EphB4 receptor forward signaling 
during angiogenic remodeling(Yancopoulos, Klagsbrun, & Folkman, 1998). Because of defects 
in the embryonic vascular system reconstruction, mice lacking ephrinB2 die in utero before 
embryonic day 11.5(Adams et al., 1999; Y. Lin, Jiang, Ng, Jina, & Wang, 2014). However, the 
ephrinB2 not only express on the vascular endothelial cell surface, but also capable of playing 
a role in the adjacent mesenchymal cells. Furthermore, ephrinB2 expression in perivascular 
mesenchyme is not sufficient to compensate for the loss of ephrinB2 in these vascular cells 
(Gerety & Anderson, 2002). 
The understanding of molecular and cellular mechanisms of EPHs/Ephrins governing vascular 
development is still poor. Some researchers claim that cell-bound ephrin ligands are the key 
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target molecules for vascular endothelial growth factor receptors (VEGFR-1 and VEGFR-
2)(Adams & Klein, 2000). The EphB4 receptor binds to the membrane-anchored ligand 
ephrinB2(Gerety & Anderson, 2002), the ephrinb2 ligand binds to VEGF, Tie-1 and Tie-2 
receptors, and the multimolecular complex then further bind to the angiopoietins, regulating 
angiogenesis.  
EPHs/ephrins in vascular smooth cells 
Until recently, there are only a few studies related to the role of EPHs/EPHRINs in vascular 
smooth muscle cell (VSMC) function. In our recent studies, we have found that EphB6, EphB4 
and EphrinB1 in concert with sex hormones regulate blood pressure (BP). The interesting fact 
is that although they are all Eph/EphrinB family members, their functions in BP regulation are 
different. While EphB6 and EphrinB1 deletion positively regulate the VSMC contractility and 
blood pressure(H. Luo et al., 2012; Z. Wu et al., 2012), EphB4 deletion has an opposite effect 
in these regards(Y. Wang et al., 2015). 
 
Part II. Hypertension 
 
Hypertension is a chronic medical condition of high arterial blood pressure. In the arterial 
system, blood pressure is measured by two parameters, the systolic and diastolic pressures. The 
most recent diagnosis recommendation was established by the Eighth Report of the Joint 
National Committee (JNC): for the person aged 30 to 59 years old, normal blood pressure should 
be below 120/80mmHg; blood pressure between 120/80mmHg and 139/89mmHg is called "pre-
hypertension; blood pressure staying at 140/90 mmHg or above means hypertension. For the 
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hypertensive persons aged 60 years or older, a BP goal of less than 150/90 mmHg will be 
suitable; while for hypertensive adults with diabetes or nondiabetic chronic kidney disease 
(CKD), the goal is recommended as for the general hypertensive population younger than 60 
years(140/90 mmHg)(James et al., 2014). 
Nowadays, hypertension has become a worldwide critical medical and public health issue. It 
was the third largest disease burden (4.5%) according to disability-adjusted-life-years (64 
million) (Ezzati et al., 2002). Approximately more than one billion people have hypertension in 
the world. Hypertension is estimated to cause 7.1 million premature deathsper year  (Whitworth 
& World Health Organization, 2003). Based on large-scale population-based studies of 
prevalence, the incidence of resistant hypertension, and associated risk factors carried out by 
US National Health and Nutrition Examination Survey (NHANES), the prevalence of resistant 
hypertension is 8–12% of adult patients with high blood pressure (6–9 million people in US). 
The increasing prevalence of resistant hypertension contrasts to the improvement in blood 
pressure control rates during the same period (Sarafidis, Georgianos, & Bakris, 2013).   
With such high disease incidence, and very high attendant risks for cardiovascular and kidney 
diseases, hypertension always ends up with a high morbidity and mortality rate. So, 
hypertension treatment is of great importance to public health.  
Symptoms and pathogenesis of hypertension 
There is no common symptom of hypertension. Some patients may suffer from different degrees 
of a headache or vertigo, but these are not always serious. Hypertension is usually detected by 
regular health check (Kaplan & Opie, 2006).  
There are two different types of hypertension, primary and secondary. Primary hypertension is 
also named essential, or idiopathic hypertension. It is defined as high BP without any known 
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causes. Primary hypertension is a polygenic disorder, accounting for 95% of all cases of 
hypertension. The diagnosis is made when no other causes for increased BP are found (Carretero 
& Oparil, 2000). Secondary hypertension is a type of hypertension with an underlying, 
potentially correctable cause, such as renovascular disease, aldosteronism, or other causes 
(Viera & Neutze, 2010). 
Both environmental and genetic factors may contribute to regional and racial variations in BP 
and hypertension prevalence. Social studies show that urbanization, and the immigrants who 
were assimilated by the environment, will have some effect on blood pressure ("Hypertension: 
uncontrolled and conquering the world," 2007). Obesity and weight gain are strong, independent 
risk factors for hypertension. It has been estimated that 60% of hypertensives are >20% 
overweight (Messerli, Williams, & Ritz, 2007). Population studies show that the diet is 
important in the prevalence of hypertension, especially sodium intake. Age is also a risk factor 
for high blood pressure, when the elderly and high-salt diet coexist, the risk of developing 
hypertension could significantly increase. Diet low in calcium and potassium content also 
increases the risk of hypertension. The urine sodium-to-potassium ratio has a stronger 
correlation to blood pressure than is either sodium or potassium alone. Alcohol consumption, 
psychosocial stress, and low levels of physical activity may also contribute to hypertension. 
A number of factors increase BP: e.g., obesity(Parati, Liu, & Ochoa, 2014), insulin 
resistance(Cutler, 1996; Grassi, 2005), alcohol and substance abuse (Chaturvedi, 2004), high 
salt intake (in salt-sensitive patients)(Gong & Hubner, 2006; Zozaya, 2000), aging, perhaps 
sedentary lifestyle, risky sexual behavior(Scott & Happell, 2011; Shimbo et al., 2013) 
stress(Oehme et al., 1987), low potassium intake(Elliott, 1991), or low calcium intake(Cormick, 
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Ciapponi, Cafferata, & Belizan, 2015). Furthermore, many of these factors are additive, such as 
obesity and alcohol intake (Oparil, Zaman, & Calhoun, 2003). 
Pathology of hypertension 
Pathology of primary hypertension 
Pathophysiology  
Cardiac output and peripheral resistance. The role of the circulatory system is to pump blood 
to various body systems. Blood flow arises because the heart muscle as a pumping organ of 
power, can generate a predetermined pressure difference. The relation between the pressure 
difference and flow can be described by the Ohm’s Law for electrical current (Mayet & Hughes, 
2003). The formula is as follows: 
ΔP = Q×R 
(Where ΔP=pressure difference; Q=bulk flow; R=resistance) 
The relation between mean arterial pressure, cardiac output, and peripheral resistance (Mayet & 
Hughes, 2003), The formula is as follows: 
MAP=CO×PVR 
(Where MAP=mean arterial pressure, CO=cardiac output (=stroke volume × heart rate), 
PVR=total peripheral vascular resistance) 
An average blood pressure is maintained by the balance of the cardiac output and peripheral 
vascular resistance. The majority of essential hypertension are caused by raised peripheral 
resistance, which is determined by small arterioles.  
Renin-angiotensin system. The most important players in the endocrine system for blood 
pressure controlling are in the renin-angiotensin system(Engeli, Negrel, & Sharma, 
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2000).(Figure 2) The renin-angiotensin-aldosterone concatenation, via two effector components, 
angiotensin II and aldosterone, simultaneously regulates body sodium and water content, arterial 
blood pressure and potassium balance(Laragh et al., 1972). Renin is responsible for converting 
angiotensinogen to angiotensin I, which is converted to angiotensin II in the lungs by 
angiotensin converting enzyme (ACE). Angiotensin II is a potent vasoconstrictor and thus 
causes a rise in blood pressure. The circulating renin/angiotensin are now thought to be directly 
responsible for the increase in BP in essential hypertension (Lavoie & Sigmund, 2003). They 
are usually regulated in response to glomerular under-perfusion or a reduced salt intake (G. 
Beevers, G. Y. Lip, & E. O'Brien, 2001). 
Angiotensin II is crucial in maintaining the structural and functional integrity of the vessel wall 
(Touyz & Schiffrin, 2000), and it plays a significant role in vascular smooth muscle cell 
contraction. Also, Angiotensin II induces vascular wall adhesion molecule-1(Kranzhofer, 
Browatzki, Schmidt, & Kubler, 1999). 
In addition to the effect on arterial pressure, angiotensin II also significantly contributes to the 
development and progression of hypertensive heart disease (Figure 3)(Ibrahim, 2006; Kobori, 
Ichihara, Miyashita, Hayashi, & Saruta, 1999).  
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Figure 3. The renin–angiotensin system  
 
Autonomic nervous system. Arteriolar constriction can also be caused by sympathetic nervous 
system stimulation, so the latter plays an important role in maintaining a normal blood pressure. 
Apparently, hemodynamics is changed in hypertension. The central nervous system seeks to 
maintain systemic blood pressure at a higher level (Julius, 1991). When vascular over-
responsiveness sets in, the less sympathetic drive is needed to maintain neurogenic hypertension 
(Julius, 1990). 
There is also an interaction between the autonomic nervous system and the renin-angiotensin 
system, both of which function together with sodium, circulating volume, and some of the more 
recently described hormones (Julius, Esler, & Randall, 1975).  
Vascular endothelial cells. The vascular endothelium is a layer of squamous epithelial cells 
which directly contact with the blood. It tweaks the reactivity of vascular smooth muscles. The 
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function of vascular endothelium includes the follows. It intervenes a physical obstruction 
between the vascular smooth muscle and hormones and other vasoactive substances circling in 
blood. It concentrates or metabolically degrades vasoactive substances, such as norepinephrine, 
serotonin, and kinins, and subsequently averts or reduces their movement in the vascular smooth 
muscle. It secretes vasoactive substances, such as nitric oxide (NO)(Forstermann & Munzel, 
2006; Moncada & Higgs, 2006), prostacyclin(Moller & Grande, 1999) and endothelin-1(Bohm 
& Pernow, 2007). It releases other so-far unidentified vasoactive inhibitory and excitatory 
factors (De Mey, Claeys, & Vanhoutte, 1982). 
Nitric oxide is a vasodilative molecule (Nathan & Xie, 1994). It has been found to play a 
significant role in many parts of the body (Figure 4(Faraci & Heistad, 1998)). It, acts not only 
as a physiological intercellular messenger but also displays cytotoxic activity in vivo (Beckman 
& Koppenol, 1996; Kroncke, Fehsel, & Kolb-Bachofen, 1997). NO serves as biological agents 
in regulating BP. Abnormal increase of nitric oxide synthase could reduce acetylcholine levels, 
and leads to a rise in 3'5'-cyclic adenosine monophosphate (cAMP) and 3'5'-cyclic guanosine 
monophosphate (cGMP) levels, and ultimately vessel relaxation (Bredt & Snyder, 1994; Hirsch 
et al., 1993; Lowenstein, Dinerman, & Snyder, 1994). 
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Figure 4. The mechanism of nitric oxide function in vessels 
Endothelin is a powerful cytokine, which is a vasoconstrictive peptide, and may lead to a salt-
sensitive rise in BP. It mainly modulates pulmonary BP (Galie, Manes, & Branzi, 2004). A 
functional isomer of endothelin, endothelin-1, is involved in essential hypertension. It modulates 
the autocrine feedback loops in vascular smooth muscle cells in vitro. It can down-regulate 
platelet-derived growth factor and transforming growth factor-beta (Hahn, Resink, Mackie, 
Scottburden, & Buhler, 1993). The endogenously generated endothelin-1 can contribute to the 
maintenance of peripheral vascular tone by regulating phosphoramidon and inhibitor of 
endothelin converting enzyme (Haynes & Webb, 1994). Besides, it can also activate local renin-
angiotensin systems, and act as a mediator in cyclosporine A (CsA)-related renal 
vasoconstriction (Lanese & Conger, 1993).  
Vasoactive substances. There are many other vasoactive systems and mechanisms. Some could 
affect sodium transport while some could maintain the vascular tone.  
Atrial natriuretic peptide (ANP) is a hormone secreted from the atria of the heart. It is released 
by cardiac muscle cells in response to high blood volume (Song, Wang, & Wu, 2015). The role 
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of ANP is to reduce the retention of water, sodium and fat in the circulation, thus reducing blood 
pressure (Jeppesen et al., 2015). 
Sodium-dependent glucose co-transporters are a family of glucose transporters. They contribute 
to renal glucose reabsorption (Wright, 2001). In renovascular hypertension, it may be 
upregulated by angiotensin II via the AT1 receptor, and then contribute to increased absorption 
of Na+ and therefore to the development or maintenance of hypertension (Bautista et al., 2004; 
Ismael-Badarneh et al., 2015). Some reports showed that it also can interrelate the calcium 
transport across of the vascular smooth muscle cell walls (McCarty & O'Neil, 1992).  
Hypertension-related pathological conditions 
Hypercoagulability: Patients with hypertension demonstrate vascular endothelial dysfunction. 
At the same time, the levels of hemostatic factors, platelet activation, and fibrinolysis increase 
abnormally, and the blood flow reduces. All those conditions suggest that hypertension confers 
a prothrombotic or hypercoagulable state (G. Beevers, G. Y. H. Lip, & E. O'Brien, 2001; Lip & 
Li-Saw-Hee, 1998). 
Insulin sensitivity: Insulin resistance syndrome (IRS) has the potential to explain a large group 
of common metabolic and cardiovascular disorders (DeFronzo, 1997). The insulin resistance 
plays a role in the pathogenesis of essential hypertension, through an antidiabetic agent such as 
Troglitazone (Ogihara, Rakugi, Ikegami, Mikami, & Masuo, 1995), sympathetic nerve activity, 
or increasing muscle blood flow stimulated by insulin (Scherrer & Sartori, 1997).  
Diastolic dysfunction: cardiac diastolic dysfunction has been found to be common in patients 
with hypertension. It will slow the maximal rate of left ventricular filling in hypertension (Fouad, 
Slominski, & Tarazi, 1984). Isolated diastolic dysfunction very often accompanies hypertensive 
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heart disease, and is also associated with myocardial ischemia and fibrosis in 
hypertension(Slama, Susic, Varagic, & Frohlich, 2002).  
Genetic disorders 
Liddle's syndrome: Liddle's syndrome is an autosomal dominant genetic disorder. It leads to 
high blood pressure associated with low plasma renin activity, increased resorption of sodium, 
metabolic alkalosis, low blood potassium, normal to low levels of aldosterone and water in the 
renal collecting tubules (Palmer & Alpern, 1998). 
Syndrome of apparent mineralocorticoid excess (AME): AME is an autosomal recessive 
disorder causing hypertension and hypokalemia (Levtchenko et al., 2007). It results from 
defective 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2), which is critical for 
mineralocorticoid synthesis. The deficiency of mineralocorticoid allows the unmetabolized 
cortisol to bind to the mineralocorticoid receptor, inducing sodium retention, hypokalemia, 
suppression hypertension (Palermo, Quinkler, & Stewart, 2004). 
Glucocorticoid-remediable aldosteronism (GRA): GRA is an autosomal dominant disorder in 
which the increase in aldosterone secretion produced by adrenocorticotropic hormone (ACTH) 
is no longer transient. It is one of the most common monogenic causes of hypertension (Halperin 
& Dluhy, 2011). The syndrome is characterized by high levels of aldosterone, suppressed 
plasma renin activity, high incidence of intracranial hemorrhage, and paradoxical sensitivity to 
glucocorticoid therapy (Kamrath, Maser-Gluth, Haag, & Schulze, 2011; Pizzolo et al., 2005). 
Pseudohypoaldosteronism type II (PHAII): PHAII is a group of genetic disorders, characterized 
by hypertension and hyperkalemia despite normal glomerular filtration rates. There are four 
types of PHAII, which are determined by the following gene mutations: WNK4 (PHA type IIB), 
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WNK1 (PHA type IIC), KLHL3 (PHA type IID), and CUL3 (PHA type IIE)(F. H. Wilson & 
Kahle, 1993). 
Vascular Function 
Vascular smooth muscle tone 
The vessel tone is mediated by vascular smooth muscle cells signaling pathways. Generate 
tension leads to vasoconstriction and the release of tension is causing blood vessels to 
relax.(Woodrum & Brophy, 2001). The intrinsic tone of vascular smooth muscle is determined 
by the balance between contraction and relaxation signals, which in turn regulates the dynamic 
caliber of the blood vessel. This balance is regulated by some extracellular signals, including 
neural, humoral, ionic, and mechanical forces, which induce contraction or relaxation of the 
vascular smooth muscle. All those factors are thought to lead to an alteration in intracellular 
calcium concentration, resulting changes in vessel tone (Hill-Eubanks, Werner, Heppner, & 
Nelson, 2011). 
Vascular smooth cell function 
The function of the vascular smooth muscle cell (VSMC) is contraction/relaxation and the 
regulation of blood vessel tone-diameter, blood pressure, and blood flow distribution. The 
control of contraction and relaxation is dependent upon intracellular and extracellular 
signals(Clark & Pyne-Geithman, 2005). The contractile function of smooth muscle is modulated 
by the Ca2+/calmodulin interaction to stimulate phosphorylation of the light chain of myosin. In 
order to maintain the force generated, the dephosphorylation of the myosin light chain by 
myosin phosphatase is inhibited by the RhoA/Rho kinase pathway (Jono et al., 2000).  
Main signaling pathways in VSMCs 
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Intracellular Ca2+: Changes in intracellular Ca2+ concentration play a vital role in the contraction 
of VSMCs. Calmodulin is one of the most important sensors of intracellular Ca2+ changes (Klee 
& Vanaman, 1982). Ca2+–calmodulin complex could associate with many downstream kinases 
including myosin light chain kinase (MLCK)(Kamm & Stull, 2011).  
Ca2+/calmodulin-dependent protein kinase II (CaMKII): It is a serine/threonine-specific protein 
kinase that is regulated by the Ca2+/calmodulin complex, and it has multiple functions. In our 
case, MLCK can be phosphorylated by CaMKII (Tansey et al., 1992), negatively modulating 
MLCK activity in VSMC (Van Riper, 1995). Thr-286 autophosphatase of CaMKII will decrease 
its sensitivity to Ca2+, leading to a Ca2+-independent function.  
Protein kinases: A protein kinase usually causes a functional change of the target proteins by 
changing their enzyme activity or cellular location. Up to 30% of all human proteins may be 
modified by kinase activity(Manning, Whyte, Martinez, Hunter, & Sudarsanam, 2002). There 
are two protein kinases play a key role in VSMC contraction: myosin light chain kinase (MLCK) 
and myosin light chain phosphatase (MLCP). 
Myosin light chain kinase catalyzes the phosphorylation of 2 residues in the myosin light chain 
(MLC): serine 19 and threonine 18(Ikebe & Hartshorne, 1985). MLC phosphorylation requires 
relatively high concentrations of active myosin light chain kinase (Hathaway, Konicki, & 
Coolican, 1985; Nishikawa, Shirakawa, & Adelstein, 1985). This MLCK pathway is 
Ca2+/calmodulin-dependented, and it can be modulated by some other kinases, such as p21-
activated kinases (Sanders, Matsumura, Bokoch, & de Lanerolle, 1999; Wirth et al., 2003). Once 
the MLCK has been phosphorylating, its activity decreases (Gallagher, Herring, & Stull, 1997). 
Myosin light chain phosphatase plays a pivotal role in smooth muscle contraction by regulating 
myosin light chain phosphorylation (Hartshorne, Ito, & Erdodi, 1998), hence MLC Ca2+ 
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sensitivity. It is a G protein-mediated pathway, controlled by cGMP (Kitazawa, Eto, Woodsome, 
& Brautigan, 2000; Kitazawa, Masuo, & Somlyo, 1991). cGMP activates MLCP indirectly by 
the small GTPase Rho and its downstream target Rho kinase(Lee, Li, & Kitazawa, 1997; Parizi, 
Howard, & Tomasek, 2000; X. Wu, Somlyo, & Somlyo, 1996).  
The small GTPase Rho and its target, Rho-associated kinase, are the major regulators of smooth 
muscle cell contract function. They mediate Ca2+ sensitization and are involved in the 
pathophysiology of hypertension (Uehata et al., 1997). Their function is to cause myosin II 
dephosphorylation mediated by MLCP and increase MLCK activity. The modulation of MLCP 
activity could be directly caused by Rho-associated kinase, independent of the Ca2+/calmodulin-
dependent myosin light chain kinase pathway(Kureishi et al., 1997; Somlyo & Somlyo, 2000, 
2003).  
Another important kinase family is protein kinase A (PKA). When smooth muscle cells are 
stimulated by platelet-derived growth factor (PDGF), mitogen-activated protein kinase (MAPK) 
and MAPK kinase (MAPKK) are activated rapidly. That will increase levels of cAMP and 
subsequently PKA activity (Graves et al., 1993).   
The plasma membrane-associated, Ca2+-sensitive form of protein kinase C can be stimulated by 
a rising of Ca2+. Furthermore, it would cause calmodulin-dependent activation of both myosin 
light chain kinase and the dissociation of caldesmon from the actin-caldesmon-tropomyosin-
myosin fibrillar domain (Rasmussen, Takuwa, & Park, 1987; Takuwa, 1996). In most smooth 
muscles, PKC has contraction-promoting effects such as phosphorylation of Ca2+ channels or 
other proteins that regulate cross-bridge cycling. 
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Mitogen-activated protein (MAP) kinases, a family of serine/threonine protein kinases are 
involved in many different cell signaling pathways. A Recent study demonstrated that an MAP 
kinase-dependent pathway could mediate Ang II synthesis (Duff, Berk, & Corson, 1992). 
Caldesmon and Ca+2/calmodulin:  
Caldesmon is a major calmodulin- and actin-binding protein found in smooth muscle cells. 
Current studies suggest a vital role for this protein in the regulation of smooth muscle 
contraction(Frid, Shekhonin, Koteliansky, & Glukhova, 1992). As a kind of regulatory 
contractile proteins, heavy caldesmon (h-caldesmon) and calponin were studied in SMCs 
development. In the actomyosin system, caldesmon inhibits the conversion of the chemical 
energy of ATP to mechanical force and inhibits the movement of actin filaments by myosin 
(Sobue & Sellers, 1991). It is also used a marker of VSMCs. 
In general, various agonists bind to specific receptors to activate contraction in smooth muscle 
(Figure 5 (Webb, 2003)). After this binding, the prototypical response of the cell is to increase 
phospholipase C activity via coupling through a G protein. Phospholipase C produces an 
extraordinary potent second messenger, named inositol 1,4,5-trisphosphate (IP3). IP3 binds to 
specific receptors on the sarcoplasmic reticulum, causing the release of activator Ca2+. Then 
Ca2+ further activates PKC, which phosphorylates specific target proteins. The activator Ca2+ 
binds to calmodulin, leading to the activation of MLCK. The concentration of free Ca2+ increase 
in sarcoplasmic under calmodulin (Calmodulin, CaM) participation. Then myosin light chain 
kinase (MLCK) is activated to catalyze the phosphorylation of myosin light chain, result in 
starting of the smooth muscle cross bridge cycling. However, the intracellular Ca2+ 
concentration increases shortly, contractile responses is mainly regulated by Rho kinase activity 
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through calcium sensitization mechanism, thereby inhibiting myosin phosphatase activity 
(Kienitz & Quinkler, 2008). 
This calcium-sensitization mechanism and phospholipase C are activated at the same time, and 
this mechanism relates to the activation of small GTP-binding protein RhoA. According to the 
literature, RhoA guanine nucleotide exchange factor (RhoGEF) involves in the activation of  
RhoA, but the whole process of RhoA activation is not entirely clear. Then RhoA activation of 
Rho kinase activity can be increased, thereby inhibiting myosin phosphatase (Webb, 2003). 
 
Figure 5. Regulation of smooth muscle contraction (Webb, 2003) 
Other molecules 
Free radicals and oxidative stress: At moderate concentrations, free radicals such as reactive 
oxygen species (ROS) play an important role as regulatory mediators in VSMC signaling 
processes. Many of the ROS-mediated responses protect the VSMC against oxidative stress. 
This include the regulation of vascular tone and erythropoietin production which is adjusted by 
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oxygen concentration, and various physiological processes of signal transduction from 
membrane receptors.(Droge, 2002). ROS and oxidant stress would be an inactive nitric oxide, 
and then modulate the vasomotor tone (Rocic, Seshiah, & Griendling, 2003). So they have the 
potential to be used a new specific therapy for hypertension patients with endothelial 
dysfunction (Cai & Harrison, 2000; Madamanchi, Vendrov, & Runge, 2005). 
Cerebral vasospasm (CV): Vasospasm is recalcitrant to vasodilators. CV remains one of the 
main causes of the deferred neurological deficit and ischemic damage after subarachnoid 
hemorrhage (SAH). 
Fatty acids: The major type of fatty acid with cardiovascular health benefits is long-chain n−3 
polyunsaturated fatty acids (PUFAs). It has an effect on the vascular wall and the vascular 
endothelium. Since the endothelium plays a central role in the regulation and maintenance of 
vessel tone, fatty acids could have beneficial effects on the cardiovascular system (Abeywardena 
& Head, 2001). 
Complications of hypertension 
Patients with high blood pressure are more likely to have other components of metabolic 
syndrome. There are many clinical outcomes that result from hypertension: it is a risk factor for 
all clinical manifestations of atherosclerosis(Hollander, 1976); it is an independent risk factor 
for cardiovascular disease, especially heart failure(Kostis, 2003) and coronary artery 
disease(Hunt, 2006); it constantly leads to stroke risk; and it is also an important risk factor for 
renal diseases and peripheral arterial diseases.  
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Complications affecting the heart 
As a major public health problem, congestive heart failure may develop as a result of long-
standing hypertension and leads to a very high mortality (Kostis, 2003; Levy, Larson, Vasan, 
Kannel, & Ho, 1996). The major reason is the increased pressure load imposed on the heart, 
once the increased muscle mass can no longer cope with the load, the myocardial insufficiency 
develops. Another reason is the associated accelerated coronary atherosclerosis promoted by 
hypertension will induce myocardial hypertrophy (which often ends up with heart failure) 
(Kannel, Castelli, McNamara, McKee, & Feinleib, 1972).  
Increased blood pressure can also make the blood vessel weak and stretch to form an aneurysm. 
If an aneurysm ruptures, it can be fatal(Krishnan & Todd, 2016). 
Complications affecting the brain 
Recent studies have demonstrated that there is a strong association between blood pressure and 
stroke (for both intracerebral hemorrhage and ischemic stroke). Hemorrhage is often caused by 
intracerebral vessel atherosclerosis. Higher blood pressure leads to lower blood flow in the small 
size vessels when lower cerebral blood flow occurs; ischemia happens. Sometimes, it may cause 
poor prognosis while sometimes the outcome will be less significant, such as troubles with 
memory and understanding, or ability to think and learn(Lawes, Bennett, Feigin, & Rodgers, 
2004). 
Complications affecting the eye 
Frequently in the aged population, retinal microvascular develops in response to raised blood 
pressure, which will cause hypertensive retinopathy. Hypertension will also cause other retinal 
vascular diseases, such as ischemic optic neuropathy and retinal artery occlusion. Besides, 
hypertension is also involved in the diabetic retinopathy exacerbation. These are all important 
 56 
hypertension-caused end-organ effects, which may result in vision loss. (Wong & Mitchell, 
2007). 
Complications affecting the kidneys 
Hypertension-caused renal dysfunction has been investigated for many years. There are three 
stages of pathogenic determinants of hypertensive renal damage: the increase of systemic BP 
loading; the high loading transmitting the pressure to the renal vascular bed; barotrauma on the 
local tissue caused by the pressure. Once hypertension-related renal dysfunction occurs, the 
renin-angiotensin system (RAS) blockade will be damaged. The BP renoprotection provided by 
RAS blockade is diminished, and then higher BP ensues. This creates a vicious circle. 
Complications associated with diabetes and hypertension 
Metabolic syndrome: The metabolic syndrome considerably increases the risk of cardiovascular 
and renal events in hypertension(Redon et al., 2008). The symptoms include insulin resistance, 
obesity, and dyslipidemia. The pathophysiology of metabolic syndrome is complex, and many 
important factors are involved in the pathogenesis of this syndrome, such as sympathetic 
nervous system, insulin, endothelin-1, adipokines and tumor necrosis factor-α. The abnormal 
functions of these factors lead to a macro-microvascular malfunction, due to 
hypertension(Mendizabal, Llorens, & Nava, 2013).  
Hypertension treatment  
Currently, the hypertension medications can help patients to control their blood pressure with 
minor side effects. Different blood pressure medications work in different ways to lower blood 
pressure. Some remove extra fluid and salt from the body, others slow down the heartbeat or 
 57 
relax and widen blood vessels. Most patients will require multiple drugs to achieve blood 
pressure goals, usually two or more medications work better than monotherapy. 
Diuretics 
Thiazide diuretics are the first effective oral antihypertensive agents. They reduce blood 
pressure by removing the extra fluid from the body, resulting in a reduction in both systolic and 
diastolic blood pressures. They are especially suitable for patients with low-renin or salt-
sensitive hypertension. It could also enhance the efficacy of other antihypertensive agents, 
reduce the risk of cardiovascular events, and hypertension-related morbidity and mortality(Ernst, 
2010). 
 
β Blockers  
Traditional β blockers are normally used for cardiovascular conditions, but it could also reduce 
blood pressure by decreasing cardiac output. However, the BP reducing effect is unstable, and 
may cause a high risk of reduced heart rates. Therefore, they are not used commonly as 
antihypertensive agents. On the other hand, vasodilatory β blockers could reduce blood pressure 
by reducing systemic vascular resistance. Furthermore, with beneficial effects on metabolic and 
lipid parameters, vasodilatory β blockers provide not only effective blood pressure control but 
also a treatment for the comorbid disease, including diabetes or coronary artery disease(Morgan, 
Anderson, & MacInnis, 2001; Ram, 2010). 
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Angiotensin-converting enzyme inhibitor (ACE Inhibitors) 
ACE inhibitors are almost the first choice of antihypertensive agents. They reduce the activity 
of RAAS in the development of hypertension (Leonetti & Cuspidi, 1995; Morgan et al., 2001). 
They are suitable for patients with hypertension, type II diabetes mellitus, myocardial infarction 
and heart failure. However, ACE is a non-specific target for blocking the renin-angiotensin 
enzymatic cascade. The availability of orally active ACE inhibitors is a therapeutic 
breakthrough for hypertension, but more specific blockade always seems desirable (2015). 
 Angiotensin II receptor blockers 
The effects of angiotensin II receptor blockers are almost equal to ACE inhibitors in 
hypertensive patients(Burnier & Brunner, 2000). It is an important new development for the 
treatment of hypertension and probably for congestive heart failure and chronic renal failure as 
well(Burnier & Brunner, 1998). 
 Calcium channel blockers 
Calcium channel blockers are a class of structurally heterogeneous drugs, used widely to control 
blood pressure and manage symptoms of angina(Eisenberg, Brox, & Bestawros, 2004). There 
are two different types: dihydropyridines and nondihydropyridines. Dihydropyridines include 
amlodipine, felodipine, nicardipine, and nifedipine, whereas nondihydropyridines comprise 
agents such as diltiazem and verapamil(Luft & Haller, 1993).  
 Nervous system inhibitors  
The activation of the sympathetic nervous system, triggered by reflex and humoral 
mechanisms(Dalakos, Streeten, Jones, & Obeid, 1974), is critical to the essential hypertensive 
state(Grassi, 1998). The importance of sympathetic activation in essential hypertension is now 
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well recognized. So nervous system inhibitors could powerfully reduce blood pressure, and 
potentially provide specific cardiovascular protection(Esler, 2000). 
 Vasodilators 
Vasodilating drugs reduce the blood pressure by reversing the major hemodynamic abnormality. 
Vasodilation cause the blood pressure decrease by three aspects: cardiac output is increased by 
the reflex sympathetic activity, plasma renin activity increase, and sodium retention reduced 
plasma volume expansion.(Kincaidsmith, 1985). 
 Treatment of hypertension during pregnancy 
Hypertension is a leading cause of maternal and fetal morbidity(Lindheimer, Taler, Cunningham, 
& American Society of, 2009). In the report of National High Blood Pressure Education 
Program working group, high BP in pregnancy has four categories: preeclampsia-eclampsia; 
chronic hypertension of any cause; preeclampsia superimposed on chronic hypertension; 
gestational hypertension(Zamorski & Green, 2001). The information about antihypertensive 
drugs during lactation remains limited. ACE inhibitors are important for treating proteinuria and 
diabetic patients while diuretics may decrease breast milk production and should be 
withheld(Lindheimer et al., 2009). 
 Children and Teens 
Until recently, the incidence of persistent hypertension in children is in a range of 1% to 
3%(Sinaiko, Gomez-Marin, & Prineas, 1989). However, due to obesity and other lifestyle 
factors, such as increased intake of high-calorie, high-salt foods, the tendency of hypertension 
in children is increasing. Hypertension in children is viewed as a significant risk factor for the 
development of cardiovascular disease in adulthood(Berenson et al., 1998). 
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The goal of treatment of hypertension in children is to reduce BP to a level below the ninetieth 
percentile and prevent the development of target-organ damage. However, few antihypertension 
drugs have been systematically tested in children. Thus little is known about the 
pharmacokinetics, the efficacy, or the safety of these agents in children (Mitsnefes, 2006). How 
to choose an appropriate antihypertension therapy during an appropriate age is still not been 
initiated; more clinical trials are still needed to establish the criteria for children (Kay, Sinaiko, 
& Daniels, 2001). 
Part III. Sex hormones and blood pressure 
Estrogen 
Estrogen is an important regulator of blood pressure. It normally regulates metabolic syndrome, 
a collection of abnormalities including obesity, insulin resistance/glucose intolerance, 
hypertension, dyslipidemia, and inflammation, which together lead to increased risk of 
cardiovascular disease and diabetes(Roberts, Hevener, & Barnard, 2013). 
The role of estrogens is mostly mediated by two nuclear receptors (ERα and ERβ) and a 
membrane-associated G-protein (GPR30 or GPER). Its function is not limited to the 
reproduction but extends to the skeletal, cardiovascular and central nervous systems. Various 
pathologic conditions such as cancer, inflammatory, neurodegenerative and metabolic diseases 
are often associated with dysfunctions of the estrogenic system. (Paterni, Bertini, Granchi, 
Macchia, & Minutolo, 2013).  
Cardiovascular diseases, especially coronary heart diseases, are the leading cause of death 
among women in the US and exceed breast cancer mortality in women of all ages. Some animal 
and observational studies have suggested female ovarian sex hormones can protect against 
cardiovascular dysfunction(Yang & Reckelhoff, 2011). However, this is not a far-gone 
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conclusion, as 5% women take estrogen-containing contraceptives develop de novo 
hypertension(Chasan-Taber et al., 1996). The mechanism of how estrogen works in regulating 
BP remains under-studied. Therefore, the further mechanistic study of the effects of estrogen on 
the vascular system is warranted.  
 
Estrogen in the cardiovascular system 
Experimental evidence suggests that estrogens protect the premenopausal heart from 
hypertension and ventricular remodeling. Clinical and basic research has revealed that ovarian 
lower estrogen levels will affect the activation of renin - angiotensin - aldosterone system 
(RAAS), which is one of the pathogenesis of postmenopausal vasodilation dysfunction (Z. Zhao 
et al., 2014).  
Obesity increases coronary artery disease caused by insulin resistance, and also increases the 
diabetes, hypertension, and dyslipidemia risk. After menopause, due to the lack of endogenous 
estrogen production, the probability of obesity greatly increases in woman(Meyer, Clegg, 
Prossnitz, & Barton, 2011). Estrogen and its receptors are important regulators of body weight 
and insulin sensitivity not only in women but also in men. (Meyer et al., 2011). On the other 
hand, overweight/obesity causes increased estrogen levels due to increased aromatase activity 
in the adipocytes(Cleary & Grossmann, 2009). 
Other experiment showed that increased estradiol can stimulate the vessel to generate more 
vascular connective tissue, and also alters the proportions of collagen and elastin so that the 
vessel is more distensible(Fischer & Swain, 1977). 
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Estrogen Receptor 
The third and non-genomic estrogen receptor has been identified, and it is called the G protein-
coupled estrogen receptor (GPER/GPR30). Filardo et al. described that in breast cancer cell 
lines, the estrogenic activation of the mitogen-activated protein (MAP) kinases and extracellular 
signal-regulated kinases (ERK)-1/2 is dependent on GPER(Filardo, 2000). A known function 
of GPER is to regulate metabolic parameters associated with obesity and diabetes (Sharma et 
al., 2013).  
17β-estradiol (E2) is the most potent human estrogen. It has several protective properties in the 
cardiovascular system: it activates a set of protective responses to protect cells from injury by 
activating signaling through the GPER cascade; influences the expression of protective heat 
shock proteins (HSP); protects the heart from ischemic injury(Booth, Flint, Lucas, Knittel, & 
Lucchesi, 2008; Knowlton & Korzick, 2014). However, the detailed mechanism is not 
elucidated. 
Many questions remain unanswered about the blood pressure regulation of estradiol, and its 
non-genomic signaling cascade. Some research provided evidence showing that estrogen 
modulates the RAAS and NOS system and related intracellular signaling pathways. This 
modulation is partly via GPER(Z. Zhao et al., 2014).  
 GPER in vascular contraction 
The cardiovascular role of estrogen is complex and far from fully understood with the 
identification of GPER(Figure 6(Prabhushankar, Krueger, & Manrique, 2014)). A better 
evaluation of this receptor may lead to more selective therapies to emulate the beneficial actions 
of estrogen in the cardiovascular system(Lindsey & Chappell, 2011). Activation of GPER exerts 
a protective effect on hypertension models and relaxes arteries in vitro. Some recent studies 
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showed that GPER-induced relaxation of small arteries is mediated via cAMP/PKA signaling. 
The experiment has also been carried out to determine downstream signals of the cAMP/PKA 
cascade and RhoA activity in cultured VSMCs and myosin light chain phosphatase (MLCP) 
activity in these artery rings. Once the RhoA activity was downregulated, GPER antagonist 
could restore it. In this case, localized cAMP/PKA signaling is involved in GPER-mediated 
vasodilation by activating MLCP via the inhibition of RhoA pathway(Prabhushankar et al., 2014; 
X. Yu, Li, Klussmann, Stallone, & Han, 2014).  
There are two different conditions when GPER loses its function. a. Chronic GPER deficiency 
is associated with increased endothelial prostanoid-mediated vasoconstriction; GPER deletion 
could increase thromboxane prostanoid (TP) receptor-mediated contraction. b. Acute GPER 
blockade enhances endothelium-dependent contractions and reduces endothelial NO 
bioactivity(Meyer et al., 2012).  
There are also animal experiments supporting the role of GPER in vasocontraction. Results 
showed that left ventricles of male Spontaneously Hypertensive Rats (SHR) express higher 
levels of GPER compared to normotensive rats. In addition, the selective GPER agonist G-1 
induces negative inotropic and lusitropic effects to a greater extent in isolated and Langendorff 
perfused hearts of male SHR compared to normal rats(De Francesco et al., 2013). These 
cardiotropic effects elicited by G-1 involved the GPER/eNOS transduction signaling. G-1 also 
induces activation of ERK1/2, AKT, GSK3b, c-Jun and eNOS, and reduces the expression of 
ACE and Ang II. Hence, GPER may be considered as a useful target for the treatment of 
essential hypertension(Han & White, 2014; X. Yu et al., 2014).  
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Figure 6. Effects of membrane estrogen receptor activation by estradiol, G1 agonist and 
aldosterone in vascular cells 
Testosterone 
There are many studies confirmed that in elderly men, the reduced plasma levels of testosterone 
might contribute to the increased arterial stiffness and blood pressure. The underlying 
mechanism is unclear. Further studies are needed to clarify the relationship between plasma 
testosterone level and BP. There are several possibilities: Testosterone induces vasodilation 
through an androgen receptor-independent and nongenomic pathway via ion channels 
(Deenadayalu, White, Stallone, Gao, & Garcia, 2001; Tep-areenan, Kendall, & Randall, 2002). 
Testosterone can promote norepinephrine synthesis by increasing tyrosine hydroxylase 
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activity(Kumai, Tanaka, Watanabe, & Kobayashi, 1994). Testosterone can also be involved in 
the adjustment of vascular connective tissue(Fischer & Swain, 1977). On the other hand, many 
animal studies indicated that testosterone causes increased BP. Possible mechanisms include 
upregulation of norepinephrine synthesis, Ang II expression and endothelin-1 action (Kienitz & 
Quinkler, 2008). 
More researches are needed to resolve above-mentioned controversial findings regarding the 
role of testosterone in BP regulation and hypertension pathogenesis. 
 
 
Concluding remarks 
 
Eph kinases are the largest receptor tyrosine kinase family. Our recent research represents the 
very first attempt to elucidate the role of EPHBs and their ligand EphrinBs in BP regulation. 
We revealed that EPHBs and its EphrinBs ligands are implicated in VSMC, contractility in 
mice, leading to BP regulation, and such effects are sex hormone-dependent. Our human 
genetic studies have confirmed our findings in mice, demonstrating the relevance of the mouse 
results to human hypertension. Details of the results of our investigation are provided in the 
following four articles. 
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Capsule 
Background: EPHB4’s role in blood pressure regulation was not previously known. 
 
Results: Male but not female smooth muscle-specific Ephb4 gene knockout mice were 
hypotensive. Two directional signaling between EFNBs and EPHB4 modulated small artery 
contractility.  
 
Conclusion: EPHB4 and sex hormones in concert regulates blood pressure. 
 
Significance: A new mechanism of blood pressure regulation has been discovered.  
 
Abstract 
EPH kinases are the largest family of receptor tyrosine kinases, and their ligands, ephrins 
(EFNs), are also cell surface molecules. This work presented evidences that EPHB4 on 
vascular smooth muscle cells (VSMCs) is involved in blood pressure (BP) regulation. We 
generated gene knockout (KO) mice with smooth muscle-specific deletion of EPHB4. The 
male not the female KO mice were hypotensive. VSMCs from male KO mice showed 
reduced contractility compared to their WT counterparts. Signaling from EFNBs to 
EPHB4 (forward signaling) and from EPHB4 to EFNB2 (reverse signaling) could 
modulate VSMC contractility. At the molecular level, a lack of EPHB4 in VSMCs resulted 
in compromised signaling from CamKII to MLCK to MLC, the last of which controls the 
contraction force of motor molecule myosin. Near the cell membrane, an adaptor protein 
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GRIP1, which can associate with EFNB2, was found to be essential in mediating the 
EPHB4-to-EFNB reverse signaling, which regulated  VSMC contractility, based on siRNA 
gene knockdown studies. Our research indicates that EPHB4 plays an essential role in 
regulating small artery contractility and BP. 
Introduction 
EPH kinases are the largest family of receptor tyrosine kinases. According to sequence 
homology, the EPHs can be classified into A and B subfamilies. There are 9 members in the 
EPHA subfamily, and 6 members in the EPHB subfamily. The ligands of EPH kinases, ephrins 
(EFNs), are also cell surface molecules("Unified nomenclature for Eph family receptors and 
their ligands, the ephrins. Eph Nomenclature Committee," 1997). There are 9 EFNs divided into 
A and B subfamilies. Interactions among EPHs and EFNs are promiscuous. One EPH can 
interact with multiple EFNs and vice versa. In general, EPHA members bind preferentially to 
EFNA members, and EPHB members to EFNB members(Pasquale, 2008; J. Wu & Luo, 2005). 
The preferred ligand of EPH4 is EFNB2, but the latter binds most EPHB subfamily members. 
 
EPHs and EFNs play important roles in the development and function of many tissues and 
organs, such as the central nervous system(Flanagan & Vanderhaeghen, 1998; Pasquale, 2008), 
immune system(Luo, Charpentier, et al., 2011; Luo, Wan, Wu, & Wu, 2001; Luo, Wu, et al., 
2011; Luo, Yu, Tremblay, & Wu, 2004; Luo, Yu, Wu, & Wu, 2002; J. Wu & Luo, 2005; Yu, 
Luo, Wu, & Wu, 2003a, 2003b, 2004; Yu, Mao, Wu, Luo, & Wu, 2006) and digestive 
system(Batlle et al., 2002). They are also vital in many biological processes, such as bone 
metabolism, angiogenesis, insulin secretion(Konstantinova et al., 2007), chemotaxis(Salvucci, 
de la Luz Sierra, Martina, McCormick, & Tosato, 2006), kidney glomerula filtration(Hashimoto 
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et al., 2007), ionic homeostasis of vestibular endolymph fluid in the inner ear(Dravis et al., 2007), 
etc. There are a few reports showing that some EPHs and EFNs are expressed in vascular smooth 
muscle cells (VSMCs) and play a role in VSMC migration (Foo et al., 2006; Gale et al., 2001; 
Shin et al., 2001). However, until our recent publications, there was no documented evidence 
that these molecules are involved in blood pressure regulation.  
 
In 2012, we published 2 articles reporting novel observations that EphB6 and EFNB1 modulate 
BP in mice (Luo et al., 2012; Z. Wu et al., 2012). The salient findings are as follows: systolic 
pressure (SP) and diastolic pressure (DP) in male and female EPHB6 KO mice are comparable 
to those in their wild type (WT) counterparts, but castrated KO mice have higher SP and DP 
than WT(Z. Wu et al., 2012), indicating that sex hormones act in concert with EPHB6 to regulate 
BP. We have identified VSMCs as one of the target tissues of EPHB6 in regulating BP, as small 
arteries from castrated EPHB6 KO mice show increased contractility in response to 
phenylephrine (PE) stimulation(Z. Wu et al., 2012). Adrenal gland chromaffin cells are another 
target tissue on which EPHB6 and androgens exert their BP regulatory effects (Z. Wu et al., 
2012). Smooth muscle-specific EFNB1 KO mice also have increased blood pressure in a sex 
hormone-dependent way, similar but not identical to EPHB6 KO mice (Luo et al., 2012). 
Stimulating EFNB1 in VSMCs with solid-phase Ab diminishes VSMC contractility, supporting 
the concept that EPHB6 reverse signaling reduces VSMC contractility.  
 
Given the new finding that the EPHB6 and EFNB1 KO leads to hypertension based on our 
previous study, we wondered whether other members of the Eph/Ephrins system would play 
similar roles in blood pressure control. To address this question, we generated floxed Ephb4 
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mice, and subsequently bred them to achieve smooth muscle-specific deletion of EPHB4. To 
our total surprise, we found the male EPHB4 KO mice were hypotensive. A series of mechanistic 
studies at the cellular and molecular levels were conducted. The results and significance of our 
unexpected findings are presented and discussed here.  
 
Materials and Methods 
Generation of smooth muscle cell-specific Ephb4 gene knockout mice 
A PCR fragment amplified with a primer set (5’-GCCCTTAAAGGACCGACTTC-3’ and 5’-
GCCTAACGCTGGAGAAAGTG-3’) based on the Ephb4 genomic sequence was used as a 
probe to isolate a genomic BAC DNA clone 4M20 from the 129/sv mouse BAC genomic library 
RPCI-22. The targeting vectors were constructed by recombination and routine cloning methods, 
using a 12-kb Ephb4 genomic fragment from clone 4M20 (illustrated in Figure 1A). The final 
targeting fragments for Ephb4 were excised from its cloning vector backbone by BamHI and 
electroporated into embryonic stem (ES) cells. After G418 selection, the FRT-flanked Neo/TK 
cassette was eliminated by subsequent transient transfection of the ES cells with a Flippase 
expression vector. The targeting scheme is shown in Figure 1A. These genetic engineering steps 
in ES cells resulted in two net insertions in the Ephb4 gene: a 118-bp LoxP-containing sequence 
(5′-AGTACGGGCC CAAGCTGGCC GCCCTAGGGG CGCGCCTGCA GATAACTTCG 
TATAATGTAT GCTATACGAA GTTATGATAT CAAGCTTATC GATACCGTCG 
AAGCTTGCTA GCGGTACC-3′) at position 26061 (based on the sequence of AL671478.9 in 
the GenBank), and a 151-bp LoxP- plus FRT-containing sequence (5′-GGCCGCCCTA 
GGGGCGCGCC TGCAGATAAC TTCGATAATG TATGCTATAC GAAGTTATGG 
ATCGAAGTTC CTATTTCTAA AAAGTATAGG AACTTCTTAA GGCCACCGCG 
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GCCGAACGCT AGAGCTTGTC GACGGTACCT AACTTCCTAG G-3′) at position 28713, 
756 bp upstream and 1285 bp downstream of the Ephb4 Exon 1, respectively. 
 
The targeted ES cell clones were injected into C57BL/6 blastocysts. Chimeric male mice were 
mated with C57BL/6 females to establish mutated Ephb4 allele germ line transmission. 
Southern blotting with probes corresponding to 5’ and 3’ sequences outside the targeting region, 
as shown in Figure 1A (hatched squares), was used to screen and confirm the gene targeting and 
the successful removal of the Neo-TK cassette in  ES cells and eventually in mouse tail DNA.  
 
Mice with floxed Ephb4 allele(s) were named Ephb4f/f (loxP insertions in both alleles). They 
were backcrossed with C57BL/6 for 10 generations and then mated with smooth muscle myosin 
heavy chain promoter-driven Cre transgenic (Tg) mice in the C57BL/6 background (smMHC-
Cre-IRES-eGFP Tg mice(Xin, Deng, Rishniw, Ji, & Kotlikoff, 2002)) to obtain smooth muscle 
cell-specific EPHB4 KO mice. They are referred to as EPHB4 KO mice or KO mice in the text 
below. 
 
PCR was used for routine genotyping of the floxed allele(s) and the Cre transgene. Primers 5′- 
GCCCT TAAAG GACCG ACTTC -3′ (forward) and 5’- GCCTA ACGCT GGAGA AAGTG-
3′ (reverse) amplified a 271-bp fragment from the floxed allele and a 133-bp fragment from the 
WT allele. Primers (forward: 5’-CCA ATT TAC TGA CCG TAC ACC-3’; reverse: 5’-GTT 
TCA CTA TCC AGG TTA CGG-3’) amplified a 310-bp fragment of the Cre transgene. The 
PCR cycling condition was as follows for both types of PCR: 4 min at 95℃, followed by 34 
cycles of 15 s at 94℃, 30 s at 58 ℃, and 60 s at 72℃, and a final incubation at 72℃ for 10 min. 
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Reverse transcription/quantitative-PCR (RT/qPCR) 
Ephb4, Grip1, PDZ-Rgs3 and Disheveled mRNA levels in VSMCs were measured by RT-qPCR. 
Total RNA from VSMCs was extracted with TRIzol® (Invitrogen, Camarillo, CA) and reverse-
transcribed with iScriptTM cDNA Synthesis Kit (BIO-RAD, Mississauga, Canada). Primers 
used are listed in Table I. iQTM SYBR® Green Supermix (BIO-RAD) was employed in qPCR. 
The cycling condition for all 4 molecules was as follows: 2 min at 50°C, 2 min at 95°C followed 
by 25-35 cycles of 10 s at 94°C, 20 s at 58°C, and 20 s at 72°C. β-actin mRNA levels were used 
as an internal control. Samples were measured in duplicate, and the data are expressed as signal 
ratios of test gene mRNA/β-actin mRNA.  
 
BP measurement by radiotelemetry 
Mice were implanted surgically with TA11PA-C10 telemetry sensors (Data Sciences 
International, St. Paul, MN, USA) in the left carotid artery for direct measurement of arterial 
pressure and heart rate (HR), as described previously(Luo et al., 2012; Z. Wu et al., 2012). For 
radiotransmitter implantation and castration/ovariectomy, mice were anesthetized with 
isoflurane (2% isoflurane with 0.75L/min O2 flow). Radiotelemetry was started 1 week after 
transmitter implantation. The raw data were processed with the Dataquest A.R.T-Analysis 
program(Lavoie, Lake-Bruse, & Sigmund, 2004) and are presented as daily means ± SE  
 
Ex vivo vessel constriction   
Mice between 18 to 20 weeks of age were used for all in vitro studies. The mice were euthanized 
with pentobarbital (400 mg/Kg body weight, i.p.) at the end of in vivo studies or for tissue 
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retrieval. Vessel constriction was studied ex vivo, as described previously (Luo et al., 2012; Z. 
Wu et al., 2012). Three measurements from 3 segments per mouse and 2 mice per group were 
pooled to construct concentration-response curves with SE.  
 
VSMC isolation  
Mouse VSMCs were isolated, as described by Golovina and Blaustein (Miller, Silver, & Stull, 
1983), with modifications (Luo et al., 2012; Z. Wu et al., 2012).  
 
Measurement of VSMC contractility 
VSMC contractility was measured as described previously (Luo et al., 2012; Z. Wu et al., 2012). 
In some experiments, an EPHB4 kinase inhibitor NVP-BHG712 (0.5μM; Tocris Bioscience, 
Bristol, United Kingdom) was added at the last 4h of the culture.  
 
Immunoblotting 
VSMCs from the aorta and mesenteric arteries of WT and KO mice were cultured for 3-4 days. 
In some experiments, EPHB4 kinase inhibitor NVP-BHG712 (0.5μM) was added for the 
indicated duration. The VSMCs were stimulated with PE (20 μM) for 3 s, then lysed by 
immunoprecipitation assay buffer, which contained PhosSTOP and protease inhibitor mixtures 
(Roche Applied Science, Meylan, France). Immunoblotting for phosphorylated myosin light 
chain (MLC) and total MLC, and phosphorylated and total MLC kinase (MLCK) were described 
before22, 23. Phosphorylated and total MLC phosphatase (MYPT), phosphorylated and total 
Ca++/calmodulin-dependent protein kinase II (CaMKII) of the VSMCs were measured using 
rabbit anti-MLCK mAb (clone EP1458Y; Abcam, Cambridge, UK), rabbit anti-phospho-
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MLCK Ab (Invitrogen), rabbit anti-MYPT Ab (#2634; Cell Signalling, Danvers, MA), rabbit 
anti-phospho-MYPT Ab (#5163; Cell Signalling), rabbit anti-CaMKII (phospho T286) 
antibody(ab32678; Abcam), and rabbit anti-CaMKII antibody (ab52476; Abcam). For α1-
adrenergic receptor detection, VSMCs were cultured and lyzed as described above without 
stimulation. Rabbit Ab against α1-AR (ab3462; Abcam) was used for blotting. All the Abs were 
used at the manufacturers' recommended dilutions. The signals were detected with SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific, Burlington, Ontario, Canada). 
 
Small interfering RNA (siRNA) transfection 
siRNAs of Disheveled, PDZ-RGS3, Grip1 and negative control siRNAs were synthesized by 
Integrated DNA Technologies (Coralville, IA, USA). Their sequences have already been 
described in our previous publication (Z. Wu et al., 2012). VSMCs were cultured in wells coated 
with recombinant EPHB4-Fc (2 μg/ml during coating) or normal human IgG (NHIgG; 2 μg/ml 
during coating) for 3 days, and then in medium free of antibiotics for an additional 24h. The 
cells were then transfected with a mix of 3 pairs of siRNAs of a particular gene (for each pair, 
the final concentration is 10 nM), as described before (Z. Wu et al., 2012). 
 
Ethics statement 
All studies were approved by the Animal Protection Committee (Le Comité institutionnel 
d'intégration de la protection des animaux) of the CHUM Research Center. 
 
Statistical analysis 
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All results were expressed as means ± SEM. Data were statistically analyzed using Student’s t-
tests, or repeated-measures ANOVA. A p-value of <0.05 was considered statistically significant. 
 
Results 
Generation and characterization of SMC-specific Ephb4 conditional gene KO mice 
To investigate the function of EPHB4 in BP regulation, we generated Ephb4 floxed mice, with 
LoxP sites flanking exon 1 of Ephb4 (Fig. 1A). The germline transmission of the mutated gene 
was confirmed by Southern blotting of tail DNA (Fig. 1B). With the 5’ probe, the floxed alle 
showed a 9.1-kb EcoRV/BclI band, and the WT alle, an 11.4-kb EcoRV/BclI band. With the 3’ 
probe, the floxed alle showed a 7.0-kb BamHI/EcoRI band, and the WT alle, a 12.6-kb 
BamHI/EcoRI band. These floxed mice were first backcrossed to the C57BL/6 background for 
9 generations, and then crossed with Tg mice expressing smooth muscle myosin heavy chain 
promoter-driven Cre recombinase (smMHC-Cre-IRES-eGFP Tg mice(Xin et al., 2002) ) to 
achieve smooth muscle-specific deletion of EPHB4. The deletion of Ephb4 at the mRNA level 
in vascular smooth muscles, but not in spleen cells, was confirmed by RT-qPCR (Fig. 1C). The 
deletion of EPHB4 at the protein level in VSMCs, but not in spleen cells, was further confirmed 
by immunoblotting (Fig. 1D).   
 
EPHB4 deletion in smooth muscle cells causes hypotension in males  
Our previous study showed that BP is significantly heightened in castrated EPHB6 KO, but not 
in uncastrated or female EPHB6 KO mice, compared to their WT counterparts, indicating that 
EPHB6 acts in concert with sex hormones in BP regulation(Luo et al., 2012). We further 
demonstrated that one of the tissues responsible for this phenotype is VSMCs(Luo et al., 2012). 
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As EPHB4 is another notable member of the EPHB subfamily, we wondered whether SMC-
specific deletion of EPHB4 would result in a similar BP phenotype. The BP and HR of EPHB4 
KO mice were measured by radiotelemetry. The mean + SE of daily SP, DP, MAP and HR of 
the mice are presented in Figure 2, and were analyzed by Student’s t tests. The hourly BP and 
HR during the entire 3-day period were also analyzed by repeated-measures ANOVA. Most 
surprisingly, male KO mice presented significantly reduced SP (by both hourly and daily 
analysis) and MAP (on day 3, by daily analysis) with normal HR compared to WT mice (Fig. 
2A). On the other hand, the BP parameters of the KO females were comparable to those of their 
WT counterparts, although the former showed reduced HR (Fig. 2B; by both hourly and daily 
analysis). BP and HR of both KO and WT mice, either males or females, all showed expected 
circadian fluctuations (data not shown). 
 
Decreased vessel contractility of male EPHB4 KO mice ex vivo 
BP is a function of cardiac output and blood vessel flow resistance, which is determined mainly 
by small arteries. As the KO mice only had EPHB4 deletion on SMC, we focused our attention 
on small arterial contractility, which determines small arterial tone. 
 
The PE-triggered contractility of mesenteric arteries from KO and WT mice was assessed ex 
vivo. The vessel contractility of male KO (Figs. 3A and 3B) but not female KO (Figs. 3C and 
3D) mice, whether with endothelium (Figs. 3A and 3C) or without endothelium (Figs. 3B and 
3D), was significantly lower than that of their WT counterparts, corroborating the hypotensive 
phenotype in male KO mice. These results also indicate that the reduced contractility of male 
KO vessels is not caused by cytokines or nitric oxide produced by the endothelium.  
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Both forward and reverse signaling between EPHB4 and its ligands is responsible for 
regulating VSMC contractility 
Since EPHB4 deletion is SMC-specific, and male mice had reduced BP and vasoconstriction, 
we conducted further experimentation at the cellular level to understand the underlying 
mechanisms. As shown in Figure 4A, VSMCs from male KO mice did indeed present decreased 
contractility upon PE-stimulation. VSMCs from male mice were then used in all subsequent 
cellular and molecular studies. 
 
EPHB4 and its ligands (mainly EFNBs) are all expressed in VSMCs(Luo et al., 2012). EPHB4 
and its ligands can trigger signaling in both directions, i.e. from the ligands to EPHB4 (forward) 
and from EPHB4 to EFNBs (reverse). We wondered which direction is essential in regulating 
VSMC contractility. When WT VSMCs were cultured in wells coated with recombinant EFNB2 
[in the form of EFNB2 tagged with human IgG Fc (EFNB2-Fc) for triggering forward signaling], 
the preferred ligand of EPHB4, their contractility on PE-stimulation was significantly increased, 
compared to WT VSMCs cultured in wells coated with control normal human IgG (NHIgG) 
(Fig. 4B). On the other hand, EPHB4 KO VSMCs did not respond to solid phase EFNB2-Fc 
and their contractility was no different from that of WT VSMCs treated with NHIgG (Fig. 4B, 
thin line). This indicates that the major receptor receiving the solid phase EFNB2 stimulation is 
EPHB4, and that enhanced EPHB4 forward signaling increases VSMC contractility. To verify 
this finding using a different approach, we treated the WT male VSMCs with an EPHB4 
inhibitor NVP-BHG712 at 0.5 μM for 4 h, and found that it could also inhibit VSMC 
contractility (Fig. 4C), rendering the WT VSMCs a phenotype similar to that of EPHB4 KO 
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VSMCs. Such inhibition is not due to general cytotoxicity of the inhibitor, as VSMCs cultured 
in 0.5 μM NVP-BHG712 up to 5 days proliferated at a similar rate as those cultured in vehicles 
(data not shown).  
 
To assess whether reverse signaling through EPHB4 ligands could also regulate VSMC 
contractility, we cultured the WT VSMCs in wells coated with recombinant EPHB4-Fc, which 
could trigger reverse signaling via EFNBs. Such treatment also enhanced VSMC contractility 
on PE stimulation (Fig. 4D), and the enhancement could be specifically neutralized by soluble 
recombinant EFNB2-Fc, indicating that the effect is mainly reversely transmitted via EFNB2. 
 
It is worth mentioning that cross-linked EPHB4-Fc or EFNB2-Fc by itself in the absence of PE 
had no effect on VSMC contractility (data not shown). 
 
Contractility-related signaling events affected by EPHB4 in VSMCs 
The reduced contractility of KO VSMCs in response to PE could in theory be due to reduced 
α1-adrenoreceptor (α1AR). However, based on immunoblotting, male WT and KO VSMCs had 
similar levels of α1AR (data now shown). Activation of AR leads to Ca++ flux, which is an event 
controlling contractility. Again, PE-triggered Ca++ flux showed no differences between male 
WT and KO VSMCs (data not shown).  
 
We then suspected that the reduced contractility of male KO VSMCs was a result of decreased 
VSMC Ca++ responsiveness, which is regulated by MLC phosphorylation. We tested MLC 
phosphorylation at different time points after PE stimulation, and found that it occurred very 
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quickly within seconds and then subsided (data not shown). We thus chose 3 s as a testing point 
as it was the earliest time point technically possible. KO VSMCs from males did indeed manifest 
a significantly lower degree of MLC phosphorylation than their WT counterparts immediately 
(Fig. 5A). Inhibition of EPHB4 kinase activity in VSMCs by NVP-BHG712 also repressed 
MLC phosphorylation (Fig. 5B). MLC is phosphorylated by MLCK. This kinase is 
phosphorylated at ser1760 by calmodulin-dependent protein kinase II (CamKII) or protein 
kinase A, and such phosphorylation reduces its kinase enzymatic activity(Miller et al., 1983). 
We found that MLCK phosphorylation at ser1760 was increased in male KO VSMCs compared 
to that in WT counterparts (Fig. 5C). The kinase enzymatic activity of CamKII is controlled by 
its phosphorylation at ser286; the phosphorylated CamKII presented lower kinase activity 
MLCK(Pfitzer, 2001; Tansey et al., 1992). In male KO VSMCs, such CamKII phosphorylation 
was increased (Fig. 5D), corroborating the increased MLCK and reduced MLC phosphorylation. 
Thus, a deletion of EPHB4 compromised the signaling from CamKII to MLCK to MLC in 
VSMCs, with enhanced CamKII phosphorylation as the upstream event. On the other hand, in 
VSMCs, phosphorylation of MLC phosphatase, which also regulates MLC phosphorylation, 
was not influenced by EPHB4 deletion (data not shown). 
 
Identification of GRIP1 as a component in the EPHB4-triggered reverse signaling leading to 
increased VSMC contractility 
To understand how reverse signaling is transmitted through EFNBs after EPHB4 triggering in 
VSMCs, we used siRNAs to knock down the expression of 3 adaptor proteins, GRIP1, PDZ-
RGS3 and DISHEVELED, which are known to associate with EFNBs(Bruckner et al., 1999; 
Lu, Sun, Klein, & Flanagan, 2001; Tanaka, Kamo, Ota, & Sugimura, 2003). The effectiveness 
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of mRNA knockdown was verified by RT-qPCR (Fig. 6A). It is to be noted that for PDZ-RGS3, 
although the knockdown reduced its mRNA levels, a statistical difference was not reached. 
VSMCs from WT males were cultured in wells coated with recombinant EPHB4-Fc to invoke 
EFNB reverse signaling. With Grip1 siRNA but not PDZ-Rgs3 or Disheveled siRNA 
transfection, the contraction enhancing effect of EFNB reverse signaling (mainly through 
EFNB2, as demonstrated in Fig. 3D) was eliminated (Fig. 6B). Grip1 siRNA transfection in WT 
VSMCs without solid phase EPHB4-Fc stimulation did not affect their contractility (data not 
shown), indicating that GRIP1 is only functional when there is EPHB4-triggered reverse 
signaling. VSMCs cultured in wells with solid phase recombinant EPHB4-Fc with GRIP1 
knockdown also manifested a significantly lower degree of CamkII phosphorylation than the 
controls (VSMCs transfected with control siRNA and cultured in wells coated with NHIgG; Fig. 
6C), suggesting that GRIP1 is upstream of CamKII.  
  
Discussion 
Our recent work demonstrates that the deletion of several EPH/EFN members in VSMCs, such 
as EPHB6 and EFNB1, leads to hypertension in mouse models, revealing a previously unknown 
BP control system(Luo et al., 2012; Z. Wu et al., 2012). In support of our findings that deletion 
of certain members of EPH/EFN families could cause hypertension, a recent publication by 
Carlstrom et al. demonstrated that mice with deletion of EPHA4 intracellular tail were also 
hypertensive(Sallstrom et al., 2013). Quite unexpectedly, we found in the present study that 
deletion of a member of the EPH/EFN system, EPHB4, in VSMCs resulted in hypotension. Such 
a phenotype was only apparent in males, suggesting that the phenotype is affected by sex 
hormones. Obviously, a tremendous amount of mechanistic study needs to be conducted to 
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elucidate how the sex hormones in concert with EPHB4 modulate VSMC contractility. Our 
present work serves as a starting point but not a complete report for a full understanding of the 
complex interaction among EPHs/EFNs, sex hormones and blood pressure regulation.  
 
The co-existence of opposing effects of these EPH/EFN molecules in VSMC contractility and 
BP regulation are reminiscent of the Yin and Yang of many other cellular and molecular events, 
such as kinases/phosphatases, osteoblasts/osteoclasts, calcium influx through L/T calcium 
channels and out flux through BK channels, etc. The co-existence of these cells/molecules with 
opposite functions likely results in better homeostatic control of different biological processes; 
in this case, the fine tuning of vascular tone and consequently, BP. The opposite effects will 
need to be modulated to achieve the fine tuning. We have found that sex hormones are one of 
these modulators with regard to EPHB4 functions in BP regulation. There is no evidence that 
sex hormones change the expression levels of EPHB4 and EFNB family members in VSMCs 
(unpublished observation). The exact underlying mechanisms for such sex hormone-mediated 
fine tuning are under investigation.  
 
We previously found that the VSMC relaxation effect of EPHB6 and EFNB1 is mediated by 
reverse signaling through EFNBs, but not by forward signaling through EPHBs. For EPHB4, 
its effect on VSMC constriction could be achieved by both forward and reverse signaling, and 
EFNB2 is the main ligand mediating the two-way signaling, consistent with the fact that EFNB2 
is the major ligand for EPHB4(Cheng, Brantley, & Chen, 2002). This indicates that the effect 
of EFNB2 in VSMCs is opposite to that of EFNB1, and implies that EFNB2 deletion in VSMCs 
might also lead to hypotension. Further experimentation by our group has proved that this 
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prediction is generally correct (unpublished observation). The bi-directional vasoconstriction-
enhancing effect between EPHB4 and EFNB2 also implies that inhibiting EPHB4 kinase 
activity could achieve a blood pressure lowering effect. We have proved in principle in vitro 
that a Novartis EPHB4 kinase inhibitor NVP-BHG712 (Martiny-Baron et al., 2010; Wnuk et al., 
2012) could effectively reduce VSMC contractility. Although NVP-BHG712 was developed as 
an EPHB4 kinase inhibitor, it is not mono-specific, but inhibits the kinase activity of other 
members of EPH kinase family members as well (Martiny-Baron et al., 2010). Therefore, the 
effect we observed in VSMCs is likely the sum of the effects it has on all the EPH kinases, some 
of which may have opposite effects to EPHB4 in terms of modulating VSMC contractility. With 
that said, we noticed that NVP-BHG712 did not further reduce the EPHB4 KO VSMC 
contractility (data not shown), suggesting that the major effect of this inhibitor is via EPHB4. It 
is worth mentioning that EPHB4 plays a critical role in angiogenesis (Salvucci & Tosato, 2012), 
and thus is a potential drug target in tumor therapy. Many pharmaceutical and biotech companies 
have been developing EPHB4 inhibitors for such an application (Martiny-Baron et al., 2010; 
Wnuk et al., 2012). They will certainly benefit from our current findings by becoming aware of 
the blood pressure lowering potential of EPHB4 inhibitors as possible side effects.   
We noticed that in female KO mice, HR was significantly lower than their WT counterparts, 
although their BP was in the normal range. As BP is a tightly regulated event with multiple 
feedback regulations, it is not surprising that reduced HR does not translate into lower BP. The 
reason why HR is affected by SMC-specific EPHB4 deletion is not clear. One possible 
explanation is that there is leaky Cre expression in cells controlling the electric conductivity that 
dictates HR, or a leaky Cre expression in cardiomyocytes, which express quite a high level of 
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EPHB4 (unpublished observation); deletion of EPHB4 in these cells in turn affects the rhythm 
of their contractions. Further investigation of this aspect is warranted.   
 
We have established that EPHB4 deletion compromises the CamKII/MLCK/MLC signaling 
cascade in VSMCs, with increased CamKII phosphorylation as the most-upstream culpable 
event. Close to the cell membrane, we have identified GRIP1, which is known to associate with 
EFNB2, as an essential component in the reverse signaling of VSMCs with regard to 
contractility. GRIP1 knockdown resulted in reduced VSMC contractility in the presence of 
EFNB2 crosslinking. The molecular events between GRIP1 and CamKII will need to be further 
elucidated for a full characterization of the signaling pathway from EFNB2 to motor molecules 
(myosin). We previously identified GRIP1 as a key molecule mediating EFNB1 reverse 
signaling: its knockdown results in increased VSMC contractility after EFNB1 crosslinking. 
This indicates that the function of GRIP1 is versatile, depending on the EFNBs it associates 
with. Under a physiological condition, it probably functions as a node receiving opposite inputs 
from various EFNBs, and its final function is based on the sum of these positive and negative 
inputs, with regard to VSMC contractility, and consequently, BP.  
 
Our current findings have revealed the existence of a previously undocumented blood pressure 
lowering mechanism. Such new knowledge will lead to a better understanding of blood pressure 
regulation mechanisms. Moreover, as EPHB4 inhibitors are been developed as cancer drugs due 
to its anti-angiogenesis effect, our findings have raised a timely caution for this previously 
unknown effect on lowering blood pressure.   
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Figure legends 
 
Figure 1. Generation of mice with smooth muscle cell-specific Ephb4 null mutation 
A. Scheme of Ephb4 f/f mouse generation  
Bold lines represent the left and right arms of genomic sequences used in gene targeting. LoxP 
and FRT sites are represented by empty and gray small arrowheads respectively. The hatched 
box represents a genomic region from which probes were produced for Southern blot analysis. 
 
B. Southern blot analysis of tail DNA of floxed Ephb4 mice 
Tail DNA was digested with EcoRV/BclI, or BamHI/EcoRI, and hybridized with the 5’ probe 
or 3’ probe respectively. For the 5’ probe (upper panel), the 11.4-kb band was derived from the 
WT allele, and the 9.1-kb band, from the mutated allele. For the 3’ probe (lower panel), the 
12.6-kb band was derived from the WT allele, and the 7.0-kb band, from the mutated allele. 
 
C. Ephb4 mRNA deletion in mesenteric arteries of Ephb4 KO mice 
RNA was extracted from mesenteric arteries and spleens from WT and Ephb4 KO mice and 
analyzed by RT-qPCR for Ephb4 mRNA levels. β-actin mRNA levels were used as an internal 
control. Samples in RT-qPCR were in triplicate, and means + SE of Ephb4 signal/β-actin signal 
ratios are shown. The experiment was conducted twice; a representative one is shown. 
 
D. EPHB4 protein deletion in EPHB4 KO VSMCs according to immunoblotting 
VSMCs from Ephb4 KO and WT mice were cultured for 4 days and then harvested. Cell lysates 
were analyzed for EPHB4 protein expression by immunoblotting. Spleens from KO and WT 
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mice were used as controls for tissue specificity. The experiment was conducted twice; a 
representative one is shown. 
 
Figure 2. Male EPHB4 KO mice were hypotensive 
BP and HR were measured for 72 h by radiotelemetry, starting at least 7 days after 
radiotransmitter implantation. The number per group and the mean ages of the mice at the time 
of BP measurement are indicated. The BP and HR values are expressed as means ± SE of h 
daily BP and HR during 48 to 72-h periods. SP: systolic pressure; DP: diastolic pressure; MAP: 
mean arterial pressure; HR: heart rate. The statistical significance of differences between the 
hourly BP and HR of the experimental groups was evaluated by repeated-measures ANOVA, 
and p-values were indicated. The daily values were additionally analyzed by Student’s t test, 
and “*” indicates p-values <0.05, “**”, <0.01; “***”: <0.001.  
 
A. BP and HR of males 
B. BP and HR of females 
 
Figure 3.  Reduced contractility of mesenteric arteries from male EPHB4 KO mice 
Segments of the third-order branch of the mesenteric artery with (A and C) or without (B and 
D) endothelium were stimulated with PE. A single cumulative concentration-response curve to 
PE (1 nM to 100 µM) was obtained. Maximal tension (Emax) was determined by challenging 
the vessels with physiological saline containing 127 mM KCl. Vessel contractility is expressed 
as the percentage of Emax. Data from 2 mice (with 3 arterial segments tested for each mouse, 
i.e., 6 determinants per group) were pooled, and means + SE are reported. Contractility 
differences were analyzed by paired Student’s t tests and p-values are indicated. *: p<0.05. 
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A. Contractility of mesenteric arteries with endothelium from male KO and WT mice 
B. Contractility of mesenteric arteries without endothelium from male KO and WT mice 
C. Contractility of mesenteric arteries with endothelium from female KO and WT mice 
D. Contractility of mesenteric arteries without endothelium from female KO and WT mice 
 
Figure 4. VSMCs stimulated by both EPHB4 forward and reverse signalings show increased 
contractility 
VSMCs from male WT and KO mice were cultured for 4 days. In some experiments, the VSMCs 
were cultured in wells coated with EFNB2-Fc (2 μg/ml for coating), EPHB4-Fc (2 μg/ml for 
coating), or NHIgG (2 μg/ml for coating, as a control for EPHB4-Fc), as indicated. VSMCs 
were stimulated with 20 μM PE at 37℃ and imaged every min for 15 min. All experiments were 
conducted 3 times independently. Means + SE of percentage contraction of more than 15-30 
cells of a representative experiment are shown. The data at 10 min and 15 min of 3 independent 
experiments were summarized and expressed as bar graphs (mean + SE) at left. The data were 
analyzed by paired Student’s t tests (*: p<0.05).   
 
A. Increased contractility of VSMCs from male EPHB4 KO mice 
VSMCs were cultured in plain wells. 
 
B. Forward signaling through EPHB4 increases WT VSMC contractility 
WT VSMCs were cultured in wells coated with EFNB2-Fc. KO VSMCs in coated wells were 
used as a negative control. WT VSMCs cultured in wells coated with NHIgG were used as an 
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additional control, and their mean contractility is presented as a thin line without SE to facilitate 
viewing. 
 
C. EPHB4 inhibitor NVP-BHG712 reduces VSMC contractility 
WT VSMCs were cultured in plain wells in the presence of NVP-BHG712 (0.5 μM) for the last 
4 hours of culture. The controls were treated with vehicle (DSMO) at the same dilution and 
same duration.  
  
D. Reverse signaling triggered by EPHB4 increases WT VSMC contractility 
WT VSMCs were cultured in wells coated with EPHB4-Fc. In one of the groups, soluble 
EFNB2-Fc (2 μg/ml) was added to the culture to block the interaction between solid phase 
EPHB4-Fc and cell surface EFNB2. WT VSMCs cultured in wells coated with NHIgG were 
used as an additional control, and their mean contractility is presented as a thin line without SE 
to facilitate viewing. 
 
Figure 5. MLC, MLCK, MYPT and CamKII phosphorylation of VSMC from WT and KO mice  
VSMCs from male KO and WT mice were cultured for 4 days, and then stimulated with 20 μM 
PE for 3 s and immediately lyzed. Total and phosphorylated MLC, MLCK, and CamKII were 
analyzed by immunoblotting. Three independent experiments were conducted. Immunoblotting 
images from representative experiments are illustrated. The signal ratios of phosphorylated (P-) 
versus total (T-) MLC, MLCK, CamKII and MYPT were quantified by densitometry. 
Densitometry data from the 3 independent experiments were pooled and are presented as bar 
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graphs (mean + SE of relative intensity) in the panels at the left. Paired Student’s t tests were 
employed for statistical analysis. “*” indicates p<0.05.  
 
A. Decreased MLC phosphorylation in VSMC from EPHB4 KO mice  
B. Decreased MLC phosphorylation in VSMCs after EPHB4 inhibitor treatment 
WT VSMCs were cultured in the presence of NVP-BHG712 (0.5 μM) for the last 4 hours of 
culture. The controls were treated with vehicle (DSMO) at the same dilution and same duration.  
C. Increased MLCK phosphorylation in VSMC from EPHB4 KO mice 
D. Increased CamKII phosphorylation in VSMC from EPHB4 KO mice 
 
Figure 6. GRIP1 mediates EPHB4 reverse signaling in controlling VSMC contractility 
A. Effective mRNA knockdown of Disheveled, PDZ-Rgs3 and Grip1 by siRNA 
Cultured WT VSMCs were transfected with a mixture of 3 siRNAs of a particular gene or 
control siRNA, as indicated. After 24-h culture, the cells were harvested and the mRNA 
expression of each gene was determined by RT-qPCR in duplicate. The experiments were 
conducted twice, and the data (4 determinants for each group) were pooled and expressed as 
means + SE of the ratios of the target gene signal versus the β-actin signal. The data were 
analyzed with Student’s t tests. *: p<0.05. 
  
B. GRIP1 knockdown by siRNAs partially reverses the enhancing effect of solid-phase EPHB4-
Fc in VSMC contractility 
VSMCs from WT males were cultured in wells coated with recombinant EPHB4-Fc (2 μg/ml 
during coating). After 2 days, they were transfected with siRNAs targeting Disheveled, PDZ-
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Rgs3 or Grip1 mRNA, or with control siRNA. On day 4 of culture, they were stimulated with 
PE (20 μM), and their percentage contraction was recorded. Means + SE of percentages are 
reported. The thin lines represent the mean percentage contraction of VSMCs cultured in wells 
coated with NHIgG (2 μg/ml) without siRNA transfection (for a better visual effect, the SE of 
each time point in this control is omitted). All experiments were conducted 3 times 
independently. Means + SE of percentage contraction of more than 15-30 cells of a 
representative experiment are shown. The data at 10 min and 15 min of the 3 independent 
experiments were summarized and expressed as a bar graph (mean + SE) at left. The data were 
analyzed by paired Student’s t tests (*: p<0.05).   
  
C. Decreased CamKII phosphorylation in VSMC after GRIP1 knockdown  
VSMCs from WT males were cultured in wells coated with recombinant EPHB4-Fc (2 μg/ml 
during coating) or NHIgG (2 μg/ml during coating). After 2 days, they were transfected with 
Grip1 siRNA or control siRNA. On day 4 of culture, they were stimulated with PE (20 μM) for 
3 s, and lyzed for immunoblotting. Phosphorylated CamKII and β-actin were analyzed by 
immunoblotting. The signal ratios of phospho-CamKII versus β-actin were quantified by 
densitometry. Densitometry data from two independent experiments were pooled and presented 
as a bar graph at left. Paired Student’s t tests were employed to examine statistical significant 
differences. “*” indicates p<0.05. 
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Tables 
Table 1  
qPCR primer sequences 
qPCR primer sequences 
Gene Sense sequence antisense sequence PCR 
Product 
β-actin 5’TCGTACCACAGGCATTGTGATGGA-
3’ 
5’-
TGATGTCACGCACGATTTCCCTCT-
3’ 
200bp 
Ephb4 5’- CTACGTCTCTAACCTCCCATCT-3’ 5’- GCTGGTCACCCTTTCTCTTT-3’ 100bp 
Disheveled 5’-
TCTCGGCTAGTTCGGGAAGCACAAA-
3’ 
5’-
TGATGTTCAGGGACATGGTGGAGT-
3’ 
112bp 
Grip1 5’-
ACAAGTCCCGTCCGGTTGTGATAA-3’ 
5’TCTATCAGCAGCGTGGCTTCTTGT
-3’ 
181bp 
PDZ-Rgs3 5’-
TGGCAACAGGAGGAACAGTCCTAT-
3’ 
5’-
ATGTCTTCCAGCAGGAATGGGTCA-
3’ 
170bp 
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Abstract 
Ephrin B2 (EFNB2) is a ligand for erythropoietin-producing hepatocellular kinases (EPH), a 
family of receptor tyrosine kinases. It has critical functions in many biological systems, but is 
not known to regulate blood pressure. We generated mice with smooth muscle cell-specific 
deletion of EFNB2 and investigated its roles in blood pressure regulation and vascular smooth 
muscle cell (VSMC) contractility. Male EFNB2 knockout (KO) mice presented reduced blood 
pressure, while female KO mice had no consistent blood pressure phenotype. Both forward 
signaling from EFNB2 to EPHs and reverse signaling from EPHs to EFNB2 were involved in 
regulating VSMC contractility, with EPHB4 as a critical molecule for forward signaling, based 
on crosslinking studies. We also found that a region from aa 313 to aa 331 in the intracellular 
tail of EFNB2 was essential for reverse signaling regulating VSMC contractility, based on 
deletion mutation studies. In human genetic study, we identified 6 SNPs in the EFNB2 gene to 
significantly associate with hypertension risk in a sex-dependent way, consistent with our 
findings in mice. We have thus discovered a previously unknown blood pressure-lowering 
mechanism mediated by EFNB2 and identified it as a gene associated with hypertension risk in 
humans. 
 
Key words: ephrinB2, blood pressure, vascular smooth muscle cells, sex hormone, single 
nucleotide polymorphism 
 
 
 
 
 104 
 
Introduction 
Erythropoietin-producing hepatocellular kinases (EPH) are the largest family of receptor 
tyrosine kinases. Based on sequence homology, they are divided into A and B 
subfamilies("Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph 
Nomenclature Committee," 1997). Their ligands, called ephrins (EFNs), are also cell surface 
molecules(Pasquale, 2008). EFNs are also divided into A and B subfamilies, based upon the 
way they anchor on the cell surface: the A subfamily anchors on the cell surface through 
glycophosphatidylinositol, and the B subfamily, through a transmembrane domain (Pasquale, 
2008). The interactions between EPH kinases and EFNs are promiscuous, but EPHA kinases 
preferably interact with EFNA ligands, and EPHB kinases with EFNB ligands, which have 3 
members, EFNB1, EFNB2 and EFNB3(Pasquale, 2008). Although EPH members and EFN 
members share homology with their respective members, each member has its distinct function 
in different cellular processes (Batlle et al., 2002; Hongyu Luo et al., 2016; Konstantinova et al., 
2007; H. Luo, Yu, Tremblay, & Wu, 2004; Salvucci, de la Luz Sierra, Martina, McCormick, & 
Tosato, 2006).  In general, the EPH kinases interact with their EFN ligands on neighboring cells, 
because EPHs and EFNs are all cell surface molecules(Pasquale, 2008). These molecules could 
be cleaved from the cell surface by enzymes such as ADAM10 (Kaushal & Shah, 2000; 
Primakoff & Myles, 2000), an unspecified matrix metalloproteinase(Georgakopoulos et al., 
2006), or γ-secretase(Tomita, Tanaka, Morohashi, & Iwatsubo, 2006); therefore, it is possible 
that the shed soluble fragments of EPH and EFN might be able to influence cells and tissues at 
a distance by blocking the interaction of EPHs and EFNs there. 
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EPH kinases and EFNs are expressed in a wide range of tissues and cells, and play vital roles in 
the development and function of different organs and systems(Batlle et al., 2002; Dumas et al., 
2000; H. Luo, Charpentier, et al., 2011; H. Luo, Wan, Wu, & Wu, 2001; H. Luo, Wu, et al., 
2011; H. Luo et al., 2004; Hongyu Luo, Yu, Wu, & Wu, 2002; J. Wu & Luo, 2005; Xin, Deng, 
Rishniw, Ji, & Kotlikoff, 2002; Yu, Luo, Wu, & Wu, 2003a, 2003b, 2004; Yu, Mao, Wu, Luo, 
& Wu, 2006). They are also vital in many biological processes(Dravis et al., 2007; Hashimoto 
et al., 2007; Konstantinova et al., 2007; Salvucci et al., 2006); however, until our recent 
publications, there were no studies investigating the roles of these molecules in blood pressure 
(BP) regulation.  
 
Recently, we reported novel observations that deletion of EFNB1 and its receptor EPHB6 leads 
to increased BP(H. Luo et al., 2012; Z. Wu et al., 2012). In an additional study, we demonstrated 
that EPHB4 deletion leads to reduced BP(Wang et al., 2015). As EFNB2 is the preferred ligand 
of EPHB4, we thus asked the question whether its deletion in vascular smooth muscle cells 
(VSMCs) will have a similar BP reduction effect. The results of our investigation are reported 
here.  
 
Materials and Methods 
Generation of smooth muscle cell-specific Efnb2 and Ephb4 gene knock-out (KO) mice We have 
previously reported on the generation of Efnb2 floxed mice(H. Luo, Charpentier, et al., 2011). 
They were backcrossed with C57BL/6J for 10 generations and then mated with smooth muscle 
myosin heavy chain promoter-driven Cre transgenic mice (smMHC-Cre-IRES-eGFP) in the 
C57BL/6J background(Xin et al., 2002) to obtain smooth muscle cell-specific Efnb2 gene KO 
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mice. The ages of the KO and WT mice for the in vivo study were described in given experiments. 
Cells from mice at 3 to 6 months of age were used for in vitro studies. 
 
In some experiments, VSMCs from smooth muscle-specific Ephb4 gene KO mice were used. 
The generation and characterization of these mice are described in our recent publication(Wang 
et al., 2015). 
 
Reverse transcription/quantitative-PCR (RT/qPCR), immunofluorescence microscopy, BP 
measurement by radiotelemetry, VSMC isolation, measurement of VSMC contractility, Ca++ 
flux measurement, lentivirus preparation and infection These methods and primers used are 
described in Supplementary Materials and Supplementary Table 1. 
 
Patients for the human genetic study The patient cohort consisted of 3409 European, Australian, 
Canadian and New Zealander Caucasians (See supplementary Table 2) who had been 
ascertained to be suffering from type 2 diabetes and at high risk for macrovascular or 
microvascular diabetes complications and who were recruited for the ADVANCE (Action in 
Diabetes and Vascular Disease: Peterax and Diamicron-MR Controlled Evaluation) clinical 
study, a factorial, multi-center, randomized controlled clinical trial of 11,140 participants 
recruited from 215 centers in 20 countries("ADVANCE trial / Action in Diabetes and Vascular 
disease: PreterAx and Diamicron MR Controlled Evaluation.  Available at: www.advance-
trial.com. Accessed Nov, 2014," ; Colagiuri, 2008). All individuals were type 2 diabetes subjects 
age 65 or older, or they were type 2 diabetes subjects age 55 or older who were diagnosed at 
age 30 or older, and had one of the following: a history of major macrovascular disease; a history 
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of major microvascular disease; diagnosis of type 2 diabetes over 10 years prior to entry into 
study; presence of another major risk factor for vascular disease including: smoking, 
dyslipidemia, microalbuminuria. 
                                                                                                                                                    
The 3409 patients were qualitatively classified as normotensive or hypertensive, which was 
defined  as being currently treated for hypertension at baseline or having a measurement of 
systolic pressure > 140 mm Hg or diastolic pressure > 90 mm Hg at entry into the study. The 
cohort included 1,789 hypertensive and 417 normotensive males, and 996 hypertensive and 206 
normotensive females. There were 4.5 times as many hypertensive as normotensive diabetic 
subjects and 1.8 times as many males as females. 
  
Genotyping The 3409 individuals were genotyped for either 440,794 SNPs on the Affymetrix 
Genome-Wide Human SNP Arrays 5.0 or 906,600 SNPs on the 6.0 Array at the genomic 
platform of the CHUM Research Center. An additional 4,547,420 SNPs were imputed for array 
5.0 and 4,768,948 for array 6.0 independently using the program IMPUTE2(Marchini & Howie, 
2010) and SHAPEIT for prephasing haplotypes31.  
Association analysis Association analysis was performed separately for the array 5.0 and array 
6.0 data sets using the PLINK program(Purcell et al., 2007).  The final p-values for the combined 
sample over both arrays were then determined using meta-analysis of the 5,045,528 SNPs 
common to both arrays using the meta-analysis subroutine of PLINK with a fixed effects model.  
This method corrected for any possible effect of cases and controls not being randomly 
distributed across the different genotype arrays. A subset (147,088) of the genotyped SNPs that 
were in Linkage equilibrium (defined as r2 ≤ 0.8) was selected to perform a principal component 
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analysis, using the Eigenstrat software(Price et al., 2006) in order to test for population 
stratification within the European and Canadian Caucasian samples. The first two independent 
principal components from this analysis (PC1 and PC2), which account for the majority of the 
covariance among genotypes due to population structure, were able to clearly separate samples 
according to geographic origin (ancestral regions of origin for Canadian, New Zealand and 
Australian samples) and were subsequently used as covariates in the association analysis in 
order to correct for population stratification. The association with hypertension was tested for 
61 SNPs both genotyped and imputed, that were common to both the Array 5 and 6 sub analysis, 
and that fell within EFNB2 or within an additional region 10 kb 5’ and 3’ of the gene and located 
within a 63.73 kb region between positions 107,133,382 and 107,197,119 on chromosome 13 
(Build 37, hg/19). Only SNPs or markers with a minor allele frequency (MAF) greater or equal 
to 0.05 and imputed SNPs with imputation quality scores greater than 0.8 were analyzed. Even 
though there were allele frequency differences noted between eastern and western European 
samples, this MAF filter was applied after genotyping across-the-board calculated over all 
samples as association analysis has very little power for SNPs with a minor allele frequency 
below 0.05. 
Association testing was performed for males and females separately. A logistic regression model 
with additive genotype coding and with principal components, PC1 and PC2 from the 
stratification analysis, and with age, and body mass index as covariates was used to perform 
association tests. 
  
Significance of associations The number of tagging SNPs that proxy for all 61 markers tested 
for association within the gene region was determined using the LDSELECT 
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program("LDSelect-Multipopulation: Download and Documentation. Available at: 
http://droog.gs.washington.edu/multiPopTagSelect.html. Accessed Nov, 2014,") using an r2 
value > 0.8 and a minimum minor allele frequency of 0.05. Fifteen tag SNPs were identified 
and were considered to represent 15 independent linkage disequilibrium (LD) blocks within the 
region around EFNB2 covered by the analyzed SNPs; subsequently, all p-values were corrected 
for multiple testing by the Bonferroni correction for 15 independent LD blocks and 2 sexes = 
30 independent tests, giving a critical p-value of 0.00167 or a critical -log10 p-value of 2.778.  
Power calculation A power calculation was conducted for the female samples using the CaTS 
power calculator(Skol, Scott, Abecasis, & Boehnke, 2006).  
Results 
Smooth muscle cell-specific deletion of EFNB2 in mice The floxed Efnb2 mice (H. Luo, 
Charpentier, et al., 2011) in the C57BL/6J background were crossed with transgenic mice 
expressing smooth muscle myosin heavy chain promoter-driven Cre recombinase (also in the 
C57BL/6J background (Xin et al., 2002)  to achieve smooth muscle cell-specific deletion of 
EFNB2. The deletion of Efnb2 at the mRNA level in vascular smooth muscles, but not in the 
spleen, heart, brain or liver, was confirmed by RT-qPCR (Fig. 1A and Supplementary Figure 1 
(S. Fig. 1)). The deletion EFNB2 at the protein level in VSMCs was further confirmed by 
immunofluorescence (Fig. 1B) and immunoblotting (Fig. 1C). These mice with smooth muscle 
cell-specific deletion of EFNB2 were called KO mice. There was no compensative upregulation 
of other EPHB and EFNB subfamily members in VSMCs after EFNB2 deletion (S. Fig. 2). The 
small artery structure of the KO mice was comparable to that of the wild type (WT) mice in 
terms of media thickness and lumen sizes (S. Fig. 3). The KO and WT VSMCs had similar 
 110 
 
proliferative rates in vitro culture (S. Fig. 4), and had similar levels of α-actin expression, a 
smooth muscle cell marker (S. Fig. 5). Although EFNB2 deletion was achieved by smooth 
muscle myosin heavy chain promoter-driven Cre, and is not specific to SMC in the vascular 
system, we did not notice gross morphological and functional abnormalities in the digestive 
system, respiratory system and reproductive system in the KO mice. 
 
BP phenotype of EFNB2 KO mice The BP of KO and WT mice was recorded every 2 min for a 
period of 72 h. All the time points in each day were analyzed with a mixed-effects linear model, 
using genotype and time as qualitative factors (SPSS Statistics 19), and the  mean + SEM of the 
daily values are presented in Figure 1. Male EFNB2 KO mice presented significantly reduced 
BP for all the parameters registered (i.e., systolic, diastolic, and mean arterial pressure) in all 
the 3 days, compared to their WT counterparts (Fig. 2A). Female KO mice had no consistent 
change in BP. On day 1, the KO mice had lower systolic pressure and mean arterial pressure, 
but on day 2, their diastolic pressure was actually higher than that of the WT counterparts (Fig. 
2B).Values of each parameter for different days for the males and females are presented in S. 
Figure 6 to give a different perspective.  
 
Both forward and reverse signaling between EFNB2 and its receptors are responsible for 
regulating VSMC contractility EFNB2 and its receptors (mainly EPHB subfamily kinases) are 
all expressed in VSMCs (S. Fig. 2) 25, providing a molecular basis for their bi-directional 
signaling, i.e. from EFNB2 to EPHBs: forward signaling; from EPHBs to EFNB2: reverse 
signaling. We investigated which direction was functional in regulating VSMC contractility. 
We demonstrated that when WT VSMCs were cultured in wells coated with recombinant 
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EFNB2-Fc tagged with human IgG Fc (EFNB2-Fc), which could crosslink EPHBs and initiate 
forward signaling, they manifested significantly augmented contractility upon phenylephrine 
stimulation, compared to the VSMCs cultured on wells coated with normal human IgG, which 
was employed as a control (Fig. 3A). The augmentation could be neutralized by soluble EPHB4-
Fc, which is a preferred receptor of EFNB2, suggesting that among different EPHB subfamily 
members, EPHB4 largely mediates forward signaling to achieve increased VSMC contractility. 
To further prove the essential role of EPHB4 in forward signaling and VSMC contractility, we 
cultured VSMCs from smooth muscle cell-specific EPHB4 KO mice (Wang et al., 2015) on 
EFNB2-Fc coated wells. As shown in Figure 3B, solid-phase EFNB2-Fc could no longer 
enhance contractility of EPHB4-deleted VSMCs, again indicating that solid phase EFNB2’s 
effect on VSMC contractility is largely via EPHB4. To assess whether reverse signaling from 
EPHBs to EFNB2 also played a role in VSMC contractility, we cultured WT VSMCs on wells 
coated with anti-EFNB2 Ab to crosslink EFNB2, mimicking the EPHB binding. Such 
crosslinking could significantly increase VSMC contractility upon phenylephrine-stimulation 
(Fig. 3C). Moreover, the augmentation could be neutralized by soluble EFNB2-Fc, confirming 
the specificity of anti-EFNB2 Ab. Thus, we have demonstrated that both forward signaling from 
EFNB2 to EPHB4 and reverse signaling from EPHBs to EFNB2 could enhance VSMC 
contractility. 
 
To identify the EFNB2 intracellular sequence critical for controlling the VSMC contractility 
during reverse signaling EFNB2 has a short intracellular tail (73 aa), which has no enzymatic 
activity. EFNB2 reverse signaling depends on the association of its intracellular tail with adaptor 
proteins, which in turn link to various signaling pathways. We conducted step-wise deletion of 
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the EFNB2 intracellular tail from the C-terminus (illustrated in Fig. 4A) and used lentiviruses 
to overexpress these deletion mutants in VSMCs from mice with smooth muscle cell-specific 
EFNB2 deletion. The infected VSMCs were then cultured in wells coated with anti-EFNB2 Ab. 
In this system, the absence of endogenous EFNB2 in VSMCs reduced constitutive reverse 
signaling from EPHB to EFNB2 occurring among neighboring cells, hence reducing the 
background noise. The overexpression of the exogenous full-length EFNB2 and its deletion 
mutants were confirmed by RT-qPCR (Fig. 4B). The titers of the lentivirus were adjusted such 
that the deletion mutant mRNA expression was at least the same or less than 15% higher than 
the full-length Efnb2 mRNA. Overexpression of full-length EFNB2 (336 aa long with 73 aa in 
the intracellular tail) in EFNB2 KO VSMCs significantly augmented their contractility upon 
PE-stimulation (Fig. 4C). The deletion of the last 5 aa in EFNB2 intracellular C-terminus 
(EFNB2-Δ2Y), which removed the PDZ domain-binding motif plus the last two of the total 5 
conserved tyrosine residues (Y333 and Y334), did not reduce VSMC contractility compared to 
the full-length EFNB2 (Fig. 4D). However, an additional deletion of 19 aa, which contains two 
additional tyrosine residues at Y314 and Y319 (EFNB2-Δ4Y), caused a drastic drop of VSMC 
contractility, which was reduced to the level of control virus-infected VSMCs (Fig. 4E). Further 
deletion of 7 aa, which contains the 5th conserved tyrosine residue Y307 (EFNB2-Δ5Y), did 
not cause more changes compared to EFNB2-Δ4Y (Figure 4F). These data suggest that the 
EFNB2 intracellular sequence between aa 313 and aa 331 containing Y314 and Y319 harbors a 
critical element(s) that could associate with other signaling proteins and regulate VSMC 
contractility. 
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Contractility-related signaling events in EFNB2 KO VSMCs We assessed several key signaling 
events in EFNB2 KO VSMC to further understand the cause of the reduced contractility of these 
cells. VSMCs from male and female KO mice showed mRNA levels of ɑ1-adrenoreceptor 
expression comparable to those from WT counterparts (S. Fig. 7A). VSMCs from male KO 
mice had comparable phenylephrine-stimulated Ca2+ influx to VSMCs from WT mice (S. Fig. 
7B). Crosslinking EFNB2 with solid-phase anti-EFNB2 Ab, which enhanced WT VSMC 
contractility, did not change phenylephrine-triggered Ca2+ flux in VSMCs from male mice (S. 
Fig. 7C). This indicates that EFNB2 does not affect Ca2+ flux in VSMCs. 
 
The reduced contractility could then be caused by the sensitivity of KO VSMCs to intracellular 
Ca2+. We investigated this possibility by examining KO VSMC myosin light chain 
phosphorylation, which is known to increase the Ca2+ sensitivity. Indeed, when stimulated with 
phenylephrine, VSMCs from male but not female KO mice manifested significantly lower 
myosin light chain (MLC) phosphorylation at ser19 (S. Fig. 7D), consistent with reduced BP in 
male but not female KO mice (Figs 2A and 2B). Myosin light chain is dephosphorylated by 
myosin phosphatase. Phosphorylation of myosin phosphatase target protein-1 (thr696), a 
process that decreases myosin light chain phosphatase activity (Ramachandran, Patil, Combrink, 
Sharif, & Srinivas, 2011), was not influenced by EFNB2 deletion (S. Fig. 7E). ERK activation 
can enhance smooth muscle activation through several proposed modes of action: 1) it might 
activate MLC kinase through a so-far un-delineated pathway (Klemke et al., 1997; Roberts, 
2004) or 2) it might phosphorylate the actin-binding protein, caldesmon, which removes 
caldesmon’s inhibitory effect on smooth muscle contraction(Hedges et al., 2000) . In both male 
and female KO VSMCs, ERK phosphorylation, a surrogate marker of ERK activation, was 
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significantly reduced upon phenylephrine stimulation (S. Fig. 7F), implicating ERK as a link in 
EFNB2 deletion-caused hypocontractility of VSMCs. The lack of sex difference in ERK 
phosphorylation suggests that although it might contribute to reduce VSMC contractility in KO 
mice, it is not responsible for the observed sex difference.  
 
Association of EFNB2 with hypertension in males in diabetic individuals We tested the 
association of 61 DNA markers falling within the EFNB2 gene or within additional 
approximately 10 kb 5’ and 10 kb 3’ of the gene (located within a 63.74-kb region between 
positions 107,133,382 and 107,197,119 on chromosome 13 (Build 37/hg19) with hypertension 
in a type 2 diabetes patient cohort; males and females were tested separately. Two  SNPs were 
found to be significantly associated with hypertension for the male-only samples (Table 1, and 
S. Fig. 8A) using a Bonferroni-corrected critical p-value of 0.00167 for 30 independent tests, 
corresponding to 15 independent (r2 ≤ 0.80) LD blocks within the region and the 2 sexes tested. 
No SNP was nominally significant for the female-only sample (Table 1 and S. Fig. 8B). A power 
calculation(Skol et al., 2006) for 1000 cases and 210 controls (our sample had 996 female 
hypertensives and 206 normotensives) using a prevalence of 0.83 for hypertensives (prevalence 
among our diabetic subjects) a major allele frequency of 0.646 and a bonferroni critical p-value 
of 0.0017 determined that the female sample had 95% power to detect a genotype relative risk 
of 1. Although this is a small dataset to have full power at a genome-wide association study 
(GWAS), it is sufficient to detect association at the level of multiple testing that we are using. 
The fact that the female sample is not significant for any SNPs is a reflection of the lack of any 
genetic association not lack of power. The odds ratios in females were 1.001 and 1.01 for the 
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two significant SNPs in males which have odds ratios of 1.3 for the major alleles, indicating that 
EFNB2 is associated with hypertension only in males. 
 
  
The locations of the 2 significant SNPs (encircled) with respect to the LD structure around the 
3’ end of the EFNB2 gene are shown in S. Figure 8C. These SNPs fall just downstream (within 
1 kb) of the 3’ untranslated region (UTR) of the gene but within an LD block that covers the 
region just 3’ of the gene but also the 3’ untranslated region (3’UTR) the gene. The two 
significant SNPs are in very high LD in our sample ( r2 = 0.977). These SNPs may well be in 
LD with a functional polymorphism which may reside within the 3’ UTR region of the gene. 
 
The case/control distributions for male and females of the A and G alleles for SNP rs7329357, 
the most significantly associated SNP, within the male sample are presented as an example in 
Table 2 along with the odds ratios (ORs) of their case-control distributions and the 95% 
confidence intervals for these ORs. Since the other significant SNP rs7328882 is in very high 
LD with rs7329357, the results are similar.  The results of chi-square tests of independence 
between major and minor allele distributions and sexes for cases and controls are presented in 
Table 3.  The frequencies of the minor A allele in male and female cases are similar and not 
statistically significant (0.343 and 0.349 respectively); however, the frequency of the A allele is 
significantly higher among male controls (0.473) than among female controls (0.352) (p = 
0.000045), suggesting that the minor A allele is protective against hypertension in the presence 
of diabetes, but only in males.   
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Discussion 
BP is a vital physiological parameter and is highly regulated with multiple compensatory 
mechanisms including blood volume, cardiac output and/or vascular tone regulation to maintain 
it within a normal range. EFNB2 deletion in VSMCs likely leads to a default phenotype of 
reduced VSMC contractility, and consequently reduced BP. However, this phenotype is 
pronounced in males but not in female due to one or more of the above-mentioned compensatory 
mechanisms, which in this case seemed to be additionally influenced by sex hormones. These 
sex hormone-dependent compensation mechanisms likely have masked the default lower blood 
pressure in female KO mice. The nature of the sex hormone-dependent compensation remains 
to be investigated.  
 
Nakayama et al. reported that smooth muscle-specific deletion of EFNB2 using SM22Δ-Cre 
results in lower body weight, reduced VSMC proliferation, thinner arterial vessel wall and 
enlarged arterial diameter40. However, none of these phenotypes was observed in our KO mice, 
in which EFNB2 was deleted using smMHC-Cre. There could be several possible explanations 
for these discrepancies. 1) The mouse genetic background might heavily influence these 
phenotypes: Nakayama’s mice are in a 129sv X C57BL/6J mixed background, while ours are in 
a pure C57BL/6J background. 2) Different smooth muscle-specific promoters might result in 
different degrees of EFNB2 deletion in target organs/tissues and of leaky deletion in untargeted 
organs/tissues. 3) Cell proliferation was assessed at different time points (postnatal day 8 in 
Nakayama’s study versus adult in our study). While Nakayama’s study focuses on EFNB2’s 
role in PGDFRβ signaling in VSMCs related to their proliferation, we are focusing on VSMCs’ 
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functionality and their signaling during contractile stimulation. Naturally, these two aspects 
have different time windows. Nevertheless, these two studies agree that EFNB2 plays a critical 
role in VSMC biology, which has not been previously appreciated.  
 
EFNB2 can transduce signals in both forward and reverse directions. We have demonstrated 
that both directions are involved in VSMC contractility. EPHB4 is the preferred EPH, with 
which EFNB2 could associate. We have proved in vitro that only WT, but not EPHB4 KO 
VSMCs, could respond to EFNB2 stimulation and augment contractility (Fig. 3B), indicating 
that the predominant effect of EFNB2 forward signaling with regard to enhancing VSMC 
contractility was mediated by EPHB4. If this is the case, then smooth muscle cell-specific 
deletion of EPHB4 should have a similar BP phenotype to that seen in the EFNB2 KO mice. 
Indeed, our recent report reveals that EPHB4 KO mice present sex-dependent hypotension, with 
male KO being hypotensive while female KO being normotensive (Wang et al., 2015), 
corroborating our results from EFNB2 KO mice. 
 
EFNB2 has a short intracellular tail (73 aa), which has no enzymatic activity. Its reverse 
signaling depends on adaptor proteins associating with the tail. EFNB2 intracellular tails are 
characterized by 2 major features: the C-terminal PDZ domain-binding motif and 5 conserved 
tyrosine residues, which could be associated with PDZ-domain-containing proteins (e.g., PDZ-
RGS3, GRIP1/2, TIAM1 and DISHEVELED) (Bruckner, Pasquale, & Klein, 1997; Cowan & 
Henkemeyer, 2001; H. Luo et al., 2004; Hongyu Luo et al., 2002; Yu et al., 2004), and SH2-
domain-containing proteins (e.g. GRB4, STAT3 and CRK(Arvanitis & Davy, 2008), 
respectively. These 2 features are located in the last 31 aa, which are highly conserved. EFNB 
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can also have PDZ- and SH2-independent functions (Lu, Sun, Klein, & Flanagan, 2001), some 
of which presumably depend on the SH3 domain of associating proteins (e.g., CRK and GRB4). 
By deleting different lengths of the EFNB2 intracellular tail, we found that the C-terminal PDZ-
domain binding motif and the last 2 tyrosine residues were dispensable for EFNB2 reverse 
signaling with regard to VSMC contractility, but a 19-aa long region (i.e., from aa 313 to aa 331) 
containing the 3rd and 4th conserved tyrosine residues (counting from the C-terminus) was 
critical. The 2 tyrosine residues (Y314 and Y319) in this region are good candidates responsible 
for reverse signaling as they could interact with SH2 domain-containing adaptor proteins 
mentioned above, although S328 should also be considered, as it may attract SH3 domain-
containing adaptor proteins. It is possible that the molecules associating with these residues are 
connected to the VSMC contraction machinery, and the function of these associating molecules 
is differentially affected by sex hormones in the absence or presence of EFNB2. A search of the 
associated proteins that mediate the effect of EFNB2 and a study of how their effects are 
influenced by sex hormones with regard to VSMC contractility are warranted.  
 
Our human genetic study revealed that 2 SNPs that are in high LD with each other and with the 
3, untranslated region of EFNB2 were associated with hypertension risk at a p-value below the 
Bonferroni-corrected p ≤ 0.00167 in the males-only sample. The minor alleles of each of the 2 
SNPs were negatively associated with hypertension risk (i.e., protective against hypertension) 
in male human subjects, while the major (more frequent) alleles were associated with increased 
hypertension risk. This supports our finding in mice that the lower BP phenotype was 
pronounced in males but female KO mice. The occurrence of a loss-of-function mutation in the 
EFNB2 gene, in LD with the minor alleles of the 2 associated SNPs, could result in reduced risk 
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of hypertension which is not inconsistent with the effect of EFNB2 deletion in mice. However, 
it must be emphasized that human gene mutation is not equivalent to mouse EFNB2 deletion, 
which invariably leads to loss of function, whereas a mutation could either lead to a loss- or 
gain-of-EFNB2-function. A gain-of-function of mutation in human males could explain the 
association of increased hypertension risks with EFNB2 mutations of the major allele.  
 
Our mouse study showed that in females, EFNB2 null-mutation did not lead to apparent 
hypotension. Therefore, EFNB2 gene mutation in female humans should not impact on BP, if 
our mouse study is of any guidance. Indeed, we observed no association with hypertension in 
females in this study. The mechanisms responsible for the influence of sex hormones regulate 
blood pressure jointly with EFNB2 are currently under investigation. 
 
Since male but not female EFNB2 KO mice had lower BP, this logically suggests that either 
testosterone is inductive to the lower BP when EFNB2 is absent, or that  EFNB2 deletion has a 
default effect lowering BP with estrogen counteracting this effect. With this conceptual frame 
work, we attempt to explain the detection of association of EFNB2 SNPs with hypertension in 
males in the ADVANCE genetic study, in which all the cases and controls are type 2 diabetics. 
 
The minimal age of male patients in the ADVANCE study was 55-years. Plasma total 
testosterone levels range from 270 to 1,070 ng/dL in “normal” males. Considering 346 ng/dL as 
a cut-off for the diagnosis of hypogonadism, as recommended by the International Society for 
the Study of the Aging Male, about 30% of men older than 40 years are hypogonadic (Traish, 
Miner, Morgentaler, & Zitzmann, 2011) . Further, male patients with the metabolic syndrome 
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are prone to hypogonadism(Zitzmann, 2009). Therefore, it is conceivable that more than 30% 
of the male patients in the ADVANCE study suffer from hypogonadism.  
 
Further, the type 2 diabetes males are generally overweight or obese. Adipose tissues are rich in 
aromatase, a rate-limiting enzyme converting testosterone to estrogen(Nelson & Bulun, 2001). 
Hence, overweight/obese males tend to have relatively higher estrogen levels locally in the 
perivascular adipose tissues or systemically.  
 
The above-described special changes of sex hormone levels in the ADVANCE males might 
make them a unique subpopulation in which the association between EFNB2 mutations and 
hypertension risks becomes easier to detect, compared to the general population. 
We queried the International Consortium for Blood Pressure (ICBP) dataset(International 
Consortium for Blood Pressure Genome-Wide Association et al., 2011), but no significant 
association of EFNB2 SNPs with BP was found. We should point out the differences in the two 
studies. The IBPC sample specifically excluded, cohorts of diabetic cases, hypertensive cases, 
and myocardial infarction cases, which is specifically the type of samples we analyzed. They 
analyzed general population samples that had incidentally been measured for systolic pressure 
(SP) and diastolic pressure (DP), and performed a quantitative analysis against DP and SP values. 
The advantage of their approach is that it allows the assembly of very large sample sizes to 
increase power; however, it also might introduce significant heterogeneity into their sample 
decreasing genotype relative risks. We used a qualitative phenotype that defined cases and 
controls for hypertension. Also, multiple BP measurements were carefully made over multiple 
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time points in the course of the ADVANCE study, and only consistently high readings were 
included as cases.  
 
The two associated SNPs are in LD with each other and are located within a large LD block that 
includes the 3` UTR region of EFNB2 and could reflect the presence a polymorphism within the 
3’ untranslated region (3’ UTR) of the gene.  3’UTRs of various genes are known to contain 
regulatory elements that can control rates of translation and mRNA stability by serving as 
binding sites for various proteins or miRNAs. Many 3'-UTRs contain AU-rich elements which 
affect the stability or decay rate of transcripts in a localized manner or affect translation initiation. 
Also the 3'-UTR contains the sequence AAUAAA that directs addition of the poly-A tail which 
is involved in mRNA stability. By binding to specific sites within the 3'-UTR, miRNAs can 
decrease gene expression of various mRNAs by either inhibiting translation or directly causing 
degradation of the transcript. Discovery of the exact location and mechanism of the associated 
polymorphism would require further extensive functional research. 
 
This study and our most recent publication show that the deletion of either of the receptor 
EPHB4 or its major ligand EFNB2 leads to a similar hypotensive phenotype in mice(Wang et 
al., 2015), corroborating the results of our human genetics study. Collectively, these novel 
findings reveal a previously unknown EPH/EFN-based mechanism for blood pressure 
regulation. 
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 Titles and Legends of Figures 
 
Figure 1. Generation of mice with smooth muscle cell-specific Efnb2 null mutation 
A. Efnb2 mRNA deletion in mesenteric arteries of EFNB2 KO mice RNA was extracted from 
the mesenteric arteries and spleens from WT and EFNB2 KO mice and analyzed by RT-qPCR 
for Efnb2 mRNA levels. β-actin mRNA levels were used as an internal control. Samples were 
in triplicate, and means + SEM of Efnb2 signal/β-actin signal ratios are shown. 
B. EFNB2 protein deletion in EFNB2 KO VSMCs according to immunofluorescence microscopy 
VSMCs from EFNB2 KO and WT mice were isolated from mesenteric arteries, and their 
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EFNB2 (red, lower row) and α-actin (green, upper row) expression was detected by 
immunofluorescence microscopy. 
C. EFNB2 protein deletion in EFNB2 KO VSMCs according to immunoblotting VSMCs from 
EFNB2 KO and WT mice were cultured for 4 days and then harvested. Cell lysates were 
analyzed for EFNB2 protein expression by immunoblotting. 
The experiments in this figure were conducted three times; representative experiments are 
shown. 
 
Figure 2. BP and heart rate of EFNB2 KO mice 
The BP and heart rate were measured every 2 min by telemetry for 72-h. The mean + SEM of 
daily BP and heart rate are shown. Parameters of all the time points in each 24-h period were 
evaluated by a mixed-effects linear model, with genotype and time as qualitative factors. P-
values are indicated: * p<0.05; ** p < 0.01. SP: systolic pressure; DP: diastolic pressure; MAP: 
mean arterial pressure; HR: heart rate. The average age of mice of each group at the time of 
telemetry measurement and the number of each group (n) are indicated. 
A. Blood pressure and heart rate of male KO and WT mice 
B. Blood pressure and heart rate of female KO and WT mice 
 
Figure 3. Both forward and reverse signaling by EFNB2 in VSMCs results in increased 
contractility 
Both forward and reverse signaling by EFNB2 in VSMCs results in increased contractility Male 
VSMCs were cultured in wells coated with EFNB2-Fc, normal human IgG (NHIgG; as a control 
for EFNB2-Fc), goat anti-EFNB2 Ab, or goat IgG (as a control for anti-EFNB2 Ab; 2 µg/ml for 
coating for all the cases) as indicated. VSMCs were stimulated with 20 μM phenylephrine at 
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37℃ and imaged every min for 15 min. Means ± SEM of percentage contraction of 15-30 cells 
are shown. Data were assessed by one way ANOVA. P-values between groups with significant 
differences are indicated. All experiments were conducted 3 times independently. Data from 
representative experiments are presented. 
A. Forward signaling triggered by EFNB2-Fc increases WT VSMC contractility Male WT 
VSMCs were cultured in wells coated with EFNB2-Fc or normal human IgG, the latter being 
presented as a thin line without SEM to facilitate viewing. In one group, soluble EPHB4-Fc (2 
µg/ml) was added to the wells to block the interaction between solid phase EFNB2 and cell 
surface EPHB4. 
B. EPHB4 is mainly responsible for EFNB2-triggered forward signaling for increased VSMC 
contractility Male WT or EPHB4 KO VSMCs were cultured in wells coated with EFNB2-Fc, 
and their contractility upon phenylephrine stimulation was measured. Male WT VSMCs 
cultured in normal human IgG-coated wells were used as an additional control; their mean 
contractility is presented as a thin line without SEM to facilitate viewing. 
C. Reverse signaling mediated by EFNB2 increases WT VSMC contractility Male WT VSMCs 
were cultured in wells coated with goat anti-EFNB2 Ab or goat IgG. In one of the groups, 
soluble EFNB2-Fc (2 µg/ml) was added to the culture to block the interaction between solid 
phase anti-EFNB2 Ab and cell surface EFNB2 for verification of the Ab specificity. 
 
Figure 4. Critical regions in EFNB2 intracellular tail for regulating VSMC contractility  
A. Illustration of EFNB2 deletion mutants the general structures [extracellular domain, 
intracellular tails, intracellular tyrosine residues (dots) and PDZ-domain-binding motif 
(rectangles)] of EFNB2 are depicted. Different deletion mutants and their nomenclatures are 
illustrated. 
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B. mRNA levels of EFNB2 in VSMCs infected with lentiviruses expressing different EFNB2 
deletion mutants Male WT VSMCs were infected with lentiviruses expressing different EFNB2 
deletion mutants or the full length EFNB2, and the mRNA overexpression of these molecules 
was measured by RT-qPCR, which detected an undeleted region in the EFNB2 sequence. Male 
WT VSMCs infected with empty viruses were used as a control. Data were expressed as the 
mean ± SEM of ratios of Efnb2 versus β-actin mRNA signals. The experiment was conducted 
3 or more times, and representative results are shown. *: p<0.05 (Student’s t test). The cells 
tested in B were the same ones used in C-F.  
C-F.  Identification of a critical region in the EFNB2 intracellular tail for regulating VSMC 
contractility Male EFNB2 KO VSMCs were infected with lentiviruses expressing the full-length 
EFNB2 or its deletion mutants, and the VSMCs were cultured in wells coated with anti-EFNB2 
Ab. VSMC contractility upon phenylephrine stimulation (20 μM) was measured. Means ± SEM 
of percentage contraction of 15-30 cells are shown. Data were assessed by ANOVA. P-values 
between groups with significant differences are indicated. Data from representative experiments 
are presented. 
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Tables 
Table 1. SNPs, alleles, allele frequencies, p-values and Odds Ratios for association with 
hypertension in the ADVANCE study for males-only and females-only samples  
SNP 
Position 
Chromoso
me 13 
(hg19/Bui
ld 37) 
Majo
r 
Allel
e 
Min
or 
Allel
e 
Males Females 
Minor 
Allele 
Frequen
cy 
aAssociati
on p-value 
bOdd
s 
Rati
o 
Minor 
Allele 
Frequen
cy 
aAssociati
on p-value 
bOdd
s 
Rati
o 
rs7265648
8 
10713920
3 
G A 0.156 0.118 
1.18
6 
0.153 0.272 
0.83
1 
rs1407584 
10713979
0 
C A 0.367 0.323 
1.08
6 
0.354 0.068 
0.80
1 
rs9555251 
10714058
7 
C T 0.349 0.00226 
1.28
5 
0.341 0.976 
1.00
4 
rs7322914 
10714091
0 
C T 0.349 0.00226 
1.28
4 
0.341 0.970 
1.00
4 
rs7328698 
10714134
9 
G C 0.348 0.00208 
1.28
6 
0.342 0.915 
1.01
3 
rs7328882 
10714143
3 
G A 0.349 0.00133 
1.29
9 
0.339 0.993 
1.00
1 
rs7329357 
10714170
5 
G A 0.354 0.00111 
1.30
8 
0.349 0.913 
1.01
3 
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rs5607744
6 
10714249
9 
A G 0.076 0.688 
0.93
9 
0.075 0.350 
0.80
5 
rs9520087 
10714432
0 
G A 0.431 0.00333 
1.26
9 
0.427 0.646 
0.94
9 
rs3742160 
10714582
9 
A T 0.265 0.200 
1.12
4 
0.256 0.575 
1.07
6 
ap-values that are ≤ critical Bonferroni-corrected p-value of 0.00167, corrected for 30 
independent tests, are in bold. 
bOdds Ratios are calculated using major allele as reference. 
 
 
 
 
 
Table 2. Case-control distribution of alleles and odds ratios for males and females for SNP 
rs7329357, the most significantly associated SNP with males 
    Allele Odds Ratio b(95% C.I.) 
calculated for minor (A) 
Allele     
aA aG Total 
Female Cases 
N 694.8 1297.2 1992   
Frequency 0.349 0.651 1 0.984 
Female Controls N 145.2 266.8 412 (0.79-1.23) 
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Frequency 0.352 0.648 1   
Male cases 
N 1227.4 2350.6 3578  
Frequency 0.343 0.657 1 0.581 
Male Controls 
N 394.7 439.3 834 (0.50-0.68) 
Frequency 0.473 0.527 1   
a The Allele counts are not integers for this imputed SNP, as imputation gives probabilitlies of 
genotypes and these totals reflect the sums of the probabilities. 
b95% CI = 95% confidence interval of odds ratio. 
 
 
 
 
 
 
 
 
Table 3. Chi-Square contingency tables for tests of independence between sexes, and allele 
distributions for cases and controls for SNP rs7329357 
      Allele   Chi-Square Test             
of Independence       A G   
Cases        
Male *N  1227.4 2350.6  χ2 =  0.202 
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  Frequency  0.34304 0.657  p = 0.653 
Female *N  694.8 1297.2    
  Frequency  0.349 0.651    
Controls        
Male *N  394.7 439.3  χ2 =  16.627 
  Frequency  0.473 0.527  p = 0.000045 
Female *N  145.2 266.8    
  Frequency  0.352 0.648    
* Distribution counts of imputed SNPs are not necessarily integers.  Counts have been rounded 
to nearest integer for performing Chi-Square test of independence. 
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Supplementary Materials 
 
Supplementary Methods 
 
Reverse transcription/quantitative-PCR (RT/qPCR) 
The Efnb1, Efnb2 Efnb3, Ephb1, Ephb2, Ephb3, Ephb4, Ephb6, and ɑ1-adrenoreceptor and 
iNOS mRNA levels in VSMCs were measured by RT-qPCR. Total RNA from mesenteric 
arteries, cultured VSMCs or the spleen was extracted with TRIzol® (Invitrogen, Burlington, 
Ontario, Canada) and reverse-transcribed with iScriptTM cDNA Synthesis Kit (BIO-RAD, 
Mississauga, Ontario, Canada). The primers used are listed in Supplementary table 1. 
Conditions for the qPCR reactions were as follows: 2 min at 50 °C, 2 min at 95 °C followed by 
40 cycles of 10 s at 94 °C, 20 s at 58 °C, and 20 s at 72 °C. β-actin mRNA levels were used as 
internal controls. The qPCR signals between 22-30 cycles were analyzed. Samples were tested 
in triplicate, and data were expressed as signal ratios of Efnb2 RNA/β-actin mRNA.  
 
Immunofluorescence microscopy 
VSMCs were cultured in 24-well plates with cover glass placed at the bottom of the wells. After 
4 to 5 days, the cells were washed twice with PBS and fixed with paraformaldehyde (4%) for 
20 min. For cell surface EFNB2 staining, cells were blocked with 10% goat IgG in PBS for 20 
min and then incubated with goat anti-mouse EFNB2 Ab (2 µg/ml: R&D System, Minneapolis, 
MN) overnight at 4°C. Cells were then reacted with rhodamine-conjugated donkey anti-goat Ab 
(0.15 µg/ml, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) overnight at 4oC. 
For intracellular β-actin staining, the cells were permeabilized with permeabilization buffer (BD 
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Biosciences, San Jose, CA) for 20 min at 4oC, and then incubated with mouse anti-human α-
actin mAb (2 µg/ml; Santa Cruz Biotechnology); Cells were then washed and reacted with 
FITC-conjugated goat anti-mouse IgG (0.2 µg/ml; Bethyl Laboratories, Montgomery, TX) at 
room temperature for 2 h, and imbedded with ProLong® Gold anti-fade reagent (Invitrogen). 
The stained cells were examined under a Zeiss microscope. 
 
Blood pressure, heart rate and activity measurement by radiotelemetry 
Mice were anesthetized with isoflurane and implanted surgically with TA11PA-C10 
radiotelemetry sensors (Data Sciences International, St. Paul, MN, USA) in the left carotid 
artery for direct measurement of systolic pressure (SP), diastolic pressure (DP) and heart rate 
(HR) in conscious free-moving mice, as described previously(Luo et al., 2012). Measurements 
were conducted at least 7 days after the radiotelemetry sensor implantation. Individual 10 s 
waveforms of SP, DP, mean arterial pressure (MAP), HR and activity were sampled every 2 
min and the data were recorded continuously for 3 days with the Dataquest acquisition 3.1 
system (Data Sciences International). The mice were on a normal diet unless specified. For some 
experiments, the mice were on a high-salt diet (containing 8% NaCl) for 3 weeks before the 
telemetry. In some experiments, the mice were immobilized in a restraining device (IITC Life 
Science, Woodland Hills, CA)(Dumas et al., 2000), and blood pressure and heart rate were 
similarly measured continuously every minute during a 30 min period. The raw data were 
processed with the Dataquest A.R.T-Analysis program (Lavoie, Lake-Bruse, & Sigmund, 2004). 
The daily blood pressure and heart rate are presented as bar graphs (means + SEM). Parameters 
of all the time points in any given 24-h period were analyzed by a multiple linear model, with 
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genotype and time as qualitative factors. The statistical significance (p<0.05 or p<0.01) is 
indicated.  
 
VSMC isolation 
VSMCs were isolated from male KO or WT mice, as described by Golovina and Blaustein4 with 
modifications (Lavoie et al., 2004; Luo et al., 2012). Briefly, the aorta and mesenteric arteries, 
including their secondary branches, were isolated by fine forceps under sterile conditions. The 
isolated vessels were digested for 20 min in HBSS containing collagenase type II (347 U/ml) 
(Worthington Biochemical Corporation, Lakewood, NJ, USA). After the first digestion, the 
blood vessels were cut into small pieces (1 mm3) and further digested at 37°C for 20 min with 
both collagenase type II (347 U/ml) and elastase type IV (6 U/ml) (Sigma-Aldrich Corporation, 
St. Louis, MO, USA) in HBSS. The dissociated cells were cultured at 37oC in Dulbecco’s 
modified Eagle’s medium (Wisent, St-Bruno, Quebec, Canada) supplemented with 15% fetal 
bovine serum for 3 to 4 days before experimentation. At such a time, about 80% of the cells 
were positive for ɑ-actin and capable of efficient contraction on phenylephrine stimulation. 
 
Measurement of VSMC contractility 
VSMC contractility was measured as described before(Lavoie et al., 2004; Luo et al., 2012). 
Briefly, the VMSCs were washed once with Ca2+-free HBSS, and then cultured in the same 
solution at 37°C with 5% CO2 under a Zeiss microscope. The cells were stimulated with 
phenylephrine (20 μM) and photographed continuously for 15 min at a rate of 1 picture per min. 
Fifteen or more cells were randomly selected, and their lengths at each time point were measured 
with Zeiss Axiovision software. The percentage contraction was calculated as follows: 
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% contraction = 100 x (cell length at time 0 – cell length at time X) / cell length at time 0.  
 
Immunoblotting 
VSMCs from the aorta and mesenteric arteries of WT and KO mice were cultured for 3-4 days. 
They were lysed by radioimmunoprecipitation assay buffer, which contained PhosSTOP and 
protease inhibitor mixture (Roche Applied Science, Meylan Cedex, France)5,6. For some 
experiments, VSMCs were stimulated with phenylephrine (20 μM) for 3 s before being lysed. 
Twenty to 80 micrograms of proteins per sample were resolved in 12% SDS-PAGE. Proteins 
from the gel were transferred to PVDF membranes (Life Technologies, Burlington, Ontario, 
Canada), which were incubated in blocking buffer containing 5% (w/v) skim milk (for MLC, 
5% BSA was used in the blocking buffer) for 1 h at room temperature, and then hybridized 
overnight at 4oC with goat anti-mouse EFNB2 Ab (R & D Systems, Minneapolis, MN, USA), 
rabbit anti-mouse ɑ-actin Ab, mouse anti-mouse phospho-myosin light chain mAb and rabbit 
anti-mouse myosin light chain Ab (both from Cell Signaling Technology, Danvers, MA), rabbit 
anti-mouse phospho-myosin phosphatase target subunit 1 Ab (from Cell signaling), and rabbit 
anti-mouse phospho-ERK Ab (from Life Technologies). The Abs were used at the 
manufacturers’ recommended dilutions or at 1:1000. The membranes were washed 3 times and 
reacted with corresponding second Abs, i.e., horseradish peroxidise-conjugated rabbit anti-goat 
IgG Ab (R & D Systems), horseradish peroxidise-conjugated donkey anti-rabbit IgG Ab (GE 
healthcare, Baie d’Urfé, Quebec, Canada), or horseradish peroxidise-conjugated sheep anti-
mouse IgG Ab (GE Healthcare) for 90 min. The signals were detected with SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA). 
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Supplementary Tables 
 
Supplementary Table 1. List of RT-PCR primers 
 
Supplementary Table 1. RT-PCR primer sequences 
Gene Sense sequence antisense sequence 
β-actin 5’-TCGTACCACAGGCATTGTGATGGA-3’ 5’-TGATGTCACGCACGATTTCCCTCT-3’ 
EphB1 5’-ACCATGAGGAGCATCACCTTGTCA-3’ 5’-TAGCCCATCGATACGTGCTGTGTT 
EphB2 5’-CCAGTGATGTGTGGAGCTATG-3’ 5’-GGAGGTAGTCTGTAGTCCTGTT-3’ 
EphB3 5’-AGTTCGCCAAGGAGATCGATGTGT-3’ 5’-TCAGCGTCTTGATAGCCACGAACA-3’ 
Ephb4 5’- CTACGTCTCTAACCTCCCATCT-3’ 5’- GCTGGTCACCCTTTCTCTTT-3’ 
EphB6 5’-AAGCCATAGCAGTGCCTCAGAACA-3’ 5’-TCCAGAGCTAGAACTGATGACCCT-3’ 
Efnb1 5’-TGCAACAAGCCACACCAGGAAATC-3’ 5’-CAAGCTCCCATTGGACGTTGATGT-3’ 
Efnb2 5’-CCCTTTGTGAAGCCAAATCCAGGT-3’ 5’-TCCTGATGCGATCCCTGCGAATAA-3’ 
Efnb3 5’-AGTTCCGATCCCACCACGATTACT-3’ 5’-TCCATGGGCATTTCAGACACAGGT-3’ 
α1-AR 5’-TGCCCTTCTCTGCCATCTTTGAGA-3’ 5’-AGCGGGTAGCTCACACCAATGTAT-3’ 
iNOs 5’-GGAATCTTGGAGCGAGTTGT-3’ 5’-CCTCTTGTCTTTGACCCAGTAG-3’ 
 
 145 
 
Supplementary Table 2. Characteristics of the ADVANCE cohort used in the human genetic 
study giving distribution of sexes by country of recruitment 
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Supplementary Figures and legends 
 
Supplementary Figure 1.  Vessel-specific deletion of Efnb2 mRNA 
RNA was extracted from different organs and tissues from male WT and EFNB2 KO mice and 
analyzed by RT-qPCR for Efnb2 mRNA levels. β-actin mRNA levels were used as an internal 
control. Samples were in duplicate, and means ± SEM of Efnb2 signal/β-actin signal ratios are 
shown. Data represent the summary of 3 independent experiments. Statistical significant 
difference is only observed in the vessels but not in the spleen (Student’s t test; **: p<0.01). 
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Supplementary Figure 2. Ephb1, Ephb2, Ephb3, Ephb4, Ephb6, Efnb1 and Ephb3 mRNA 
expression in EFNB2 KO VSMCs are comparable to those of WT counterparts according to 
RT-qPCR 
RNA was extracted from VSMCs of male KO and WT mice and analyzed by RT-qPCR for 
Ephb1, Ephb2, Ephb3, Ephb4, Ephb6, Efnb1, Efnb2 and Ephb3 mRNA levels. β-actin mRNA 
levels were used as an internal control. Samples were in duplicate, and means ± SEM of Ephb 
and Efnb signal/β-actin signal ratios are shown. Data represent the summary of 3 independent 
experiments. **: p<0.01 (Student’s t test).  
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Supplementary Figure 3. Histology, media thickness and lumen size of resistance arteries in 
EFNB2 KO mice are comparable to those of WT mice 
Right and left carotid arteries at comparable positions in the neck of male WT and KO mice 
were isolated, sectioned and stained by hematoxylin and eosin.  
 
A. Carotid arteries from male KO and WT mice show comparable histology  
Representative hematoxylin and eosin-stained male KO and WT carotid artery sections are 
shown.  
 
B. Media thickness and lumen size of carotid arteries from male KO and WT mice are 
comparable 
Means ± SEM of tunica media thickness (left panel) and lumen size (right panel) of male KO 
and WT carotid arteries at comparable locations (3 randomly selected sections per each of the 
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right and left carotid arteries per mouse, and 3 mice per group; i.e., 18 determinants per group) 
are presented in a bar graph. No statistical significant difference is observed (Student’s t test). 
 
 
 
Supplementary Figure 4. Normal proliferation of VSMCs from EFNB2 KO mice 
VSMCs from male KO and WT mice were cultured for 3, 4 and 5 days, and means ± SEM of 
their proliferation indices of on these days are calculated based on pooled results of 2 
independent experiments, with samples of each experiment in duplicate. No statistical 
significant difference is observed (Student’s t test).  
 
The proliferation index is calculated as follows. 
 
Proliferation Index = VSMC cell number after culture / VSMC cell number on day 1 (the 
beginning of the culture) 
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Supplementary Figure 5. Similar SMC marker ɑ-actin expression in KO and WT VSMCs     
Male KO and WT VSMCs were cultured for 4 days, and then stained by FITC-conjugated anti-
ɑ-actin Ab.  
 
A. Typical immunofluorescence staining of male WT and KO VSMC for smooth muscle cell 
-actin  
 
B. Quantitative assessment of the intensity of ɑ-actin signal in male WT and KO VSMC  
More than 15 VSMCs per group were randomly selected and quantified for their levels of ɑ-
actin signals. Means ± SEM of ɑ-actin signal intensity per unit cell area (1 pixel) of the ɑ-actin-
positive cells are shown. No statistical significant difference is observed (Student’s t test).  
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Supplementary Figure 6. KO and WT mouse BP parameters grouped according to SP, DP, 
and MAP with male and female data shown in the same panel 
The blood pressure and heart rate were measured every 2 min by telemetry. The daily mean ± 
SEM of daily blood pressure and heart rate during a 72-h period are shown. The daily values 
were evaluated by a multiple linear model, with genotype and time as qualitative factors, and 
significant p-values are indicated: * p<0.05; ** p<0.01. The average age of mice of each group 
at the time of telemetry measurement and the number of each group (n) are indicated. 
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Supplementary Figure 7. The effect of EFNB2 deletion on signaling events of VSMCs 
A. Normal adrenoreceptor mRNA expression in male EFNB2 KO VSMC according to RT-
qPCR  
VSMCs from male EFNB2 KO and WT mice were cultured for 4 days and then harvested. Cell 
lysates were analyzed for ɑ1-adrenoreceptor (α1-AR) mRNA expression by RT-qPCR. Pooled 
data from 3 independent experiments were presented as mean ± SEM of ɑ1-adrenoreceptor 
versus α-actin signal ratios.  
 
B and C. Normal Ca2+ flux in EFNB2 KO VSMCs or in WT VSMCs stimulated by solid phase 
EFNB2-Fc 
VSMCs from male EFNB2 KO or WT mice were cultured for 4 days (B). VSMCs from male 
WT VSMCs were also cultured in wells coated with EFNB2-Fc (2 μg/ml for coating; C). The 
cells were then loaded with Fura2. They were then placed in HBSS and stimulated with 
phenylephrine (20 μM). The arrow indicates the time point at which phenylephrine was added. 
The ratio of emissions at 510 nm triggered by 340 nm versus 380 nm excitation in each cell was 
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registered every 3 s for 60 sec. The experiments were conducted 3 times. Means ± SEM of the 
ratio of more than 15 randomly selected VSMCs of a representative experiment are illustrated. 
No statistically significant differences were found between the KO and WT groups according 
to ANOVA. 
 
D-F. MLC, MPTK and ERK phosphorylation of VSMCs from WT and KO mice  
VSMCs from male KO and WT mice were cultured for 4 days and then stimulated with 20 μM 
phenylephrine for 3 s and immediately lysed. Phosphorylated (P-) MLC (D), MPKT (E) and 
ERK (F) were analyzed by immunoblotting. Total (T) MLC or ɑ-actin was used as loading 
controls. Three independent experiments were conducted. Immunoblottings from representative 
experiments are illustrated; ratios of phosphorylated and total protein (or ɑ-actin) signals 
according densitometry of the 3 independent experiments are presented as bar graphs on the 
right. 
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Supplementary Figure 8. Association of SNPs within human EFNB2 gene and its adjacent 
regions with hypertension in the ADVANCE study 
 
A. Distribution of SNP association -log p-values for males 
B. Distribution of SNP association -log p-values for females 
C. Location of Associated SNPs in Males with respect to LD structure in 3’ region of 
EFNB2 
 
 
  155 
CHAPTER 4 ARTICLE-3 
 
TITLE: Estrogen and testosterone in concert with EFNB3 regulate vascular smooth 
muscle cell contractility and blood pressure  
1#Yujia Wang,1#Zenghui Wu, , 2Eric Thorin, 1Johanne Tremblay, 1,3Julie L. Lavoie, 1Hongyu 
Luo, 1Junzheng Peng, 1Shijie Qi, 4Tao Wu, 4Fei Chen, 4Jianzhong Shen, 4Shenjiang Hu and 
1,5Jiangping Wu 
From the 1Research Centre and 4Nephrology Service, Centre hospitalier de l’Université de 
Montréal (CRCHUM), Montreal, Quebec H2X 0A9, Canada; 2Montreal Heart Institute, 
Montreal, Quebec H1T 1C8, Canada; 3Département de Kinésiologie, Université de Montréal, 
Montreal, Quebec, H3T 1J4; 4Institute of Cardiology, First Affiliated Hospital, Zhejiang 
University Medical College, Hangzhou, 310003, China 
 
Running title: EFNB3 regulates blood pressure 
Address correspondence to: Dr. Jiangping Wu, CRCHUM, 900 Saint-Denis Street, Rm. 
R12.428, Montreal, Quebec, Canada H2X 0A9. 
Footnotes: #These authors contributed equally to this work.  
 
Key words: ephrinb3, estrogen, blood pressure 
Published on Am J Physiol Heart Circ Physiol. 2016 Apr 1;310(7):H861-72 
 
 
 
  156 
Abstract 
 
EPH kinases and their ligands, ephrins (EFNs), have vital and diverse biological functions, 
although their function in blood pressure (BP) control has not been studied in detail. In the 
present study, we report that Efnb3 gene knockout (KO) led to hypertension in female but not 
male mice. Vascular smooth muscle cells (VSMCs) were target cells for EFNB3 function in BP 
regulation. The deletion of EFNB3 augmented contractility of mesenteric arteries and VSMCs 
from female but not male KO mice, compared to their WT counterparts. Estrogen augmented 
VSMC contractility while testosterone reduced it in the absence of EFNB3, although these sex 
hormones had no effect on the contractility of VSMCs from WT mice. The effect of estrogen 
on KO VSMC contractility was via a non-genomic pathway involving GPR30, while that of 
testosterone was likely via a genomic pathway, according to VSMC contractility assays and 
GPR30 knockdown assays. The sex hormone-dependent contraction phenotypes in KO VSMCs 
were reflected in BP in vivo. Ovariectomy rendered female KO mice normotensive, while 
castration, male KO mice hypertensive. At the molecular level, EFNB3 KO in VSMCs resulted 
in reduced MLC kinase phosphorylation, an event enhancing sensitivity to Ca++ flux in VSMCs. 
Our investigation has revealed previously unknown EFNB3 functions in BP regulation and 
shown that EFNB3 is a hypertension risk gene in certain individuals. 
 
New and noteworthy 
 
We have revealed EFNB3 as a novel component in blood pressure regulation. Its deletion caused 
hypertension in a sex-dependent fashion. Vascular smooth muscle is the target tissue mediating 
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such an effect of EFNB3. This finding may lead to sex hormone level-specific treatment of 
hypertension in individuals with EFNB3 mutations. 
 
Introduction 
 
EPH erythropoietin-producing human hepatocellular carcinoma receptor kinases are the largest 
family of receptor tyrosine kinases. They are divided into A and B subfamilies according to 
sequence homology ("Unified nomenclature for Eph family receptors and their ligands, the 
ephrins. Eph Nomenclature Committee," 1997). Ephrins (EFNs), which are also cell surface 
molecules, are ligands of EPHs. EFNs are also classified into A and B subfamilies; members of 
the A subfamily attach to the cell surface through glycosylphosphatidylinositol anchoring, 
whereas members of the B subfamily attach through transmembrane tails (Flanagan & 
Vanderhaeghen, 1998; Pasquale, 2008; Wilkinson, 2000). Interactions among EPHs and EFNs 
are promiscuous, but in general, EPH A members interface preferentially with EFN A family 
members, and EPH B members with EFN B family members (Flanagan & Vanderhaeghen, 1998; 
Pasquale, 2008; Wilkinson, 2000). EFNs can stimulate EPH receptors, and this is called forward 
signaling. Interestingly, EPHs are also capable of stimulating EFNs which then transmit 
signaling reversely into cells, a phenomenon known as reverse signaling.  
 
EPHs and EFNs are expressed in many tissues and organs. They play important roles in the 
central nervous system (Flanagan & Vanderhaeghen, 1998; Pasquale, 2008; Wilkinson, 2000), 
immune system (Luo, Charpentier, et al., 2011; Luo, Wan, Wu, & Wu, 2001; Luo, Wu, et al., 
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2011; Luo, Yu, Tremblay, & Wu, 2004; Luo, Yu, Wu, & Wu, 2002; J. Wu & Luo, 2005; Yu, 
Luo, Wu, & Wu, 2003a, 2003b, 2004; Yu, Mao, Wu, Luo, & Wu, 2006), digestive system 
(Batlle et al., 2002), bone metabolism (Davy, Bush, & Soriano, 2006; Zhao et al., 2006), 
angiogenesis (H. U. Wang, Chen, & Anderson, 1998) and other processes (Dravis et al., 2007; 
Hashimoto et al., 2007; Konstantinova et al., 2007). 
 
Until recently, limited studies assessed the role of EPHs and EFNs in vascular smooth muscle 
cell (VSMC) function. VSMCs with an EFNB2 deletion show compromised migration(Foo et 
al., 2006). In cultured rat and human VSMCs, EFNA1 triggers EPHA4 signaling and actin stress 
fiber assembly (Ogita et al., 2003).  Whether such signaling elicits changes in VSMC 
contractility has not been investigated.  
 
We recently reported that EPHB6, in concert with sex hormones, is crucial in VSMC contraction 
and blood pressure (BP) regulation (Luo et al., 2012). Male but not female Ephb6 gene knockout 
(KO) mice are hypertensive. VSMC are targets through which EPHB6 exerts its effect on BP 
control. Since EPHB6 and all its major ligands of the EFN B family, i.e., EFNB1, EFNB2 and 
EFNB3, are expressed in VSMC (Luo et al., 2012), there exists a molecular framework for their 
function in these cells. We showed that while solid-phase recombinant EPHB6 reduces VSMC 
contraction in response to phenylephrine (PE) stimulation, solid-phase anti-EPHB6 antibody 
(Ab) does not (Luo et al., 2012). Since anti-EPHB6 Ab serves as an EPHB6 agonist surrogate, 
this indicates that reverse signaling from EPHB6 to EFNBs, but not forward signalling from 
EFNBs to EPHB6 is responsible for dampening VSMC contractility. Deletion of Efnb1 in 
smooth muscle cells also elicits hypertension in mice (Z. Wu et al., 2012), while deletion of 
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Ephb4 in these cells results in hypotension (Y. Wang et al., 2015). Therefore, multiple members 
of the EPHB/EFNBs family compose a previously unknown BP regulation system. 
 
So far, there is no report on the regulation of EPH/EFN function by sex hormones, except a 
study by Nikolova showing that estrogen could modulate EPHB4 and EFNB2 expression in 
mammary glands (Nikolova, Djonov, Zuercher, Andres, & Ziemiecki, 1998). The classic 
estrogen receptor (ER) is an intracellular protein. ER has α and β subunits. They form 
heterodimers (αβ) or homodimers (αα or ββ) upon binding of estrogen, which enter the cells 
passively. The estrogen/ER complex then enters the nucleus serving as transcription factors, 
regulating target gene expression (Levin, 2005). In addition to the classical intracellular ERs, 
there is also GPR30, a G protein-coupled cell membrane estrogen receptor, which mediates fast 
nongenomic responses to estrogens (Prossnitz & Barton, 2014). Androgen receptors are also 
intracellular proteins, and when they bind to androgens, they will translocate into the nuclei, and 
serve as DNA-binding transcription factors, regulating genes with androgen-responsive 
elements (Kerkhofs, Denayer, Haelens, & Claessens, 2009). There are also cell membrane 
androgen receptors, which are less well-defined and might also be G-protein-associated 
receptors (Benten et al., 1999), mediating fast non-genomic actions. 
 
In the present study, we discovered that female but not male Efnb3 KO mice were hypertensive. 
Castration rendered male KO mice hypertensive, and ovariectomy, female KO mice 
normotensive. VSMCs were the major cell type responsible for these phenotypes. Non-genomic 
effect of estrogen via GPR30 promoted KO VSMC contractility, while genomic effect of 
testosterone reduced it.  
  160 
Materials and Methods   
 
Efnb3 KO mice  
Efnb3 KO mice (referred to KO mice) were generously provided to us by Regeneron 
Pharmaceuticals (Kullander et al., 2001b). They had been backcrossed to the C57BL/6J 
background for more than 10 generations. Age- (16-26 weeks) and sex-matched WT mice were 
served as controls and are referred to as WT mice. The animals were housed in specific 
pathogen-free rooms with 12-h light and 12-h dark cycles. Females were not monitored for their 
estrous cycles. For radiotransmitter implantation and castration/ovariectomy, mice were 
anesthetized with isoflurane (2% isoflurane with 0.75L/min O2 flow). In some experiments, the 
mice with radiotransmitter implantation were castrated or ovariectomized, and telemetry was 
conducted at least 3 weeks after the gonadectomy. The mice were euthanized with pentobarbital 
(400 mg/Kg body weight, i.p.) at the end of in vivo studies or for tissue retrieval.   
 
VSMC isolation 
Mouse VSMCs were isolated, as described by Golovina and Blaustein (Golovina & Blaustein, 
2006) with modifications (Luo et al., 2012; Z. Wu et al., 2012). The aorta and mesenteric arteries, 
including their secondary branches, were pooled and digested with collagenase type II (347 
U/ml) (Worthington Biochemical Corporation, Lakewood, NJ, USA). They were further 
digested with both collagenase type II (347 U/ml) and elastase type IV (6 U/ml) (Sigma-Aldrich 
Corporation, St. Louis, MO, USA). The dissociated cells were cultured at 37oC in Dulbecco’s 
modified Eagle’s medium (Wisent, St-Bruno, Quebec, Canada) supplemented with 15% fetal 
bovine serum for 4 to 5 days before experimentation.  
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Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
Efnb3 and GRP30 mRNA levels in VSMCs were measured by RT-qPCR (Luo et al., 2012). For 
Efnb3, the 5’ primer was 5’-AGTTCCGATCCCACCACGATTACT-3’, and the 3’ primer was 
5’-AGAAGCACCTTCATGCCTCTGGTT-3’. For GPR30, the 5’ primer was 5’- 
CATCATTGGCCTCTGCTACTC-3’, and the 3’ primer was 5’- 
GAAGATCATCCTCAGGGCTTTC -3’. β-actin mRNA served as an internal control, and 
primers for β-actin was described previously(Z. Wu et al., 2012). The following qPCR condition 
was employed: 2 min at 50 °C and then 2 min at 95 °C followed by 45 cycles of 10 s at 94 °C, 
20 s at 58 °C, and 20 s at 72 °C. Signals between 20-30 cycles were analyzed. Samples were 
tested in triplicate, and the data are expressed as signal ratios of test gene mRNA/β-actin mRNA. 
 
BP measurement 
Mice were implanted surgically with TA11PA-C10 radiotransmitters (Data Sciences 
International, St. Paul, MN, USA) in the left carotid artery as described previously (Lavoie, 
Lake-Bruse, & Sigmund, 2004). At least 7 days were allowed for recovery before the 
measurement of systolic, diastolic and mean arterial pressure (MAP), systolic pressure (SP), 
diastolic pressure (DP) and heart rate (HR).  
BP and HR in conscious, free-moving mice were then recorded continuously for 3 days with the 
Dataquest acquisition 3.1 system (Data Sciences International). Individual 10-s waveforms of 
SP, DP, MAP and HR were sampled every 2 min throughout the monitoring period. The raw 
data were processed with the Dataquest A.R.T-Analysis program (Lavoie et al., 2004), and 
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means + SEM of hourly BP and HR are calculated and presented. ANOVA was used to compare 
the 72 hourly values of each group (area under the curve) for statistical significance. 
 
Ex vivo vessel constriction 
Third order mesenteric arteries were employed in these vessel constriction experiments. In some 
experiments, the endothelium was removed by scrapping the luminal surface of the arterial 
segments with a human hair. The lack of endothelium-dependent relaxation induced by 
acetylcholine (1 µM) was confirmed on a test-contraction induced by phenylephrine (10 µM). 
The artery rings of 2 mm were mounted on 20-μm tungsten wires in microvessel myographs 
(IMF, University of Vermont, Burlington, VT) as described previously(Luo et al., 2012; Thorin, 
Huang, Fishman, & Bevan, 1998). An optimal basal tension of ~ 300 mg was determined for 
vessels while no differences in basal tension were observed among groups (data not shown). 
The mounted vascular ring was equilibrated for 30 to 45 minutes, after which the contractility 
of each arterial ring was determined by a 40 mM KCl-PSS solution, followed by two washout 
periods; then, vessels were allowed to further equilibrate for 30 to 45 minutes. Contraction 
curves to phenylephrine (0.1 nM to 10 μM) were obtained.  
 
During equilibration and experiment, vascular segments were bath in a physiological salt 
solution at pH 7.4 containing 119 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 
24.9 mM NaHCO3, 1.6 mM CaCl2, 0.023 mM EDTA, and 10 mM glucose, aerated with 12% 
O2 / 5% CO2 / 83% N2 at 37°C. At the end of the protocol, maximal tension (Emax) was 
determined by changing the PSS to a solution containing 127 mM KCl. The data are expressed 
as percentages of Emax.  
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Contractility of 3 segments of mesenteric arteries per mouse was measured and data from 3 
independent experiments per group were pooled to construct mean concentration-response 
curves with SEM. ANOVA is performed to compare concentration-response curves using the 
percentage of the Emax. 
 
VSMC contractility 
VSMC contractility was measured as described previously(Luo et al., 2012; Z. Wu et al., 2012). 
Briefly, primary VSMCs were cultured for 3-4 days and then stimulated with PE (20 μM). They 
were photographed continuously for 15 min at a rate of 1 picture per min. In experiments testing 
the effect of sex hormones, the VSMC were cultured charcoal-stripped sera in the presence of 
human 5α-dihydrotestosterone (6.49 ng/ml), cell membrane impermeable testosterone-3-(O-
carboxymethyl)oxime-BSA (Aviva Systems Biology Corp., San Diego), or 17-β-estradiol (100 
ng/ml) for periods indicated. 
 
Fifteen or more cells were randomly selected, and their length was measured at each time point 
with Zeiss Axiovision software. Percentage contraction was calculated as follows: 
 
% contraction = 100 x (cell length at time 0 – cell length at time X) / cell length at time 0.  
 
Immunofluorescence microscopy 
VSMC surface EFNB3, α1-adrenergic receptor (α1-AR) and GPR30 expression was assessed 
by immunofluorescence microscopy (Luo et al., 2012). Cells were blocked with 10% goat IgG 
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in PBS for 20 min and then incubated with rabbit anti-mouse EFNB3 Ab (OAAF01784, Aviva 
Systems Biology Corporation, San Diego, CA) rabbit anti-mouse α1-AR Ab, (ab3462, Abcam 
Inc., Cambridge, MA) or rabbit anti-mouse GPR30 Ab (ab39742, Abcam Inc., Cambridge, MA). 
Cells were then washed and reacted with FITC-conjugated sheep anti-rabbit IgG Ab (0.2 µg/ml; 
Chemicon International, Temecula, CA) at room temperature for 2 h, and imbedded with 
ProLong® Gold anti-fade reagent (Invitrogen). The stained cells were examined under a Zeiss 
microscope. The total fluorescence intensity of a cell and cell size were measured using 
AxioVision software from Zeiss; results from measurements of more than 15 cells are then 
presented as fluorescence intensity per arbitrary unit of cell area (1 pixel). 
 
Immunoblotting 
VSMCs from WT and KO mice were isolated and cultured for 3-4 days. VSMCs were 
stimulated with PE (20 μM) for 3 s and then lyzed. Total and phosphorylated MLC kinase 
(MLCK) and MLC phosphatase (MYPT) of the VSMCs were measured similarly, using rabbit 
anti-mouse MLCK mAb (clone EP1458Y; Abcam, Cambridge, UK), rabbit anti-mouse 
phospho-MLCK Ab (Invitrogen, Camarillo, CA), rabbit anti-mouse MYPT Ab (#2634; Cell 
Signaling, Danvers, MA), and rabbit anti-mouse phospho-MYPT Ab (#5163; Cell Signaling). 
 
Measurement of Ca++ flux 
PE-stimulated Ca++ flux in VMSC was measured by immunofluorescence microscopy(Golovina 
& Blaustein, 2006; Luo et al., 2012) Briefly, VSMC were culture in medium containing Ca++ 
for 4 days. They were then loaded with Fura-2-AM, stimulated with PE (20 μM) at 37oC in 
medium without Ca++, as most of the Ca++ flux in VSMC was from sarcro-endoplasmice 
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reticulum. The cells were imaged for 60 s at a rate of 1 picture per 3 s. Excitation wavelengths 
were switched between 340 nm and 380 nm, and emission wavelength was 510 nm. Signals 
from more than 15 randomly-selected cells were recorded, and the results expressed as ratios of 
fluorescence intensity at 510 nm excited by 340 nm versus 380 nm. 
 
Small interfering RNA (siRNA) transfection 
Gpr30 siRNAs and negative control siRNAs were synthesized by Integrated DNA Technologies 
(Coralville, IA, USA). Their sequences are presented in supplementary table 1 (Table 1). 
VSMCs were cultured for 40 h in regular medium. They were then transfected with a mix of 3 
pairs of Gpr30 siRNAs (for each pair, the final concentration was 10 nM), or control siRNA, 
and cultured in medium free of antibiotics, as described before (Z. Wu et al., 2012). Forty eight 
hours after the siRNA transfection, VSMC contractility upon PE stimulation was assessed. 
 
Urinary catecholamine measurement 
Twenty four-hour urine under a fasting condition was collected by placing 15- to 17-week old 
KO and WT mice individually in metabolic cages. Urinary catecholamines were quantified by 
competitive enzyme immunoassays (3-CAT Research ELISA kits) according to the 
manufacturer’s instructions (Labor Diagnostika Nord GmbH & Co. Nordhorn, Germany). The 
reaction was monitored at 450 nm. Urine samples were measured in duplicate. 
   
 
Ethics statement 
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All animal studies were performed according to guidelines of Canadian Council for Animal 
Protection and were conducted according the protocols approved by CRCHUM Animal 
Protection Committee.  
Statistics  
Statistical significances were determined using a one-way ANOVA or paired Student’s t tests.  
 
Results 
 
Efnb3 KO deletion in VSMCs 
RT-qPCR demonstrated that Efnb3 mRNA was virtually absent in endothelium-stripped 
mesenteric arteries from Efnb3 KO mice (Fig. 1A). Efnb3 KO was also confirmed at the protein 
level in isolated EFNB3 KO VSMCs by immunofluorescence microscopy (Fig. 1B). 
 
EFNB3 deletion caused hypertension in females but not males  
BP of the aged-matched Efnb3 KO and WT mice was measured by radiotelemetry. The MAP, 
SP, and DP of male KO mice showed no significant differences from their WT controls, 
although the HR of the KO mice was higher (Fig. 2A). Females KO had increased MAP, SP 
and DP compared to their WT counterparts, while their HR were normal (Fig. 2B). These results 
clearly show that EFNB3 deletion caused hypertension in a sex-dependent way.  
 
Increased contractility of small arteries and VSMCs from female KO mice 
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The ex vivo contractility of mesenteric arteries from KO and WT mice was assessed after 
stimulation with PE. Female but not male KO vessels showed greater contractility than their 
WT counterparts (Figs. 3A and 3B), corroborating the BP phenotype in KO mice. This 
contractility phenotype remained unchanged in the presence or absence of endothelium, 
indicating that VSMCs but not the endothelium were responsible for the phenotype, and that 
nitric oxide or endothelin-1 produced by the endothelium was not required to enhance female 
vessel contractility in the absence of EFNB3. In this experiment, WT and KO vessels had no 
significant difference in their EC50 to PE stimulation (data not shown). 
 
When isolated VSMCs were stimulated with PE, those derived from female Efnb3 KO mice but 
not male KO mice showed increased contractility compared to their WT counterparts (Figs. 3C 
and 3D), consistent with the findings in ex vivo vessel contraction studies. 
 
The increased contractility of female KO VSMCs upon PE stimulation might be due to 
heightened adrenoreceptor signaling strength. However, we found no difference in α1-AR 
expression in KO and WT VSMCs, regardless of the sex, according to either 
immunofluorescence (Figs. 4A).  
 
Ca++ flux (Fig. 4B) in KO VSMCs was comparable to that of the WT counterparts, whether they 
were from males or females. Thus, the increased contractility of VSMCs from female KO mice 
was likely not due to increased Ca++ flux but augmented Ca++ responsiveness, which is regulated 
by MLCK. When MLCK is phosphorylated at ser1760 by calmodulin-dependent protein kinase 
II or protein kinase A, its MLCK enzymatic activity is reduced (Giembycz & Newton, 2006; 
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Miller, Silver, & Stull, 1983; Raina, Zacharia, Li, & Wier, 2009). Conversely, reduced 
phosphorylation at ser1760 will lead to increased VSMC contractility. We assessed MLCK 
phosphorylation at ser1760 and observed that VSMCs from female but not male KO mice had 
significantly lower values upon PE stimulation than WT controls (Fig. 4C). This result implies 
higher MLCK activity and hence higher Ca++ responsiveness in VSMCs from female KO mice, 
compatible with the finding that female VSMCs presented augmented contractility. VSMC 
contractility is also modulated by MYPT, which dephosphorylates MLC and reduces VSMC 
contractility (Kawano et al., 1999). MYPT phosphorylation at T695 prevents its binding to MLC 
and thus diminishes its phosphatase activity (Muranyi et al., 2005). We investigated the outcome 
of EFNB3 deletion on MYPT phosphorylation in VSMCs. After PE stimulation (3 s), MYPT 
phosphorylation at T695 in VSMCs from both female and male KO mice was similar to that of 
their WT counterparts (Fig. 4D). This observation suggests that MYPT is not influenced by 
EFNB3 deletion and does not participate in the contractility upregulation of female KO arteries. 
 
Nongenomic effect of estrogen augments while genomic effect of testosterone reduces KO VSMC 
contractility 
The default function of EFNB3 signaling is to reduce VSMC contractility, and hence EFNB3 
KO deletion led to the increased VSMC contractility (Fig. 3D). However, such an increase only 
occurred in VSMCs from female but not male KO mice, suggesting that either estrogen is 
permissive for this phenotype, or androgen antagonizes it, or both.  
 
To assess the role of estrogen in this regard, we cultured VSMCs from male KO mice in the 
presence of a physiological concentration of estrogen (17β-estradiol). VSMCs from male but 
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not female mice were used in order to minimize intracellular estrogen carry-over from in vivo 
exposure. The fetal calf sera used in these sex hormone studies were absorbed by charcoal to 
remove residual sex hormones in the sera. 
 
We found that after 3-4 day culture in the presence of 17β-estradiol, the contractility of male 
KO VSMCs, which had no difference from WT counterparts in the absence of estrogen, was 
increased compared to vehicle controls, while estrogen did not affect the contractility of male 
WT VSMCs (Fig. 5A).  
 
In the above-described experiments, estrogen was present in the culture for 3-4 days. So its 
effect could be either genomic or nongenomic, or both. A short-term estrogen treatment was 
employed to discern these two possibilities. When VSMCs from male KO mice were incubated 
with 17β-estradiol, their contractility were increased within as short as 15 min, while the 
contractility of WT VSMCs were not influenced by such a treatment (Fig. 5B). The speed of the 
estrogen effect suggests that the non-genomic pathway is involved in the effect of estrogen on 
male KO VSMCs.  
To assess whether androgen has protective effect against the augmented VSMC contractility 
after EFNB3 deletion, we cultured VSMCs from KO females in the presence of physiological 
concentration of 5α-dihydrotestosterone for 3-4 days. The female VSMCs but not male VSMCs 
were used in this experiment to minimize the intracellular androgen carry-over from the in vivo 
environment. 5α-dihydrotestosterone effectively reduced the augmented female KO VSMC 
contractility to the WT level (Fig. 5C), while had no effect on female WT VSMC. However, 
short-term (15 min) 5α-dihydrotestosterone (6.49 ng/ml) treatment (Fig. 5D) or a long-time (3 
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days) treatment of a cell membrane-impermeable BSA-conjugated testosterone (testosterone-3-
(O-carboxymethyl)-oxime-BSA (testosterone-BSA; Aviva Systems Biology Corporation, San 
Diego, CA) used at an equal molar concentration (1.1 μg/ml) as 5α-dihydrotestosterone (6.49 
ng/ml) could not reduce the female KO VSMC contractility (Fig. 5E). These results suggest that 
the genomic but not non-genomic effect of testosterone is responsible for countering the VSMC 
contractility-augmenting effect of EFNB3 deletion, and explains the normal contractility of 
VSMCs from male KO mice, and the normal BP of those mice.   
 
The above in vitro study showed that in the absence of EFNB3, estrogen promoted VSMC 
contractility, while testosterone reduced it. Is this conclusion valid in vivo where VSMC 
contractility is reflected in BP? Indeed, when male KO mice were castrated, they became 
hypertensive (Fig. 5F), and when females KO mice were ovariectomized, they lost the 
hypertensive phenotype (Fig. 5G), in agreement with our in vitro results.   
 
GPR30 mediates the non-genomic effect of estrogen in KO VSMC contractility 
GPR30 is a G-protein-associated cell surface molecule mediating the nongenomic effects of 
estrogen(Evans, Bayliss, & Reale, 2014). We found that its mRNA (Fig. 6A) and protein 
expression (Fig. 6B), as detected by RT-qPCR and immunofluorescence, respectively, was 
significantly augmented KO VSMCs, compared to the WT counterparts, consistent with the 
obvious non-genomic effect in KO VSMC. 
 
To further prove GPR30’s role in mediating estrogen’s effect in VSMC contractility, we 
transfected VSMCs with Gpr30 siRNA. The knockdown Gpr30 expression at the mRNA level 
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was confirmed by RT-qPCR (Fig. 6C). Such knockdown resulted in failed augmentation of male 
KO VSMC contractility by estrogen (Fig. 6D).  
   
Investigation of the effect of EFNB3 KO on the sex hormone levels and levels of BP-related 
endocrine molecules 
The serum testosterone and estrogen levels of males and females, respectively, of  KO and WT 
mice were measured, but no apparent difference between the KO and WT mice was observed 
(data not shown).    
 
We showed that in male or female mice, EFNB3 KO did not alter 24-h urine catecholamine 
contents (Fig. 7). Serum AngII levels in KO and WT mice, whether males or females, were 
comparable (data not shown). 
  
Discussion 
 
Our data indicate that VSMCs are a target tissue for EFNB3 function in BP regulation. In the 
absence of EFNB3, the VSMCs contracted stronger, hence increased BP. However, such 
phenotype was only revealed under permissive conditions, i.e., the presence of estrogen or 
absence of testosterone. 
 
In our in vivo BP measurement, in some test and control groups, there was 3 to 5-week age 
difference. The BP difference between the KO and WT mice is not caused by such age 
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difference, as we have confirmed that the BP in mice with 10- to 20-week age difference are 
similar (data not shown). 
 
We demonstrated EFNB3 can modulate VSMC contractility by reverse signalling. EFNB3 is a 
transmembrane protein without enzymatic activity in its intracellular tail. How does it regulate 
VSMC contractility? EFNB intracellular tails are known to associate with GRIP1 (Dong et al., 
1997), Dishevelled (Tanaka, Kamo, Ota, & Sugimura, 2003), PDZ-RGS3 (Lu et al., 2012), 
TIAM1 (Tanaka, Kamata, Yanagihara, & Sakai, 2010) and GRB4(Segura, Essmann, Weinges, 
& Acker-Palmer, 2007). We have demonstrated that the association of EFNB3 with GRIP1 is 
critical for its function in regulating VSMC contractility (Yujia Wang et al.). In VSMCs, EFNB3 
might also associate with other so-far unidentified binding proteins. During reversesignalling, 
some of these proteins might interact with and modulate the functions of other pathways that 
control VSMC contractility, the MLCK pathway being one of them. As shown in Figure 4C, in 
female KO VSMCs, MLCK phosphorylation was reduced compared to that of the WT 
counterparts. Reduced MLCK phosphorylation augments the MLCK activity, and then MLC 
phosphorylation, which promotes Ca++ sensitivity of VSMCs, hence increased contraction. 
MLCK can be phosphorylated by Cam-kinase II, kinase A or kinase C, resulting in its 
inactivation. In our previous publication related to the role of EphB4 in VSMC contractility, we 
reported that EphB4 deletion modulates Cam-kinase II (Y. Wang et al., 2015). As EphB4 
interacts with EFNB2, a molecule belonging to the same subfamily as EFNB3 does, it is possible 
that EFNB3 deletion also modulates Cam-kinase II. The intermediate signalling molecules 
between EFNB3/GRIP1 and Cam-kinase II/MLCK/MLC remain to be identified. In addition, 
EFNB3 could also modulate MLC function through other pathways. For example, Zip kinase in 
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the Rho kinase pathway could directly activate MLC(Brozovich, 2002). Putative connection 
between EFNB3 and the Rho pathway is quite relevant, as among EFNB-associating proteins, 
Tiam1 is a guanine exchange factor for Rho GTPase(Tanaka et al., 2010). 
 
The default function of EFNB3 with regard to VSMC contractility should be an inhibitory one, 
but such a default function was only revealed in the presence of estrogen or absence of 
testosterone. What are possible mechanisms by which sex hormones in concert with EFNB3 
modulate VSMC contractility? A possible one is that, in the absence of EFNB3, sex hormones 
regulate the expression of certain cell surface receptors or their signalling involved in VSMC 
contractility. These receptors include vasoconstrictor receptors, such as type 1a α-
adrenoreceptor, AT1 receptor (the major angiotensin II receptor) and ETα/ETβ2 (endothelin-1 
receptors for constriction). Another possible mechanism is that that some EFNB3-associating 
proteins start to respond to sex hormones only when EFNB3 is deleted, with regard to their 
downstream connection/modulation of VSMC contracting machinery. In other words, although 
they are capable of associating with EFNB3, they still regulate VSMC contractility in the 
absence of EFNB3, but such regulation is now being modulated by sex hormones. The above-
described two mechanisms are not mutually exclusive. 
 
The HR of male but not female KO mice was significantly higher than that of the WT 
counterparts, especially during night when the mice were active (Fig. 2A). The Efnb3 KO mice 
used in this study have a general deletion of the gene. One of the possible reasons of the 
increased HR is that EFNB3 has a functional role in heart rhythm pacing cells, and such a role 
is sex-dependent. Another possibility is that as EFNB3 has known function in the central 
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nervous system(Kullander et al., 2001a) , it might influence the circadian neural outflow to the 
pacing cells. These possibilities are under investigation. However, such a HR increase did not 
influence BP in males, likely due to multiple BP compensation mechanisms. Such HR 
phenotype did not appear in KO females, and therefore, does not contribute to the increased BP 
in them. In castrated KO males, the HR also increased and such an increase might contribute to 
the higher BP. However, increased VSMC contractility remains a significant contributor to the 
elevated BP, as evidence by our ex vivo and in vitro data.  
 
Estrogen was required to manifest the hypertensive phenotype in KO females, while androgen 
suppressed this phenotype, as proved by KO mice with ovariectomy and castration (Figs. 2A, 
2B, 5F and 5G). If the mouse results are relevant to humans,, for men with loss-of-function 
mutations in the EFNB3 gene, a decrease of testosterone level will increase their hypertension 
risks, and menopause will confer a protective effect against hypertension for the affected 
females. Male hypogonadism has high prevalence: about 30% males above age of 40 years are 
hypogonadic(Zitzmann, 2009). Reports overwhelmingly indicate that hypogonadism in men, 
whether evoked by ageing, diabetes, chemical castration or other unidentified factors, correlates 
with hypertension(Garcia-Cruz et al., 2012; Liu, Death, & Handelsman, 2003; Reckelhoff & 
Granger, 1999; Svartberg et al., 2004; Torkler et al., 2011; Traish, Miner, Morgentaler, & 
Zitzmann, 2011; Zitzmann, 2009). We discovered that contractility of male KO VSMCs could 
be enhanced by the nongenomic effect of estrogen. This is consistent with the finding that KO 
VSMCs presented augmented GPR30 expression(Huang, Jacobson, & Schaller, 2004; Prossnitz 
& Barton, 2014; Roman-Blas, Castaneda, Largo, & Herrero-Beaumont, 2009). With that said, 
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our results could not rule out the involvement of the genomic effect of estrogen on KO VSMC 
contractility.  
 
There is existing literature related to the inhibitory effect of estrogen on vessel contraction. 
However, most of such data come from rat or rabbit experiments(Gui, Zheng, Zheng, & Walsh, 
2008; Koga, Hirano, Nishimura, Nakano, & Kanaide, 2004), and such effect is often attributed 
to the regulation of nitric oxide production by endothelium(Farhat, Lavigne, & Ramwell, 1996). 
Controversies remain in this regard. For example, α2-AR antagonist-induced mouse tail artery 
constriction is not affected by estrogen(Eid et al., 2007) ; estrogen has no effect on the PE-
induced constriction in aortic rings from iNOS KO mice(Zhu et al., 2002) . Further, in women 
taking estrogen-containing contraceptives, about 5% will develop de novo hypertension. 
Therefore, we regard the effect of estrogen on BP regulation and VSMC contractility as 
unresolved controversy. In our model, VSMCs are totally devoid of endothelial cells. Possible 
explanations for such controversy include species differences, and difference in how completely 
the endothelial cells are removed from the vessels during experimentation.  
 
The effect of estrogen on enhancing male KO VSMC contractility might have relevance to our 
current health problems: estrogen levels in males tend to increase in industrialized countries. 
This is caused by 2 factors. Firstly, adipose tissue is a major periphery source of aromatase 
activity, which converts testosterone into estrogen(Nelson & Bulun, 2001), hence increased 
estrogen levels locally (particularly in the perivascular adipose tissue) or systemically in 
overweight/obese individuals. Secondly, our exposure to environmental xenoestrogens 
(chemical compounds mimicking endogenous estrogen) in industrialized world is on the 
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rise(Danzo, 1998). Therefore, for male patients with loss-of-function EFNB3 mutation, if their 
GPR30 expression is increased as is the case in mice, they will have increased hypertension risk 
if they are overweight or obese, as would be expected in metabolic syndrome. Similarly, due to 
exposure to xenoestrogens, living in industrialized countries also poses increased risks of 
hypertension for males carrying EFNB3 mutations.  
 
Our additional human genetic study revealed that 5 single nucleotide polymorphisms (SNPs) in 
the EFNB3 gene present higher frequency in hypertensive patients than in normotensive ones, 
and are thus significantly associated with hypertension risks (data not shown). Such data 
corroborate our findings in the EFNB3 KO mice and demonstrate the relevance of the data from 
our animal studies to human hypertension. Based on this, we could propose the following 
therapeutic options. For those men with hypertension caused by a combination of EFNB3 loss-
of-function plus hypogonadism, testosterone might be a safe and effective personalized 
medicine. Elevated estrogen levels in males might represent a l hypertension risk if they carry 
the EFNB3 mutations, and estrogen antagonists might be an effective therapy. For females with 
loss-of-fucntion EFNB3 mutations, avoiding estrogen replacement therapy after menopause 
might reduce their risk of hypertension. Of course, a large amount of clinical study will be 
needed to validate our proposed therapeutic strategies.  
 
Our previous work has shown that several members of the Eph/EFN family (e.g., EphB6 and 
EFNB1) have default negative impacts on VSMC contractility, as their deletion leads to 
hypertension(Luo et al., 2012; Z. Wu et al., 2012) . This study has added a new member to this 
category. On the other hand, certain other members of the family, such as EphB4 has defaults 
  177 
positive impacts on VSMC contractility and its deletion results in reduced VSMC contractility 
and lower BP(Y. Wang et al., 2015). Collectively, our research has revealed a previously 
unknown Eph/EFN-based mechanism for blood pressure regulation. An interesting question is 
why there needs to have opposing forces from members of the same families to regulate blood 
pressure. In the biological systems, such opposing forces are widely present. Examples are: 
protein phosphorylation versus dephosphorylation; calcium influx versus outflux in a cell; 
sympathetic versus parasympathetic neurological activities, etc. Such opposing forces, which 
can also be called Yin and Yang, provide a mechanism for achieving the rejuvenation or 
homeostasis of biological processes and systems to cope with ever-changing external 
environments. Co-existing positive and negative regulatory effects on VSMC contractility by 
different members of the EPH/EFN family likely provide an additional layer of stabilizing force 
to maintain blood pressure within an acceptable range. EFN and Eph members are constitutively 
expressed on VSMCs and engaged with each other constantly. Therefore, they are probably not 
for rapid regulation of blood pressure or for rejuvenation of each other’s signalling pathways, 
but rather for some chronic fine-tuning of vascular tone.  
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Tables 
Table 1.  
Gpr30 siRNA sequences 
Gene Sense sequence antisense sequence 
Gpr30 5’-GCUCUGUUAAUCUAACGAUCAGACUUA-3’ 5’-CGAGACAAUUAGAUUGCUAGUCUGA-3’ 
5’- UUGAGAGUAUGACAUAGCUUAGCCCAC-3’ 5’- AACUCUCAUACUGUAUCGAAUCGGG-3’ 
5’-AGAUCCAUUUACAGCUCGCUGUUCCCA -3’ 5’-TCUAGGUAAAUGUCGAGCGACAAGG-3’ 
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Figures and Legends 
 
Figure 1. Efnb3 deletion in vascular cells from Efnb3 KO mice 
The experiments were conducted twice, and data from representative experiments are reported.  
A.  Efnb3 mRNA deletion in mesenteric arteries of Efnb3 KO mice 
Efnb3 mRNA expression in mesenteric arteries from WT and Efnb3 KO mice was measured by 
RT-qPCR with β-actin mRNA as internal control. Samples in RT-qPCR were in triplicate, and 
means + SEM of Efnb3 signal/β-actin signal ratios are reported. 
B. EFNB3 deletion in VSMC 
WT and EFNB3 KO VSMC cultured for 4-5 days were stained with mouse anti-human α-actin 
mAb (in pseudo-green color) followed by Rhodamine-conjugated goat anti-mouse IgG Ab, and 
goat anti-mouse-EFNB3 Ab followed by Rhodamine-conjugated bovine anti-goat IgG Ab (in 
pseudo-red color). Nuclei were identified by DAPI staining.  
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Figure 2. Increased BP in female Efnb3 KO mice 
BP and HR of male (A) and female (B) KO and WT mice were measured by radiotelemetry 
starting at least 7 days after transmitter implantation. Number per group and the mean ages of 
the mice at the time of BP measurement are indicated. The BP and HR of all mice were measured 
for 72 h. Means ± SEM of hourly BP and HR are plotted. MAP: mean arterial pressure; SP: 
systolic pressure; DP: diastolic pressure; HR: heart rate. The 72 hourly values were used for 
statistical analysis (ANOVA). P-values are indicated.  
 
Figure 3. Female but not male VSMC contractility is augmented by EFNB3 deletion  
All experiments were conducted 3 times independently. Data from representative experiments 
are presented.  
 
A and B. Contractility of mesenteric arteries from Efnb3 KO mice  
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Segments of the third-order branch of the mesenteric artery with or without endothelium from 
male (A) or female (B) KO and WT mice were stimulated with PE. A single cumulative 
concentration-response curve to PE (1 nmlo/L to 100 µmol/L) was obtained. Maximal tension 
(Emax) was determined by challenging the vessels with physiological saline containing 127 
mmol/L KCl. Vessel contractility is expressed as the percentage of Emax. Data from 3 pairs of 
mice (WT versus KO; tested independently in 3 separate days) per group were pooled, and 
means + SEM are reported. Statistically significant differences were assessed by Student’s t test. 
*: p<0.05. 
 
C and D. Increased contractility of VSMCs from female but not male Efnb3 KO mice 
VSMCs were isolated from the mesenteric arteries and aorta of male (C) or female (D) WT and 
KO mice, and cultured for 4 days. They were then stimulated with 20 μM PE at 37oC and imaged 
every min for 15 min. Means + SEM of percentage contraction of more than 15 cells per group 
are reported. The experiment was conducted 3 times, using 3 pairs of WT and KO mice in 3 
different days, and data from a representative one are shown. Statistically significant differences 
were assessed by Student’s t test. *: p<0.05. 
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Figure 4. Signalling events related to contractility of KO and WT VSMCs 
A.  Normal α1-AR expression in Efnb3 KO VSMCs according to immunofluorescence 
microscopy 
VSMCs from female (left panel) and male (right panel) Efnb3 KO or WT mice were cultured 
for 4 days, then stained with Ab against α1-AR and α actin. For each experiment, more than 15 
α-actin-positive cells were randomly selected, and their total α1-AR immunofluorescence 
intensity and cell size were measured. The upper panels are the micrographs of α1-AR 
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immunofluorescent staining. The lower panels present means + SEM of α1-AR fluorescence 
intensity per unit of arbitrary cell area (pixel) of all cells examined in a group of a representative 
experiment. The data were analyzed by paired Student’s t test, but no significant difference was 
found. The experiment was performed three times independently and data of a representative 
one are shown. 
 
B. Normal Ca++ flux in VSMCs from Efnb3 KO mice 
VSMCs from male (right panel) and female (left panel) Efnb3 KO or WT mice were cultured 
for 4 days and loaded with Fura2. They were then placed in HBSS at 37oC and stimulated with 
PE. Arrows indicate the time points at which PE (20 μM) was added. The ratio of emissions at 
510 nm triggered by 340 nm versus 380 nm excitation in each cell was registered every 3 s for 
1 min. The experiments were conducted 3 times independently. Means + SEM of the ratio of 
more than 15 randomly selected VSMC of a representative experiment are illustrated. No 
statistical significant difference between the KO and WT groups are found according to 
ANOVA. 
 
C-D. Phosphorylation of MLCK and MTPT in VSMCs from KO and WT mice 
VSMC from female and male KO and WT mice were cultured for 4 days, then stimulated with 
20 μM PE for 3 s and immediately lysed. Total (T-) and phosphorylated (P-) MLCK (C) and 
MYPT (D) were analyzed by immunoblotting, which was conducted twice. Immunoblotting 
from representative experiments are illustrated. Data from densitometry of all the immunoblots 
are presented as bar graphs with mean + SD shown. 
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Figure 5. Estrogen enhances but testosterone suppresses and VSMC contractility and hence BP 
in the absence of EFNB3 
VSMCs were cultured in medium containing charcoal-stripped FCS for 3-4 days. Means + SEM 
of percentage contraction of more than 15 cells per group are registered. Statistically significant 
differences were assessed by ANOVA followed by post hoc examination. P-values between 
groups with significant differences are indicated. All experiments were conducted 3 times 
independently. Data from representative experiments are presented. 
 
A. Long-term estrogen treatment augments contractility of VSMCs from KO but not WT mice 
VSMCs from WT and KO males were cultured for 3-4 days in the presence of 17β-estradiol 
(100 pg/ml) or vehicle, and then stimulated with PE (20 μM). Cell contractility was registered.  
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B. Short-term estrogen treatment augments contractility of VSMCs from KO but not WT male 
mice 
VSMCs from male KO or WT mice were cultured for 3-4 days and then stimulated with 17β-
estradiol (100 pg/ml) or vehicle for 15 min. In the same last 15 min of culture, PE (20 μM) was 
also added and VSMC contractility was recorded. 
C. Long-term testosterone treatment suppresses contractility of VSMCs from female KO but not 
WT mice 
VSMC from WT and KO females were cultured for 3-4 days in the presence of 5α-
dihydrotestosterone (6.49 ng/ml) or vehicle, and then stimulated with PE (20 μM). VSMC 
contractility was recorded. 
D. Short-term testosterone treatment has no effect on contractility of VSMCs from female KO 
or WT mice 
VSMCs from female KO or WT mice were cultured for 3-4 days and then stimulated with 5α-
dihydrotestosterone (6.49 ng/ml) or vehicle for 15 min. In the last 15 min of culture, PE (20 μM) 
was also added and VSMC contractility was recorded. 
E. Cell membrane-impermeable testosterone-3-(O-carboxymethyl)-oxime-BSA has not effect on 
contractility of VSMCs from female KO or WT male mice 
VSMCs from female KO or WT mice were cultured for 3-4 days in the presence of cell 
membrane-impermeable testosterone-3-(O-carboxymethyl)-oxime-BSA (1.1 μg/ml) and then 
stimulated with PE (20 μM). VSMC contractility was recorded. 
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F and G. Castrated male KO mice are hypertensive and ovariectomized female KO mice are 
normotensive 
BP and HR of castrated male (F) and ovariectomized female (G) KO and WT mice were 
measured by radiotelemetry as described in Figure 2. Telemetry transmitters were implanted in 
the mice, and after at least 1 month, they were castrated or ovariectomized. Telemetry was 
conducted 3 weeks after gonadectomy. Number per group and the mean ages of the mice at the 
time of BP measurement are indicated. The BP and HR of all mice were measured for 72 h. The 
72 hourly values were used for statistical analysis (ANOVA). P-values are indicated.  
 
Figure 6. EFNB3 deletion enhances GPR30 expression and results in increased VSMC 
contractility in the presence of estrogen 
A. EFNB3 KO VSMCs present enhanced Gpr30 mRNA expression according to RT-qPCR 
VSMCs from male KO or WT mice were cultured in medium containing charcoal-stripped FCS 
for 4 days, and their Gpr30 mRNA levels were measured by RT-qPCR. The samples were in 
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triplicate. Data from 3 independent experiments are pooled and mean + SD of signal ratios of 
Gpr30 versus β-actin are shown. The data were analyzed by Student’s t test. *: p<0.05.  
B. EFNB3 KO VSMCs present enhanced GPR30 protein expression according to 
immunfluoscence  
VSMCs from male KO or WT mice were prepared as described in A, and their GPR30 protein 
expression was detected by immunofluorescence. Micrographs are shown at left. For each 
experiment, more than 15 α-actin-positive cells per type of VSMCs were randomly selected, 
and their total immunofluorescence intensity and cell size were recorded AxioVision software. 
Means + SEM of fluorescence intensity per unit of arbitrary cell area (pixel) of all cells 
examined in a given type of VSMCs of 3 independent experiments are pooled and summarized 
in a bar graph at right. The data were analyzed by Student’s t test. *: p<0.05. 
 
C and D. GPR30 knockdown by siRNA abolishes estrogen-promoted KO VSMC contractility  
VSMCs from male KO and WT mice were cultured for 40 h in regular medium containing 
charcoal-stripped FCS. They were then transfected with a mix of 3 pairs of Gpr30 siRNAs (for 
each pair, the final concentration was 10 nM), or control siRNA, and cultured in medium free 
of antibiotics, as described before (Z. Wu et al., 2012). Forty eight hours after the siRNA 
transfection, VSMCs were treated with 17β-estradiol (100 pg/ml) or vehicle for 15 min. In the 
same last 15 min of culture, PE (20 μM) was also added and VSMC contractility was assessed 
(D). The cells were then harvested, their Gpr30 mRNA levels were determined by RT-qPCR 
(C). The experiment was conducted 3 times. Data (mean + SEM) of a representative one are 
shown. *: p<0.05 (Student’s t test) between cells treated with Gpr30 siRNA plus estrogen versus 
control siRNA plus estrogen. 
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Figure 7. Normal 24-hour urinary catecholamine levels in Efnb3 KO mice 
Male and female Efnb3 KO and WT mice were placed in metabolic cages. Urine was collected 
during a 24-h fasting period. Urinary catecholamines were measured by competitive enzyme 
immunoassay. Means + SEM of hormones excreted during the 24-h period and mouse number 
per group (n) are presented. No statistically significant differences were found between KO and 
their WT counterparts (unpaired Student’s t test). 
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Abstract 
Several EPHB receptor tyrosine kinases and their ligands, ephrinBs (EFNBs), are involved in 
blood pressure regulation in animal models. We selected 522 single nucleotide polymorphisms 
(SNPs) within the genes of EPHB6, EFNB2, EFNB3 and GRIP1 in the EPH/EFN signalling 
system to query the International Blood Pressure Consortium dataset. A SNP within the GRIP1 
gene presented a p-value of 0.000389, approaching the critical p-value of 0.000302, for 
association with diastolic blood pressure of 60,396 individuals. According to echocardiography, 
we found that Efnb3 gene knockout mice showed enhanced constriction in the carotid arteries. 
In vitro studies revealed that in mouse vascular smooth muscle cells, siRNA knockdown of 
GRIP1, which is in the EFNB3 reverse signalling pathway, resulted in increased contractility of 
these cells. These data suggest that molecules in the EPHB/EFNB signalling pathways, 
specifically EFNB3 and GRIP1, are involved blood pressure regulation.  
 
Key words: GRIP1, EFNB3, blood pressure, SNPs 
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Introduction 
EPH kinases are the largest family of receptor tyrosine kinases. They are divided into A and B 
subfamilies according to sequence homology("Unified nomenclature for Eph family receptors 
and their ligands, the ephrins. Eph Nomenclature Committee," 1997). Ephrins (EFNs), which 
are also cell surface molecules, are ligands of EPHs. EFNs are classified as A and B subfamilies. 
EFNAs attach to the cell surface through glycosylphosphatidylinositol anchoring, whereas 
EFNBs attach through transmembrane sequences(Flanagan & Vanderhaeghen, 1998; Pasquale, 
2008; Wilkinson, 2000). Interactions among EPHs and EFNs are promiscuous but, in general, 
EPHA members interface preferentially with EFNAs, and EPHBs with EFNBs(Flanagan & 
Vanderhaeghen, 1998; Pasquale, 2008; Wilkinson, 2000). Such redundancy suggests that these 
kinases are crucial in various biological contexts. EFNs can stimulate EPH receptors, and this 
is called forward signalling. Interestingly, EPHs are also capable of stimulating EFNs which 
then transmit signalling reversely into cells, a phenomenon known as reverse signalling.  
EPHs and EFNs are expressed in many tissues and organs. They play important roles in the 
central nervous system(Flanagan & Vanderhaeghen, 1998; Wilkinson, 2000), immune 
system(Luo, Charpentier, et al., 2011; Luo, Wan, Wu, & Wu, 2001; Luo, Wu, et al., 2011; Luo, 
Yu, Tremblay, & Wu, 2004; Luo, Yu, Wu, & Wu, 2002; J. Wu & Luo, 2005; Yu, Luo, Wu, & 
Wu, 2003a, 2003b, 2004; Yu, Mao, Wu, Luo, & Wu, 2006), digestive system (Batlle et al., 
2002), bone metabolism (Davy, Bush, & Soriano, 2006; Zhao et al., 2006), angiogenesis (H. U. 
Wang, Chen, & Anderson, 1998)and other processes (Dravis et al., 2007; Hashimoto et al., 2007; 
Konstantinova et al., 2007). 
We recently reported that EPHB6, in concert with sex hormones, is crucial in VSMC contraction 
and blood pressure (BP) regulation(Luo et al., 2012). Ephb6 gene knockout (KO) mice after 
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castration manifest higher blood pressure that their wild type (WT) counterparts(Luo et al., 
2012). Vascular smooth muscle cells (VSMC) are a target tissue through which EPHB6 exerts 
its effect on BP control. Since EPHB6 and all its major ligands of the EFNB family, i.e., EFNB1, 
EFNB2 and EFNB3, are expressed in VSMCs(Luo et al., 2012), there is a molecular framework 
for their function in these cells. We showed that while solid-phase recombinant EPHB6 reduces 
VSMC contraction in response to phenylephrine (PE) stimulation, solid-phase anti-EPHB6 
antibody (Ab) does not(Luo et al., 2012), indicating that reverse signalling from EPHB6 to 
EFNBs but not forward signalling from EFNBs to EPHB6 is responsible for dampening VSMC 
contractility. In support of this notion, we have shown that deletion of EFNB1, a ligand of 
EPHB6, results in a hypertensive phenotype in mice(Z. Wu et al., 2012). Therefore, we 
identified EPHB6 and, by logical extension and with certain experimental evidence, its ligands 
(EFNBs) as novel BP regulatory factors in animal models. 
In order to establish the relevance of our findings in mice to human blood pressure regulation, 
we selected 522 single nucleotide polymorphisms (SNPs) within the genes of EPHB6, EFNB2, 
EFNB3 and GRIP1, which is a key molecule in EFNB reverse signalling, to query the 
International Blood Pressure Consortium (IBPC) dataset, which contains SNP information on 
69,395 individuals. We found that a SNP in the GRIP1 gene approached statistical significance 
for association with diastolic blood pressure in humans. Additional animal studies revealed roles 
of EFNB3 and GRIP1in regulating arterial tone and VSMC contractility, providing phenotypic 
evidence supporting the genetic findings in humans. 
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Materials and Methods 
Meta-analysis of SNPs in EPHB and EFNB genes and a related gene GRIP1 for association 
with BP phenotypes in humans 
The p-values for association with diastolic pressure (DP) and systolic pressure (SP) were 
calculated for a total of 528 SNPs found within the regions of 4 genes (EPHB6, EFNB2, EFNB3 
and GRIP1) and within 10 kb 5’ and 3’ of these genes, employing the LocusZoom genome 
browser(http://csg.sph.umich.edu/locuszoom/) to query the IBPC dataset(International 
Consortium for Blood Pressure Genome-Wide Association et al., 2011), which contains SNP 
information on 69,395 individuals of European ancestry in 29 general population-based cohorts.  
These 528 SNPs represented 166 independent linkage disequilibrium (LD) blocks, as 
determined by the Tagger program(de Bakker et al., 2005) on the HapMap 
website(http://hapmap.ncbi.nlm.nih.gov.). Table 1A lists the genes and regions in which the 
SNPs are located. Query of 166 independent LD blocks resulted in a Bonferroni-corrected 
critical p-value of 0.0003012 for a given BP phenotype (systolic or diastolic pressure). Looking 
for the best results between systolic or diastolic pressure phenotypes would require a lower 
critical p-value; however, correcting for 2 X 166 tests (p=0.000151) would be overly 
conservative as these 2 measurements are not independent. 
Efnb3 KO mice 
Efnb3 KO mice were produced by Regeneron Pharmaceuticals, as described 
previously(Kullander et al., 2001), and generously provided to us. They had been backcrossed 
to the C57BL/6 background for more than 10 generations. Age- and gender-matched wild type 
(WT) littermate mice served as controls and are referred to as WT mice. The mice were housed 
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in ambient temperature (22oC) with 12-h light and dark cycles. For all the in vivo experiments, 
mice were housed one per cage.  
Echocardiography 
Transthoracic echocardiography was undertaken in mice lightly anesthetized with isoflurane. 
The experiments were always conduced around noon time. The oestrus cycles of the females 
were not monitored. Their carotid vessels and heart were imaged with a high-resolution 
ultrasound biomicroscope (Vevo770; Visualsonics, Toronto, ON, Canada) equipped with a 100% 
bandwidth 30-MHz central frequency transducer (RMV-707, 12.7 mm focal length, 6 mm 
aperture). Lateral and axial resolutions with this probe are ~115 μm and ~55 μm, 
respectively(Zhou et al., 2004). Preheated ultrasound transmission gel (Aquasonic 100, Parker 
Laboratories, Orange, NJ, USA) was placed on regions of interest to provide acoustic coupling 
medium between the transducers and animals. The left and right common carotid arteries were 
imaged longitudinally in B mode to guide recordings of Doppler time-varying flow velocities 
for 2 s. Doppler sample volume was positioned 1-2 mm prior to the carotid bifurcation at a 60o 
angle. Acquired angle-corrected Doppler data were analyzed to measure the mean Pourcelot 
index (PI) over 10 consecutive cardiac cycles, according to Stoyanova et al.(Stoyanova, Trudel, 
Felfly, Garcia, & Cloutier, 2007). The PI is a dimensionless echocardiographic parameter that 
characterizes vascular hemodynamics downstream of a measurement point. It depends on both 
arterial compliance and downstream vascular resistance. 
The heart was also imaged in B mode via the parasternal long-axis view to assess aortic 
hemodynamics and cardiac output (CO). The M-mode sampling line was positioned 
perpendicularly to the ascending aorta, 0.5-1.5 mm downstream of the aortic valve, and time-
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varying tracings tracked changes in aortic diameter (AoD). Mean AoD was assessed over 5 
consecutive cardiac cycles. Doppler velocity waveforms were then recorded in the ascending 
aorta by positioning sampling volume at the exact same location where M-mode tracings were 
obtained. The envelope of angle-corrected (60o) Doppler tracings was delineated manually to 
compute the velocity time integral (VTI), which was averaged over 10 cardiac cycles. Assuming 
a parabolic velocity profile in the ascending aorta(Stoyanova et al., 2007), stroke volume (SV) 
was calculated (in ml) as ½ (AoD / 2)2 × π × VTI, and CO (in ml/min) was estimated as SV  
heart rate (HR), where HR was mean HR of the animals. 
Left ventricle (LV) dimensions (in mm) at end-systole and end-diastole were finally assessed to 
quantify fractional shortening, ejection fraction and LV mass. B-mode parasternal long-axis 
viewing guided the capture of M-mode tracings through the anterior and posterior LV walls at 
the level of the papillary muscle. For each mouse, LV end-diastolic diameter (LVEDD), LV 
end-systolic diameter (LVESD), LV end-diastolic posterior wall thickness (LVEDPW) and 
intra-ventricular septum dimension at end-diastole (IVSED) were quantified, and LV mass 
ascertained in mg with the following equation(Pollick, Hale, & Kloner, 1995; Yang et al., 1999): 
LV mass (mg) = 1.055  [(LVEDD + LVEDPW + IVSED) – LVEDD] 
A visual illustration of methods of mouse cardioechography can be found in a video publication 
by Respress and Wehren(Respress & Wehrens, 2010). 
VSMC isolation 
Mouse VSMC were isolated from aortic and mesenteric arteries, including their secondary 
branches as described before(Luo et al., 2012; Z. Wu et al., 2012).  
siRNA transfection and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
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The sequences of Grip1, Pdg-rgs3, and Disheveled siRNA and siRNA transfection procedures 
are described in our previous publication(Luo et al., 2012). Their mRNA levels in VSMCs were 
measured by RT-qPCR; the primer sequences and qPCR cycling program are detailed 
before(Luo et al., 2012). -actin mRNA served as internal control. Samples were tested in 
triplicate, and the data were expressed as signal ratios of test gene mRNA/α-actin mRNA. 
VSMC contractility 
VSMC contractility was measured as described before(Luo et al., 2012; Z. Wu et al., 2012). 
Briefly, the cells were cultured in wells coated with goat anti-mouse EFNB3 Ab (sc-7281, Santa 
Cruz Biotechnology, Dallas, Texas) or control goat IgG (2 µg/ml during coating). After 3-4 days,  
they  were stimulated with PE (20 μmol/L), and photographed continuously for 15 min at a rate 
of 1 picture per min. Fifteen or more cells were randomly selected, and their length was 
measured at each time point with Zeiss Axiovision software. Percentage contraction was 
calculated as follows: 
 
% contraction = 100 x (cell length at time 0-cell length at time X) / cell length at time 0.  
Ethics Statement 
This study was carried out in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was 
approved by the Institutional Committee on Animal Care of Research Centre, Centre hospitalier 
de l’Université de Montréal (Permit Number: 4I14033JWs). All surgery was performed under 
isoflurane anesthesia, and all efforts were made to minimize suffering. 
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Results 
Association of SNPs in the EPHB/EFNB system with BP phenotypes 
Our previous studies(Luo et al., 2012; Z. Wu et al., 2012) along with some of our unpublished 
observations indicate that molecules in the EPHB and EFNB families (e.g., EPHB6, EFNB1, 
EFNB2, and EFNB3) and a certain adaptor protein (GRIP1) within their signalling pathways 
are novel factors that can modulate BP in mice. The relevance of these molecules in human BP 
regulation was investigated. The IBPC conducted a meta-analysis of genome-wide association 
scanning (GWAS) in 69,395 individuals of European ancestry in 29 cohorts from European and 
North American countries(International Consortium for Blood Pressure Genome-Wide 
Association et al., 2011). Two and a half million genotyped or imputed SNPs were tested for 
their association with SP and DP in these individuals. We queried the results of this meta-
analysis for association of 528 SNPs in EPHB6, EFNB2, EFNB3 and GRIP1 genes with systolic 
or diastolic pressure in these individuals. EFNB1 was not included in the analysis because it is 
an X-linked gene, and its SNP information is not available in the IBPC dataset. The p-values of 
these SNPs for their association with systolic or diastolic pressure are illustrated in 
Supplementary Figure 1 (S. Fig. 1). Table 1B summarizes the names of SNPs with the most 
significant association and their p-values. The minimum observed p-value for any association 
(0.000389) was for the association of SNP rs1495496 located within the GRIP1 gene with 
diastolic pressure. This value approaches the critical p-value of 0.000302. For the other 3 genes 
analyzed, i.e., EPHB6, EFNB2 and EFNB3, the minimum p-values of their SNPs did not 
approach the critical p-value. The implications of these findings are elaborated in the Discussion. 
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Table 1. Association of SNPs in the EPHB6/EFNB system with BP phenotypes in 69,396 human 
subjects 
A. Locations of 4 genes for which 528 SNPs were tested 
 Build 36 Build 37 
Gene Location 
Size 
(kb) 
Location size (kb) 
EPHB6 
chr7:                
142,252,914 -
142,288,969               
36.06 
chr 7:                    
142,542,792 - 
142,578,847 
36.06 
EFNB2 
chr13:                 
105,930,097-
105,995,338 
65.24 
chr 13:       
107,132,079-
107,197,388 
65.31 
EFNB3 
chr17:               
7,539,245-7,565,418 
26.17 
chr 17:                    
7,598,520-7,624,693 
26.17 
GRIP1 
chr12:    
65,019,066-65,369,020 
349.95 
chr 12:  
66,731,211-67,082,925 
351.71 
 
B. Minimum p-values from IBPC meta-analysis among SNPs examined within EPHB6, EFNB2, 
EFNB3 and GRIP1 genes 
Gene 
Number of 
SNPs examined 
LD  
Blocks 
r2=0.8 
Diastolic Pressure Systolic Pressure 
SNP p-value SNP p-value 
EPHB6 48 4 rs1009848 0.0373 rs2299557 0.404 
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EFNB2 54 24 rs2057408 0.077 rs9520087 0.218 
EFNB3 6 6 rs3744258 0.201 rs3744258 0.191 
GRIP1 420 132 rs1495496 0.000389 rs1495496 0.00144 
Total 528 166 Critical p value: 0.05/166 = 0.0003012 
 
 
Small artery resistance in EFNB3 KO mice in vivo  
EFNB3 is an EPHB6 ligand, and its function might contribute to the BP phenotype observed in 
Ephb6 KO mice(Luo et al., 2012). We assessed several BP related parameters in Efnb3 KO mice 
(called KO mice hereafter) using echocardiography.  
BP is a function of CO, blood volume and blood vessel flow resistance. Echocardiography was 
employed to examine CO, the PI (a parameter reflecting blood vessel flow resistance) of carotid 
arteries, and LV mass in live KO and WT mice. Due to technical limitations, we were not able 
to conduct echocardiography in smaller arteries. CO in male (Table 2A) and female (Table 2B) 
KO mice was comparable to that in WT controls, indicating that this parameter, which could 
affect BP, is not under the influence of EFNB3. However, the left carotid PI in female KO (Table 
2B) but not male KO (Table 2A) mice was significantly higher than that of WT counterparts 
(p=0.0218), reflecting heightened resistance of these small arteries. LV mass increased 
significantly in female but not in male KO mice, compared to their WT counterparts (p=0.0397, 
Table 2B). This hypertrophy might be the result of augmented cardiac workload in female KO 
mice to overcome the heightened blood flow resistance of their small arteries. 
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Table 2. Echocardiographic analysis of CO, carotid artery resistance and left ventricle mass of 
Efnb3 KO and WT mice 
BP-related echocardiographic parameters of individual Efnb3 KO and WT mice are reported. 
Means + SD are shown at the end of each group, and p values (unpaired one-way Student’s t 
test) are indicated at the bottom of Tables 2A and 2B. PI: Pourcelot index; LV: left ventricle.  
A. Echocardiographic parameters of male Efnb3 KO mice 
Mouse Type Age Cardiac 
output(ml/min) 
Left Carotid PI Right Carotid 
PI 
LV 
Mass(mg) 
KO male 15wk 14.65 0.75 0.72 103.7 
KO male 15wk 21.46 0.87 0.68 125.8 
KO male 15wk 24.79 0.73 0.78 154.1 
KO male 15wk 17.23 0.74 0.70 91.7 
KO male 15wk 14.93 0.78 0.78 89.7 
KO male 14wk 18.2 0.73 0.72 133.6 
KO mean  18.54 0.77 0.73 116.4 
SD  3.939 0.0533 0.041 25.65 
      
WT male 14wk 21.5 0.83 0.84 116.0 
WT male 15wk 15.33 0.74 0.70 140.5 
WT male 15wk 23.52 0.75 0.77 115.6 
WT male 15wk 18.21 0.73 0.72 133.6 
WT male 14wk 31.85 0.77 0.86 115.0 
  212 
WT male 14wk 28.57 0.77 0.81 145.1 
WT male 14wk 24.19 0.74 0.76 152.7 
WT male 14wk 30.95 0.79 0.83 175.6 
WT mean  24.265 0.77 0.78 126.4 
SD  5.92 0.030 0.047 12.57 
p value (t 
test) 
 0.0637 0.9075 0.08200 0.4967 
 
 
 
B.  Echocardiographic parameters of female Efnb3 KO mice 
Mouse Type Age Cardiac 
output(ml/min) 
Left Carotid PI Right Carotid 
PI 
LV 
Mass(mg) 
KO female 15wk 21.89 0.75 0.78 112.3 
KO female 15wk 16.29 0.77 0.8 92.5 
KO female 14wk 20.16 0.81 0.81 121.1 
KO female 15wk 27.57 0.76 0.77 143.3 
KO female 15wk 20.54 0.94 0.76 130.5 
KO female 14wk 27.71 0.75 0.73 134.3 
KO female 15wk 19.13 0.8 0.77 135.8 
KO female 14wk 18.38 0.81 0.82 122 
KO mean  21.45 0.79 0.78 123.9 
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SD  4.153 0.062 0.029 16.04 
      
WT female 14wk 33.49 0.72 0.72 109 
WT female 14wk 18.92 0.69 0.67 118.1 
WT female 14wk 29.03 0.71 0.8 110.9 
WT female 14wk 28.06 0.81 0.79 95.9 
WT female 14wk 15.96 0.68 0.76 114.6 
WT female 14wk 22.46 0.7 0.74 72.2 
WT mean  24.65 0.71 0.74 93.4 
SD  6.664 0.047 0.048 29.98 
p value(t 
test) 
 0.289 0.0218 0.132 0.0397 
 
GRIP1 knockdown by siRNA cancelled the effect of solid phase anti-EFNB3 Ab on the 
contractility of WT VSMCs  
The echocardiography results suggest that the default function of EFNB3 is vessel relaxation, 
and hence the EFNB3 KO carotid artery manifested increased resistance. To prove this at the 
cellular level, we triggered EFNB3 reverse signalling by incubating WT VSMCs in wells coated 
with anti-EFNB3 Ab and tested their contractility. Such solid phase anti-EFNB3 Ab serves as 
an agonist to EFNB3, because it acts at the bottom of the cells and will not block putative 
EFNB3/EPH interaction which might exist at the vertical side of neighboring VSMCs. Further, 
during to the low density used in culture, such fraternal cell interaction is rare. A similar strategy 
of solid phase anti-EFNB1 Ab as an agonist to trigger EFNB1 reverse signalling in VSMCs has 
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been previously published (Z. Wu et al., 2012). As shown in Figures 1A and 1B, WT VSMCs 
crosslinked with anti-EFNB3 Ab presented significantly reduced contractility, compared to 
those cultured in wells coated with normal goat IgG. On the other hand, KO VSMC contractility 
was not affected by anti-EFNB3 crosslinking, as expected, because they have no EFNB3 
expression (data not shown). These results corroborate that of echocardiography and confirm 
that EFNB3 reverse signalling leads to reduced VSMC contractility. The solid phase anti-
EFNB3 Ab indeed triggered signalling in VSMCs in that their ERK phosphorylation upon PE 
stimulation was increased(S. Fig. 2). 
 
Figure 1. Crosslinking EFNB3 on VSMCs results in decreased contractility  
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WT VSMCs were cultured in wells coated with goat anti-mouse EFNB3 Ab or control goat IgG 
(2 µg/ml during coating) for 4 days The cells were then stimulated with PE (20 μmol/L), and 
their percentage contraction was recorded by microscopy.  
A. Micrographs showing the contraction of WT VSMCs in the presence or absence of solid phase 
anti-EFNB3  
Lower row: WT VSMCs cultured in wells coated with goat anti-mouse EFNB3 Ab. The images 
were taken at 0, 7 and 15 min after PE stimulation. Arrows mark the same cells in each row at 
different time points, to show the shortening of the cells. 
B.  Reduced contractility of WT VSMCs cultured in the presence of solid phase anti-EFNB3 Ab 
WT were cultured in wells coated with normal goat IgG or goat anti-mouse EFNB3 Ab for 4 
days. The cells were then stimulated with PE, and were imaged at one frame per min for 15 min.  
Means + SD of the percentage contraction during a 15-min period are reported. The percentage 
contraction is calculated as follows. 
%  contraction = length of cells at a given time point/length of the cells at time 0. 
The data were analyzed with one-way ANOVA, and p-value is indicated. The experiment in this 
figure was repeated three times, and representative data are shown. 
 
EFNBs had no enzymatic activity. However, EFNBs engage adaptor proteins to link their 
intracellular tails to various signalling pathways. Grip1 siRNA was used to knock down the 
expression of this adaptor protein in the WT and KO VSMCs, as it is known to associate with 
EFNBs(Bruckner et al., 1999; Lu, Sun, Klein, & Flanagan, 2001; Tanaka, Kamo, Ota, & 
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Sugimura, 2003). The effectiveness of mRNA knockdown was verified by RT-qPCR (Fig. 2A). 
EFNB3 expression in the WT VSMCs was not affected by the knockdown (S. Fig. 3). WT 
VSMCs were cultured in wells coated with anti-EFNB3 Ab to invoke EFNB3 reverse signalling, 
and KO VSMCs were used as controls. In WT VSMCs, such treatment (Fig. 2B) dampened 
VSMC contractility of WT VSMCs transfected with control siRNA, but such dampening effect 
was reversed by Grip1 siRNA (Fig. 2B). KO VSMCs cultured in wells coated with anti-EFNB3 
Abs had a higher contraction, as they had no EFNB3 and were not affected by anti-EFNB3-
evoked reverse signalling, which could reduce contractility. As expected, Grip1 siRNA 
knockdown did not affect KO VSMC contractility, because GRIP1 was not utilized by the KO 
VSMCs. The effect of GRIP1 knockdown on the augmentation of WT VSMC contractility 
depended on the existence of EFNB3 reverse signalling, as Grip1 siRNA had no effect on the 
contractility of WT VSMCs cultured in wells without anti-EFNB3 Ab coating (Fig. 2C). 
DISHEVELLED AND PDZ-RGS3 are two other proteins capable of associating with the 
EFNB3 intracellular tail [36,37]. However, their knockdown by siRNA had no effect on WT 
VSMC contractility (Fig. 3), suggesting that they were not involved in EFNB3 reverse signalling 
in VSMCs. 
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Figure 2. GRIP1 in the EFNB3 reverse signaling pathway in VSMCs 
Experiments in this figure were repeated more than twice, and representative data are shown. 
A. Effective mRNA knockdown of Grip1 by siRNA 
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Cultured WT VSMC were transfected with siRNAs of a particular gene or control siRNA, as 
indicated. After 24-h culture, the cells were harvested and the mRNA expression of each gene 
was determined by RT-qPCR. The data are expressed as means + SD of the ratios of the target 
gene signal versus the ɑ-actin signal. The data were analyzed by one-way Student’s t test. *: p< 
0.05. 
B. GRIP1 knockdown by siRNAs reverses the effect of solid-phase anti-EFNB3 Ab on reducing 
VSMC contractility 
VSMC from WT and KO mice were cultured in wells coated with goat anti-mouse EFNB3 Ab 
(2 μg/ml during coating). After 2 days, they were transfected with siRNAs targeting Grip1, or 
with control siRNA. On day 4 of culture, they were stimulated with PE (20 μmol/L), and their 
percentage contraction was recorded. Means + SD of the percentage are reported. The thin line 
represents mean contractility of VSMCs cultured in well without coating of anti-EFNB3 Ab as 
an additional control; for better viewing, SD was not added to the line. The data were analyzed 
with one-way ANOVA followed by ad hoc analysis, and p-values of significant difference are 
indicated.  
C.  Grip1 siRNA in the absence of EFNB3 reversing signaling had no effect on VSMC 
contractility 
WT VSMCs were cultured in plain wells without Ab coating. They were transfected with Grip1 
or control siRNA and then stimulated with PE as described in A. Mean + SD of percentage 
contraction are shown. The data were analyzed with one-way ANOVA but not statistically 
significant difference between the test and control groups is found. 
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Figure 3. DISHEVELLED AND PDZ-RGS3 ARE NOT in the EFNB3 reverse signaling 
pathway in VSMCs 
Experiments in this figure were repeated more than twice, and representative data are shown. 
A. Effective mRNA knockdown of Disheveled and PDZ-RGS3 by siRNA 
Cultured WT VSMC were transfected with siRNAs of Disheveled and PDZ-RGS3 as described 
in Figure 2.  The mRNA expression of each gene was determined by RT-qPCR. The data are 
expressed as means + SD of the ratios of the target gene signal versus the -actin signal. The 
data were analyzed by Student’s t test. *: p< 0.05. 
B. Dishevelled and PDZ-RGS3 knockdown by siRNAs had no effect on WT VSMC contractility 
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Contractility of VSMCs from WT mice were assessed in the presence of EFNB3 reverse 
signalling and DISHEVELLED/PDZ-RGS3 knockdown, as described in Figure 2B. The data 
were analyzed with one-way ANOVA but no significant difference was observed.  
 
These results corroborate the finding of the human genetic study, indicating that GRIP1 is 
involved in EFNB3 reverse signalling and VSMC contractility regulation, and it is hence a factor 
modulating blood pressure.  
 
Discussion 
EPHs and EFNs perform critical functions in many tissues and organs. In our previous studies, 
we found that Ephb6 KO and Efnb1 KO mice have augmented BP(Luo et al., 2012; Z. Wu et 
al., 2012). In the current investigation, we provided additional human genetic evidence showing 
that the mutations in GRIP1, a molecule in the EPHB6/EFNB signalling pathway and an adaptor 
protein capable of binding to EFNBs, were associated with human blood pressure phenotype.  
We also provided mouse experimental data showing that the default function of EFNB3, one of 
the ligands of EPHB6, was to reduce arterial tone, and such function depended on signalling via 
GRIP1, corroborating the human genetic findings. 
As of today, no genes in the EPHB/EFNB family have been identified as hypertension risk genes 
in several large-scale GWAS(Adeyemo et al., 2009; Guo et al., 2012; Hiura et al., 2010; 
International Consortium for Blood Pressure Genome-Wide Association et al., 2011; Levy et 
al., 2009; Org et al., 2009; Padmanabhan et al., 2010; Slavin, Feng, Schnell, Zhu, & Elston, 
2011; Wellcome Trust Case Control, 2007). There are a couple of possible reasons. 1) The 
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contribution of genes in the EPHB/EFNB family to the BP phenotype might be relatively small, 
and the possible association is rendered undetectable due to heavy statistical penalties of 
multiple testing in GWAS. 2) In order to reduce the effect of type 2 error resulting from multiple-
testing correction in genome-wide association studies, the IBPC study has assembled very large 
samples by combining cohorts from many sub-studies. The hypothesis is that increasing sample 
size will increase power, allowing the decrease in both type 1 and type 2 errors. However, p-
value is controlled by both sample size and effect size (odds ratio) and, of the two, a slight 
decrease in effect size has a more dramatic impact on p-value. Assembly of large disparate 
cohorts does increase sample size but it also introduces increased heterogeneity, both phenotypic 
and genetic. Such heterogeneity may reduce the average effect size.  
We conducted a more focused query of the IBPC dataset, using only 4 genes in the EPHB/EFNB 
signalling pathway, and discovered that a SNP, rs1495496, located between exons 22 and 23 of 
GRIP1, had a p-value of 0.000389 for its association with DP, which approaches the Bonferroni 
corrected critical p-value 0.000302. This finding is very promising since Bonferroni correction 
by itself was deemed to be quite conservative. Considering our observation that EPHBs/EFNBs 
likely influence vessel tone in mice, the possible association of this SNP in GRIP1 gene with 
DP seems logical. Why does only a SNP from GRIP1 approach significance and not those from 
3 EPHB6/EFNBs queried? GRIP1 is situated in a node of EPHB6, EFNB1 and EFNB3 reverse 
signalling pathway; it thus probably carries more weight than each individual EPHB or EFNB 
member and, hence, is easier to detect for its associations with BP phenotypes. Our recent 
published results(Luo et al., 2012; Y. Wang et al., 2015) and unpublished observations in animal 
models indicate that the effect of EPHBs and EFNBs on blood pressure regulation is not only 
sex-dependent, but also sex hormone level-dependent. It is possible that in a cohort stratified by 
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sex and sex hormone levels, more significant association of BP phenotypes with SNPs from 
GRIP1 and EPHB/EFNB family members will be detected in humans, and this will fully 
establish the relevance of our findings from animal models to human blood regulation. 
Our cardioechogrphy data using EFNB3 KO mice suggest a default sex/sex hormone-dependent 
vasolaxative role of EFNB3 in that its deletion led to increased blood flow resistance in the 
carotid artery of female KO but not male KO mice, compared to their WT counterparts. Such 
increased resistance is not due to developmental changes of the arteries in the KO mice, as we 
found no abnormalities in the aorta and mesenteric arteries in terms of histology and diameters 
(S. Figure 4). 
Using telemetry, we have recently revealed that female but not male KO mice have increased 
BP, but after ovariectomy, the female KO BP returns to the normal range(Y et al.). This finding 
corroborates the data from cardioechography, suggesting that after EFNB3 deletion, increased 
vascular tone results in increased BP, but such effect is sex- and sex hormone level-dependent. 
We demonstrated EFNB3 can modulate VSMC contractility by reverse signalling. EFNB3 is a 
transmembrane protein without enzymatic activity in its intracellular tail. How does it regulate 
VSMC contractility? We have demonstrated that the association of EFNB3 with GRIP1 is 
critical for its function in regulating VSMC contractility. In VSMCs, EFNB3 might also 
associate with other so-far unidentified binding proteins. During reverse signaling, some of 
these proteins might interact with and modulate the functions of other pathways that control 
VSMC contractility, the MLCK pathway being one of them. The intermediate signalling 
molecules between EFNB3/GRIP1 and MLCK/MLC remain to be identified.  
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What is the possible mechanism by which estrogen in concert with EFNB3 modulates VSMC 
contractility? We have demonstrated that estrogen augments KO but not WT VSMC 
contractility, and this is mediated by its nongenomic effect via cell surface receptor GPR30. 
GRP30 can directly regulate ERK activity (Gros et al., 2011), which in turn controls VSMCs 
contractility (Bhattacharya & Roberts, 2003). As EFNB3 reverse signalling can activate ERK 
as shown in S. Figure 2,  ERK or molecules in this category which modulates VSMC activity 
both in the presence or absence of EFNB3,  can function as a node on which EFNB3 and GPR30 
signalling pathways converge. This could be a possible mechanism by which EFNB3 and 
estrogen act in concert in regulating VSMC contractility. 
Our research on the roles of EPHBs/EFNBs in VSMC contractility has revealed a group of 
previously unknown molecules capable of regulating vascular tone and blood pressure. Among 
this group of molecules, we have shown that the default function of EPHB6, EFNB1 and EFNB3 
is to reduce vascular tone (Luo et al., 2012; Z. Wu et al., 2012; Y et al.), and thus their deletion 
leads to increased vessel contractility and blood pressure. Our most recent finding indicates that 
among the EPHBs and EFNBs, there are another group of molecules such as EPHB4 and 
possibly its major ligand EFNB2, whose default function is opposite, i.e., to enhance the 
vascular tone (Y. Wang et al., 2015); consequently, their deletion lead to reduced blood pressure. 
These opposing forces of different member of EPHBs and EFNBs are like Yin and Yang and 
probably play a role for the fine tuning of the vascular tone. A better understanding of the 
physiological relevance and mechanisms of action of these molecules for their role in vascular 
contractility and blood pressure regulation will afford us a novel personalized therapeutic 
approach to blood pressure management. For example, female hypertensive patients with 
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EFNB3 mutations could be identified by genetic testing, and for this subpopulation of patients, 
avoidance of oral contraceptive/hormone replacement will reduce their hypertension risks. 
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Supplementary Figure 1. LocusZoom plots of -log10  p-values (left hand vertical axis) from IBPC meta-
analysis of specific queried genes  
The positions of all SNPs in the query are indicated at the top of the plot as short, thin vertical lines, and 
as diamonds and circles in the plots. Diamonds represent reference SNPs with the highest -log10 p-value 
in the region, and their names are indicated above the diamonds. R2 refers to LD between the reference 
SNP and respective SNPs within the region. Blue lines refer to recombination rates (right hand vertical 
axis) in centimorgans/megabase at each position. Thus, peaks in blue lines indicate low LD regions of 
high recombination rates or recombination hotspots. 
 
Supplementary Figure 2. Reduced ERK phosphorylation in WT VSMCs stimulated with solid phase anti-
EFNB3 Ab 
WT VSMCs were cultured in wells coated with anti-EFNB3 Ab, and then stimulated with PE, as 
described in Figure 1. The cells were harvested 3 sec after PE stimulation, and their ERK phosphorylation 
was determined by Western blotting. The experiment was conducted 3 times and a representative result 
is shown. 
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Supplementary Figure 3. Unaltered EFNB3 mRNA expression in WT VSMCs transfected with Grip1 
siRNA  
WT VSMCs were transfected with control and EFNB3 siRNA. After 48 h, their EFNB3 mRNA 
expression was determined by RT-qPCR.  The mean + SD of the ratios between EFNB3 and -actin 
signals in two independent experiments are presented. No significant difference is observed between 
control and EFNB3 siRNA transfected samples (Student's t-test). 
 
Supplementary Figure 4. Histology and lumen diameters of KO and WT vessels 
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A. HE-stained sections of the aorta, and mesenteric of WT and KO mice  
B. Lumen sizes of WT and KO vessels 
The lumen sizes of the aorta, and mesenteric artery of WT and KO mice were measured using Image J 
and mean + SD of data from 3 WT and 3 KO mice of similar age are presented. No significant difference 
is found (Student's t test). 
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CHAPTER 6 General Discussion 
 
Yin and Yang of the novel BP regulation system  
One of the first reports on EPH was published by Hirai et al. about 20 years ago (Hirai et al., 
1987). Since then, many works have been carried out, studying the function of EPHs and their 
ligands EFNs. Recent studies have demonstrated that EPHs and EFNs have critical functions in 
many systems. Investigations on the roles of EPH/EFN in the cardiovascular system (except 
angiogenesis) are limited.  Based on our studies, several types of EPHs and EFNs were 
discovered as being essential for BP regulation. The general findings are summarized in Table 
1 below. While EPHB6, EFNB1 and EFNB3 deletion lead to increased BP, EFNB2 and EphB4 
deletion results in a BP decrease. Moreover, such regulation is often sex hormone level-
dependent.  
Table 1.  
The phenotypes of blood pressure in various EPHB and EFNB KO mice of different sexes 
 EPHB4 EPHB6 EFNBb1 EFNB2 EFNB3 
 M* F* M F M F M F M F 
BP ↓* −* − − − n/a* ↓ − − ↑ 
HR ↑ ↑* ↑ ↑ − n/a − ↓ ↑ − 
Vasocontractility ↓ ↑ ↓ ↑ ↓ n/a ↓ − − ↑ 
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 EPHB4 EPHB6 EFNB1 EFNB2 EFNB3 
 C* O* C O C O C O C O 
BP − − ↑ ↑ − n/a − − ↑ − 
HR − − − − − n/a − − ↑ − 
Vasocontractility n/a n/a ↑ − ↑ n/a n/a n/a − − 
Role in 
maintaining BP 
EphB4 + 
testosteron → 
increase BP 
EphB6 + 
testosteron 
→increase BP 
EFNB1 + 
testosteron 
→reduce BP 
EFNB2 + 
testosteron 
→increase BP 
EFNB3 + 
estrogen 
→reduce BP 
*: F: female; M: male; C: castrated; O: ovariectomized; −: no difference between KO and WT; 
↑: KO increased; ↓:  KO decreased; n/a: not applicable (Efnb1 is an X-linked gene, and null 
mutation of Efnb1 causes embryonic lethality. So only male smMHC-Cre-Efnb1 KO mice could 
be generated.) 
These functions of EPHBs and EFNBs are mainly mediated by VSMCs, based on our studies 
using smooth muscle-specific gene deletion and using isolated VSMCs. It is interesting to 
observe that different members of EPHBs and EFNBs have opposing effects in BP regulation. 
Such opposing forces, which may also be called Yin and Yang, are widely present in biological 
systems. The coexistence of positive and negative regulatory effects on VSMC contractility by 
different members of the EPH/EFN family likely controls homeostasis of vascular tone and 
consequently blood pressure. As EFN and EPH members are constitutively expressed on 
VSMCs and are engaged with each other constantly, they are probably not for rapid regulation 
of BP. The EPH and EFN signaling are more likely to achieve some fine-tuning of the vascular 
tone and help the individuals to adapt to the gradually changing environment. The physiological 
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and pathophysiological factors that are capable of modulating the Yin and Yang of EPH/EFN 
signaling in VSMCs will be the topic of our next phase of research. 
EPH/EFN-related downstream signaling pathways 
Changes in intracellular Ca2+ concentration play a vital role in the contraction of VSMCs. 
Calmodulin is one of the most important sensors of intracellular Ca2+ changes (Klee & Vanaman, 
1982). Ca2+–calmodulin complex could associate with many downstream kinases including 
myosin light chain kinase (MLCK) (Kamm & Stull, 2011). In our study, both female and male 
EPH/EFN KO mice presented normal Ca2+ flux. This suggests that the change of contractility 
in these cells is achieved in a Ca2+ flux-independent way.  
Ca2+ /calmodulin-dependent protein kinase II (CaMKII) is a serine/threonine-specific protein 
kinase that is regulated by the Ca2+/calmodulin complex. In our case, MLCK can be 
phosphorylated by CaMKII (Tansey et al., 1992), resulting negative modulation of MLCK 
activity in VSMCs (Van Riper, 1995). With Thr-286 autophosphorylation of CaMKII, its 
sensitivity to Ca2+ activation is decreased (Shifman, Choi, Mihalas, Mayo, & Kennedy, 2006). 
Our study on EPHB4 and EFNB2 showed increased CaMKII and MLCK phosphorylation in 
male KO VSMCs, and this led to decreased activity of MLCK. On the other hand MLCK 
phosphorylation was reduced in EFNB3 female KO VSMCs. These signaling changes finally 
led to the modulation of myosin light chain (MLC) phosphorylation, which is the major 
modulatory event cause for VSMC contractility.  
Another important protein for regulating the contraction of smooth muscle is myosin light chain 
phosphatase (MLCP), which promotes contraction by dephosphorylating myosin light-chain 
proteins (D. P. Wilson, Susnjar, Kiss, Sutherland, & Walsh, 2005). MLCP is present in smaller 
amounts compared with MLCK. In our experiments of EPHB4, EFNB2 and EFNB3, the MLCP 
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phosphorylation levels remained unchanged in KO VSMCs with no sex difference. This result 
suggests that MLCP is not involved in VSMC contractility in the absence of EPHBs and EFNBs 
that are examined. (Figure 1). 
 
Figure 1. Possible signaling pathways downstream of EPHBs/EFNBs 
EFNB2 and EFNB3 are two important EPHB kinase ligands; they have short intracytoplasmic 
tails with no enzymatic activity. There are five conserved tyrosine phosphorylation sites in the 
tails in addition to a PDZ-binding motif at the C-terminus. EFNB2 and EFNB3 are capable of 
binding to several proteins, such as GRIP1, RGS3 and DISHEVELLED (Bruckner et al., 1999; 
Lu, Sun, Klein, & Flanagan, 2001; Tanaka, Kamo, Ota, & Sugimura, 2003). Among these three 
associating molecules, we discovered that knocking down GRIP1 but not Dishevelled or PDZ-
RGS3 expression in VSMCs by siRNAs partially reversed the KO contraction phenotype, 
suggesting that GRIP1 is mediating EFNB2 and EFNB3 reverse signaling, leading to the altered 
contractile phenotype of the KO VSMCs. 
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GRIP1 has 5 PDZ domains that can associate with signaling molecules that contain PDZ-
binding domains and mediate EFNB2/EFNB3 reverse signalling (Figure 2A). Therefore, GRIP1 
is situated in a node of signaling pathways emanating from the EphB/ephrinB family of 
molecules concerning their roles in BP regulation. GRIP1 can associate with a Rho-GDI (Su, 
Wang, & Garabedian, 2002) and a Ras-GEF (Ye et al., 2000) through its PDZ domains. It is 
possible that the remaining PDZ domains in GRIP1 might interact with modulators of RhoA 
activity such as GDP dissociation inhibitors (GDI) or GDP exchange factors (GEF) and 
influence their functions, which will, in turn, regulate RhoA activity. The net effect of GRIP1 
could be positive or negative regarding VSMC contractility, depending on the context of 
signaling pathways it mediates in EFNB2 versus EFNB3. Such dual effect of signaling 
molecules does exist in other systems, such as suppressors of cytokine signaling (SOCS) have 
dual effects of inhibition and restoration on growth hormone signal transduction (Favre, 
Benhamou, Finidori, Kelly, & Edery, 1999). 
We conducted analysis of the International Blood Pressure Consortium dataset, which contains 
SNP information on a large number of healthy individuals, and found a tag SNP in GRIP1 gene 
having a strong association with diastolic BP (Figure 2B).This finding corroborates our data in 
mice and shows the relevance of our mouse results to human BP control. 
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Figure 2. GRIP1 is in the EPH/EFN signaling pathways leading to VSMC contractility 
The mutations identified in human genetics studies could be loss-of-function, or gain-of-
function or alternation-of-function mutations 
Although genetic mutation can lead to a loss of function, it is not always the case. Sometimes, 
the mutations may cause enhancement of the original function, or even evoke functions 
unrelated to the original function.  For example, mutations in the leucine-rich repeat kinase 2 
gene (LRRK2) could enhance GTP-binding and kinase activities to neuronal toxicity(West et 
al., 2007). 
In our EFNB2 human genetic study, we revealed that 6 SNPs, apparently in high linkage 
disequilibrium with each other, were associated with hypertension risks in males-only samples. 
This in contrast to our finding in mice that the hypotension phenotype of the KO mice was more 
pronounced in males. While the major allele in humans is associated with hypertension risk, the 
minor alleles are protective against hypertension. On the other hand, there is no positive or 
negative association of these EFNB2 SNPs to hypertension in females in this study. The results, 
in general, match the findings of our mouse study: EFNB2 null-mutation manifested low BP 
phenotype in males but not females under normal condition. How do we explain the fact that 
the major allele of EFNB2 SNPs is associated with hypertension risks? As mentioned above, it 
is possible that the mutation in the major allele leads to a gain of function, enhancing the default 
function of EFNB2, i.e., augmenting VSMC contractility, hence increased BP. 
We also conducted human genetic studies on EFNB3. The results from several large-scale 
GWAS (Adeyemo et al., 2009; Guo et al., 2012; Hiura et al., 2010; International Consortium 
for Blood Pressure Genome-Wide Association et al., 2011; Levy et al., 2009; Org et al., 2009; 
Padmanabhan et al., 2010; Slavin, Feng, Schnell, Zhu, & Elston, 2011; Wellcome Trust Case 
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Control, 2007) datasets do not reveal a significant association of t EFNB3 to BP and 
hypertension.  There are several possible reasons such as high heterogeneity of the samples; the 
relatively small contribution of EFNB3 to the BP phenotype; and the heavy statistical penalties 
due to genome-wide SNP analysis.   
Why is then a SNP of GRIP1 found to be almost significantly associated to BP? The possible 
reason might be that GRIP1 is involved in signaling of multiple EPHBs and EFNBs. Thus the 
statistical weight of GRIP1 is probably much heavier than each EPHB or EFNB member alone, 
and consequently the association of GRIP1 to BP is easier to detect. 
Sex hormones differentially influence the BP of males and females 
We revealed that the function of EPH and EFNs in BP regulation was strongly related to sex 
and sex hormone level. Androgen deficiency, also known as hypoandrogenism or 
hypogonadism in males, is caused primarily by dysfunction, failure, or absence of the gonads. 
As determined  by the International Society for the Study of the Aging Male, about 30% of men 
older than 40 years are hypogonadism(Traish, Miner, Morgentaler, & Zitzmann, 2011). Further, 
male patients with the metabolic syndrome are prone to hypogonadism (Zitzmann, 2009). There 
are two common etiologies of abnormal estrogen levels in males and females. In males, 
overweight/obesity may lead to increased estrogen levels. As adipose tissue is an important 
peripheral source of aromatase activity, which converts testosterone to estrogens (Nelson & 
Bulun, 2001). In females, the leading cause of estrogen level change is menopause, which leads 
to a rapid reduction of estrogen. 
Subpopulation of people with abnormal sex hormone levels will have increased or decreased 
hypertension risks if they also have some mutations in EFNBs or EFNBs  
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Genetic diagnosis and hormone therapy  
Our observations confirm that EPHBs and EFNBs are involved in blood pressure regulation. 
Base on that finding, several diagnostic and treatment methods can be generated. 
First, from the perspective of prevention, it is valuable to develop genetic tests based on our 
current polymorphism studies. If the presence of Eph/ephrins mutations is found, then the sex 
hormone levels will be assessed. For the patients with both genetic mutations in EPHB and 
EFNB genes and sex hormone changes, further intervention can be performed. For example, for 
male hypertensive patients with hypogonadism or elevated estrogen levels, combines with 
EFNB3 mutations, testosterone replacement therapy or estrogens blockers (such as tamoxifen) 
can be used. In contrast, the reduced estrogen levels in old females after menopause could have 
a protective effect against hypertension if they happen to have EFNB3 mutations. For this 
subpopulation, avoidance of hormone replacement therapy will be a prudent measure to reduce 
hypertension risks. In subpopulations males with EPHB4 and/or EFNB2 loss-of-function 
mutations, maintaining sufficiently high testosterone levels should have protective effects 
against hypertension. These are personalized treatment/management of hypertension. As Eph 
are kinases, small molecule kinase inhibitors could also be used regulate BP. NVP-BHG712 is 
a small molecule synthesized based on a rational design. It is a potent EPHB4 inhibitor, although 
it also inhibitor several other EPH kinases.  (Martiny-Baron et al., 2010; Wnuk et al., 2012). In 
our study, NVP-BHG712 was shown to be able to significantly reduce VSMC contractility. We 
found that this EPHB4 inhibitor could drastically reduce BP in mice (data not shown), consistent 
with the EPHB4 KO BP phenotype. Thus, EPHB4 inhibitors might be a new category of BP 
regulation agents.  
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A brief summary Nowadays, hypertension has become a worldwide critical medical and public 
health issue. Approximately more than one billion people have hypertension in the world. 
Currently, research on the pathogenesis of hypertension has made significant progress. Although 
we are still far away from a full understanding of the mechanisms underlying the disease. Our 
research has revealed that Eph/ephrins are previous unknown components of BP regulation. 
This has opened a new area of investigation into the pathogenesis of hypertension and 
hypertension treatment. 
Contribution to sciences and future research directions 
This research for the first time revealed that in the Eph/ephrin system, there were components 
whose deletion led to reduced BP. We also established the relevance of our mouse results to 
human hypertension according to human genetic studies. We elucidated certain aspects of 
signaling pathways by which sex hormones in concert with EFNs regulated VSMC contractility. 
We need to study further the detailed signaling events from Eph/ephrin in the cell surface to the 
contraction machinery of VSMCs, and the interaction of sex hormone signaling with the 
Eph/ephrin signaling.  
 
We have found that EFN and EPH deletion also affects heart rates. The mechanisms by which 
these molecules control the rhythm of the pacing cells will also be an interesting aspect of future 
research.  
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